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THESIS 
Feeding of 0.33% cholesterol rich diet to rabbits for 22.4 weeks was 
associated with a substantial hyperiipidemia. The efficacy of TRF or Tocomin in 
the prevention of experimental hyperiipidemia in rabbits has been shown by 
feeding of 16.2 mg% TRF or 6.97 mg% Tocomin together with a cholesterol rich 
diet for 22.4 weeks. TRF and Tocomin significantly prevented the increase in 
plasma TG, TC, VLDL-C, and LDL-C levels in comparison to rabbits fed 
cholesterol rich diet alone. However, elevated plasma HDL-C, HDL3-C and 
HDL2-C levels were not reduced significantly in TRF and Tocomin treated rabbits. 
Both Tocomin and TRF caused a substantial improvement in the ratios of HDL-C/ 
TC, HDL-C/ LDL-C, TC/ HDL-C and LDL-C/ HDL-C, in comparison to ratio 
values of hyperlipidemic control indicating the initiation of normalization process 
of lipid parameters. 
In response to oxidative stress, evoked in experimental hyperiipidemia in 
rabbits, as reflected by increased formation of plasma lipid peroxides, higher base 
line levels of diene conjugation (BDC) of LDL, as modified in vivo, increased 
rates of conjugated diene formation in LDL and decrease in lag phase time of LDL 
oxidation in vitro, was substantially blocked by TRF or Tocomin when fed 
together with cholesterol rich diet. Similarly, TRF and Tocomin significantly 
blocked the LDL oxidation and restored the lag phase time close to normal value. 
The combined results demonstrate that strong hypolipidemic impacts of TRF or 
Tocomin in conjunction with it's potent antioxidant property can provide an 
additional therapeutic benefit in the prevention and treatment of hyperiipidemia 
and atherosclerosis. Consistent with above results, feeding of the cholesterol rich 
diet to rabbits for 22.4 weeks was also associated with the formation of fatty streak 
lesions in the aortas of hyperlipidemic rabbits. The average areas in aortas of these 
rabbits covered by fatty streak lesions was 21.5%, whereas TRF or Tocomin 
supplemented groups revealed an average lesion areas of 10.3%) and 13.3%), 
respectively. Therefore, feeding of dietary TRP or Tocomin together with 
cholesterol rich diet caused a significant reduction in the formation of aortic fatty 
streak lesions by 2.1- and 1.6-fold, respectively. These results demonstrate that 
tocotrienols (TRF or Tocomin) being a potent anticholesterol and antioxidant 
agents mediated a significant protection against the formation of early 
atherosclerotic lesions in the aortas induced by cholesterol feeding to rabbits. 
Based on strong hypolipidemic, antioxidant and antiatherosclerotic 
properties of tocotrienols (TRF or Tocomin) fed together with a cholesterol rich 
diet to rabbits for 22.4 weeks; we have investigated the role of dietary oxidized 
cholesterol in experimental hyperlipidemia, oxidative modification of LDL and in 
the acceleration of fatty streak lesions in the aorta of rabbits. In addition, 
therapeutic role of TRP in the prevention and treatment of experimental 
hyperlipidemia and atherosclerosis induced by cholesterol oxidation products was 
investigated. After 10 weeks of feeding to rabbits either a 0.33% cholesterol rich 
diet or the same diet containing 0.33% cholesterol of which 5% was oxidized, 
plasma TG, TC including FC and EC, VLDL-C, LDL-C, HDL-C and it's 
subfractions, HDL3-C and HDL2-C were substantially increased but to a similar 
extent. Supplementation of 50 mg% of TRF to these diets significantly blocked the 
increase in the above lipid parameters, except HDL-C, HDL3-C and HDL2-C 
levels were not reduced significantly. Similarly, HDL-C/ TC and HDL-C/ LDL-C 
ratios were increased, whereas TC/ HDL-C and LDL-C/HDL-C ratios were 
reduced in TRF-treated rabbits, when compared to ratios obtained from respective 
hyperlipidemic controls, indicating a strong antiatherogenic property of 
tocotrienols. In contrast to plasma TC, feeding of cholesterol rich diet containing 
5% oxidized cholesterol was associated with a significantly higher increase in 
hepatic TC level than nonoxidized cholesterol fed rabbits. In addition, the decrease 
in liver TC mediated by TRF in oxidized cholesterol fed rabbits was two-fold 
greater than TRF plus nonoxidized cholesterol fed animals. The combined results 
demonstrate a strong cholesterol lowering propeity of tocotrienols (TRF), which 
were significantly more effective in the livers of oxidized cholesterol fed rabbits. 
The oxidative stress, evoked in oxidized cholesterol fed rabbits was 
significantly higher than nonoxidized cholesterol fed rabbits. This differential 
effect was reflected in several indices of oxidative stress, such as plasma and liver 
lipid peroxidases, baseline levels of ex vivo diene conjugation of LDL, rates of 
conjugated diene formation and TBARS contents of LDL, and lag phase time of in 
vitro LDL oxidation. These oxidative parameters were substantially more 
pronounced in rabbits fed oxidized cholesterol, apparently due to the presence of 
cholesterol oxidation products. Tocotrienols being very potent antioxidants, 
significantly blocked the above mentioned oxidative parameters in both groups. 
However, tocotrienols were significantly more potent in blocking the increasing 
plasma and liver lipid peroxidases as well as ex vivo and in vitro LDL oxidation, 
when supplemented with a diet enriched in oxidized cholesterol. Feeding of 0.33% 
cholesterol rich diet containing 5% oxidized cholesterol, which is rich in 
cholesterol oxidation products, caused a further increase in oxidative stress, which 
in turn decreased the lag time from a control value of 75 to 15 min, in comparison 
to a decline of 30 min in nonoxidized cholesterol fed rabbits. Similarly, feeding of 
TRF together with oxidized cholesterol rich diet significantly increased the 
resistance of LDL to oxidative modification, as shown by an increase in lag time 
from 15 to 70 min, which is very close to normal value of 75 min. However, in 
nonoxidized cholesterol plus TRP fed rabbits the restoration of lag time was only 
from 30 to 60 min. 
Consistent with the above results, feeding of nonoxidized cholesterol rich 
diet resulted in the formation of fatty streak lesions in the aorta of rabbits, which 
covered an area of 14.3%. An average fatty streak lesion area of 27.7%o was found 
in the aortas of rabbits fed a cholesterol rich diet containing 5% oxidized 
cholesterol. Thus, intake of a very small quantity, that is, 16.4 mg/ day of dietary 
oxidized cholesterol increased the fatty streak lesions by -100%. These results 
demonstrate that cholesterol in the diet is considerably more atherogenic when 
part of it is in the oxidized form. Consistent with a strong hypolipidemic and 
antioxidant action of tocotrienols, supplementation of TRP with oxidized 
cholesterol blocked the formation of fatty streak lesions by 4.1-fold, whereas TRP 
feeding together with nonoxidized cholesterol caused a reduction of 2.4-fold. 
These results show that the efficacy of dietary tocotrienols in terms of inhibiting 
the formation of vascular lesions in oxidized cholesterol fed rabbits was 
significantly higher than non-oxidized cholesterol plus TRF fed animals. These 
results indicate that for moderate experimental hypercholesterolemia, a situation 
more relevant to physiological hypercholesterolemia in humans, circulating 
cholesterol oxidation products may play an important role in inducing formation 
of early atherosclerotic lesions. Because cholesterol oxidation products are often 
present in cholesterol containing diets, foam cell lesion formation induced by 
oxidized cholesterol rather than cholesterol needs to be further investigated. In 
addition, the mechanism of action of tocotrienols in the inhibition of accelerated 
aortic atherosclerosis in rabbits fed a cholesterol rich diet containing 5% oxidized 
cholesterol also needs further investigation. 
It is well established that Western as well as Asian, including Indian diets, 
contain high concentrations of oxidized cholesterol products, and our results 
suggest that these foods may be a risk factor for atherosclerosis. Based on our 
combined results of long-term (22.4 weeks) cholesterol feeding experiment and a 
10-week cholesterol feeding experiment containing 5% oxidized cholesterol, it can 
be concluded that dietary tocotrienols (TRF or Tocomin) are potent 
hypolipidemic, antioxidant and antiatherosclerotic agents. Therefore, daily intake 
of dietary TRF or Tocomin will be useful in the prevention and treatment of 
Ti 
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atherosclerosis. Furthermore, tocotrienols (TRF or Tocomin) will be an excellent 
source of vitamin E with substantial and potent antioxidant activity. 
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Introduction 
Cardiovascular disease (CVD) is a global health problem causing half of 
deaths in developed countries and 30-40% deaths in developing countries. Since 
the mid-sixties a number of countries including USA. Australia and New Zealand 
have reported a decline in CVD mortality. However, in developing countries 
including India, there is a rapid increase in the prevalence of mortality due to CVD 
(Murray and Lopez, 1996; The World Health Report, WHO. 1999). There are 
relatively few mortality studies from India, as there is no uniform completion of 
death certificates and no centralized death registry for CVD (Reddy, 1993). 
However, the WHO and the World Bank estimate that deaths attributable to CVD 
have increased in parallel with the expanding population in India, and that CVD 
now accounts for a large proportion of disability adjusted life years lost (Murray 
and Lopez. 1996; The World Health Report, WHO 1999). Of all deaths in 1990, 
approximately 25% were attributable to CVD, compared with 10% from diarrhoeal 
diseases, 13% from respiratory infections and 8% from tuberculosis (Murray and 
Lopez, 1996). South Asian (people who originate from India, Sri Lanka, 
Bangladesh and Pakistan) migrants to the United Kingdom, South Africa, 
Singapore and North America experience 1.5-4.0 times higher coronaiy heart 
disease (CHD) mortality compared with Indigenous populations (Enas et ai, 
1992). By the year 2015, the proportion of deaths cause by CVD will be almost 
twice the level in 1985 that is from 19% in 1985 to 35% in 2015 (Lopez, 1993; 
Khor. 1997). In the Indian urban population, the prevalence of hypertension and 
coronary arteiy disease (CAD) is 3-4 times higher than in rural subjects. In South 
India (Malhotra, 1967; Raman ef al, 1993). the prevalence rates are higher in the 
urban as well as the rural population. CAD is more common in males than 
females. It seems that differences in diet, life style and the ageing of populations 
may be important in the pathogenesis of hypertension and CAD in different 
population groups of Indians (Beegom and Singh, 1995; Singh et ai, 1995a). In 
the United States alone. CAD accounts for fully one-half of the nearly 1 million 
deaths each year from cardiovascular disease, and is leading cause of death in both 
genders (American Heart Association, 1994). Each year, about 1.5 million 
Americans suffer acute myocardial infarction, and almost all myocardial 
infarctions are due lo the atherosclerosis of coronary heart arteries. Among the iwo 
thirds who survive the mjocardial infarction, about two thirds do not make a full 
recovery. In 19 percent of Americans aged 15 years or older who are categorized 
as disabled, the disability is from CAD or other cardiovascular disease (American 
Heart Association, 1994). 
Risk factor reduction is the primaiy clinical approach in preventing CAD 
morbidity and mortality. Epidemiological studies have clearly demonstrated that 
risk factor such as dyslipidemia. hypertension and the use of tobacco products act 
in a synergistic manner (Anderson et a/., 1991). High levels of total cholesterol, 
triacylglycerols (TAG), LDL-cholesterol, VLDL-cholesterol, apoB. Lp(a) and low 
levels of HDL-choIesterol. HDL2-cholesterol. HDLrcholesterol, apoA-1 are some 
of the Hpid risk factors associated with CAD. Other non lipid risk factors include 
physical inactivity, obesit)'. family histoiy of CAD, age, gender, homeostatic 
factors, homocysteinemia, alcohol consumption and psychological factors. The 
identification of risk factors provide a means for decreasing CAD risk, through the 
modification of modifiable risk factors, and for informing treatment decisions, 
through more accurate determination of overall risk status. The understanding of 
risk factors and their relationship to the incidence of CAD evolved from 
prospective epidemiological studies in United States and Europe (Dawber et al, 
1957; Report of the Working Group on Arteriosclerosis of NHLBL 1981; Cooper, 
1993; American Heart Association. 1994). These studies identify consistent 
association between characteristics observed at one point of time in apparently 
healthy individuals, with the subsequent development of CAD in them. Probably 
the single most important contributory lactor that has been impHcated by various 
epidemiological studies in the development of CAD, is hypercholesterolemia. 
Cholesterol, which is widely distributed in the animal kingdom, occurs in 
free form (unesterified) in all cell membranes (Myant, 1981), while in the plasma 
most of the cholesterol occurs in esterified form. Cholesterol has many biological 
functions. For instance, the concentration of cholesterol influences the fluidity of 
cell membranes and thereby biological activities of the cell. The cholesterol acts as 
a precursor for the synthesis of bile acids and steroid hormones. The total body 
cholesterol is derived from two sources: (i) dietary and (ii) de novo biosynthesis. 
Cholesterogenesis mostly occurs in the liver, which also regulates the level of 
circulating plasma cholesterol and serum lipoproteins. The biosynthesis of 
cholesterol also occurs in the other organs like the intestines, adrenal cortex, 
reproductive organs and skin. Although other cells and tissues do not synthesize 
cholesterol, they have the genomic information for its synthesis. Under normal 
circumstances, these cells and tissues take up cholesterol from serum lipoproteins. 
Starting from the 2-carbon unit acetyl-CoA, the biosynthesis of the 
cholesterol proceeds to several intermediates, including mevalonate and 
isopentenyl pyrophosphate (Fig. 1.1). Isopentenyl pyrophosphate is further 
processed in a series of steps to two branched pathways, one leading to 
isopentenyl tRNA and isopentenyl adenine, and the other to farnesyl 
pyrophosphate. Farnesyl pyrophosphate is in turn channeled to synthesis of 
cholesterol, ubiquinone or dolichols (Ross and Glomset, 1973; Brown and 
Goldstein. 1983). The observation that cancer cells lose feedback control 
of cholesterol biosynthesis, show elevated cholesterol levels, and exhibit a higher 
rate of cholesterogenesis provided the first indication of the link between 
cholesterol biosynthesis and cancer cell growth (Coleman and Laviets, 1981). The 
subsequent realization that not onh cancer cells but also preneoplastic and normal 
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Fig LL The biosynthefic pathways of mevalonatcs sterols and isoprenoid compounds. 
proliferating cells show elevaled levels of cholesterol as well as higher rates of 
cholesterogenesis indicated that cholesterol biosynthesis is likely to play an 
important role not only in carcinogenesis but also in normal cell growth (Rao, 
1986). Hepatic level of cholesterol are maintained by a precised balance between 
reactions catalyzed by 3-hydrox}'-3-methylg!iitary! coenzyme A reductase (HMG-
CoA reductase, EC 1.1.1.34). cholesterol 7-a hydroxylase, acyl CoA: cholesterol 
acyltransferase and cholesteryl ester hydrolase. The first two enzymes are the rate 
limiting enzymes for cholesterol and bile acid synthesis, respectively. Acyl CoA: 
cholesterol acyltransferase catalyzes esterification of free cholesterol, whereas 
cholesteryl ester hydrolase mediates release of free cholesterol from stored 
cholesteryl esters. 
The primary feedback loop for regulation of cholesterol synthesis appears 
to be at the site where HMG-CoA is converted to mevalonic acid by the rate-
limiting enzyme HMG-CoA reductase (Luskey, 1991). Cholesterol and other 
oxysterols inhibit the activity of HMG-CoA reductase. Because of the strong link 
between cholesterol and CHD and its link with cancer (Rao, 1986), there is 
currently a renewed interest in studying the regulation of HMG-CoA reductase and 
several other key enzymes in cholesterol biosynthetic pathway. HMG-CoA 
reductase regulates the synthesis of cholesterol and other polyisoprenoid 
compounds (Rodwell et al, 1976: Goldstein and Brown, 1977; Brown and 
Goldstein, 1979; Brown and Goldstein, 1980; Beg et al., 1981; Beg and Brewer, 
1982). In mammalian cells. HMG-CoA reductase is a transmembrane glycoprotein 
with its active site facing the cytosol and a carbohydrate containing site oriented 
toward the luminal surface of the endoplasmic reticulum (Liscum et al., 1983a; 
Brown and Simoni, 1984). HMG-CoA reductase is an approximately 100 kDa 
protein (Chin et al., 1982; Edwards et al., 1983a; Hardeman et al., 1983; Chin et 
al, 1984; Beg et al, 1985). Proteolysis of the native protein results in a 53 kDa 
molecular weight fragment that contains the active site of the enzyme (Chin et al.. 
1982; Liscum et al.. 1983a; Edwards et al., 1983a; Hardeman et a/., 1983; Chin el 
al., 1984; Beg et al., 1985). HMG-CoA reductase is a protein of 887 amino acids 
containing three potential sites for aspargine-linked glycosylation. The N-terminal 
half of the peptide is anchored to the membrane and contains seven hydrophobic 
regions, each of which is comprised of 20 amino acids and spans the microsomal 
membrane (Chin et al., 1984). The N-terminal lacks the signal sequence and the 
hydrophilic C-terminal half of HMG-CoA reductase contains the catalytic site of 
the enzyme (Chin et al.. 1984). Since, the catalytically active hydrophilic tail of the 
enzyme extends into the cytoplasm, it is more accessible to the action of 
modulators and permits the observed multifaceted regulation of HMG-CoA 
reductase and cholesterol synthesis. The complex homeostatic mechanism by 
which the enzyme activit}' of HMG-CoA reductase and cholesterol biosynthesis 
are coordinately regulated in response to various physiological stimuli has been 
extensively studied. Isolation, purillcation. and characterization of rat hepatic 
HMG-CoA reductase have been well documented (Kawachy and Rudney, 1970; 
Heller and Gould, 1973; Brown et al., 1973; Heller and Gould, 1974; Heller and 
Shrewsburg, 1976; Kleinsek et al, \911; Srikantaiah et al, 1977; Edwards et al, 
1979). HMG-CoA reductase has also been studied in several other species 
including chicken liver (Beg et al, 1978; Beg et al, 1979), human liver (Beg et 
al, 1982a; Beg et al, 1982b) and human fibroblasts (Brown and Goldstein, 1983; 
Beg et al, 1987). Several different mechanisms for the regulation of enzymes in 
metabolic pathways have been elucidated such as modulation by isosteric and 
allosteric effectors, regulation of enzyme synthesis and degradation, feed-back 
control, and covalent modification (Siperstein, 1970; Holzer and Duntze, 1971; 
Segal, 1973; Carlson and Kim. 1973; Lee et al, 1976; Greengard, 1978). Three 
basic control mechanisms for HMG-CoA reductase have been reported, (a) Long-
term regulalion. which involves the modulation of HMG-CoA reductase activity 
by changes in enzyme concentration through the regulation at transcriptional level 
and post-transcriptional regulatory mechanisms such as niRNA and enzyme 
protein degradation (Kirsten and Watson, 1974; Jakoi and Quarfordt. 1974; Chan 
et al, 1981; Koizumi et al., 1982; Faust et al., 1982; Edwards et al., 1983a; 
Edwards et al., 1983b; Liscum et al.. 1983b; Clarke et al., 1983; Sinensky and 
Logel, 1983; Clarke et al.. 1984). For instance, the product feedback regulation by 
mavalonate (Kita et al.. 1987; Brown and Goldstein, 1980; Cohen et al.. 1982). in 
vivo inhibition of HMG-CoA reductase by cholesterol feeding (Arebalo et al., 
1981), cholestyramine and mevinolin (Eisenberg and Levy, 1975), and 
mevalonolactone (Arebalo et al.. 1980; Beg et al., 1984) has been reported. 
Tocotrienols, a naturally occurring class of compounds of vitamin E family, have 
also been reported to regulate HMG-CoA reductase activity at the post-
transcriptional level (Pearce et al.. 1992; Parker et al.. 1993). (b) Control of HMG-
CoA reductase activit}' through changes in the membrane composition and 
membrane fluidity in the microsomal environment in the immediate vicinity of the 
enzyme (Finkel and Volpe, 1979; Mitropoulous et al, 1981; Siptal and Sabine, 
1981; Richert et al, 1984). (c) Short-term regulation, that involves reversible 
covalent modification (phosphorylation and dephosphoiylation) of HMG-CoA 
reductase (Ingebritson and Gibson, 1980; Beg et al, 1981; Beg and Brewer, 1982; 
Kennelly and Rodwell, 1985). Three separate kinase systems for the regulation of 
HMG-CoA reductase involving short-term covalent modification have been 
demonstrated (Ingebritson and Gibson. 1980, Beg et al., 1987). Studies involving 
incubation of rat hepatocytes with insulin and glucagon or administration of 
glucagon to rats have been shown to modulate the bicyclic cascade system 
involving phosphorylation of both HMG-CoA reductase and HMG-CoA reductase 
kinase (Ingebritson and Gibson, 1980; Gibson, 1985; Beg et al, 1987; Gibson and 
Parker, 1987). 
Although cholesterol is essential to life, excess or deficit of free cholesterol 
is known to be harmful. Several factors are known which cause an overall increase 
in cholesterol concentration in the liver (Fig. 1.2) (i) uptake of lipoproteins by 
receptor mediated endocytosis. (ii) non-receptor mediated intake of lipoproteins, 
(iii) uptake of free cholesterol from the cholesterol rich lipoproteins by cell 
membranes, (iv) de novo synthesis of cholesterol, and (v) hydrolysis of cholesterol 
esters by cholesteiyl ester hydrolase. Under above situations, not only increased 
cholesterol levels inhibits its own synthesis by inhibiting HMG-CoA reductase and 
suppressing low-density lipoprotein (LDL) receptors (Russel, 1983), but also by 
activating cholesterol 7-a hydroxylase and acyl CoA: cholesterol acyltransferase 
which utilize free cholesterol for bile acid synthesis and formation of cholesteryl 
esters, respectively. Conversely, some factors are involved in the decrease of 
hepatic cholesterol, they are (a) efilux of cholesterol from membrane to nascent 
high-density lipoproteins (HDL) and HDL3 which is catalyzed by lecithin: 
cholesterol acyltransferase, (b) esterification by acyl CoA: cholesterol 
acyltransferase and (c) utilization of cholesterol for synthesis of steroids and bile 
acids. Under these conditions, increase in cholesterol is achieved by activation of 
HMG-CoA reductase and cholesteryl ester hydrolase activities as well as induction 
in synthesis of LDL receptors in order to receive cholesterol from non-hepatic 
tissues by receptor mediated endocytosis (Fig. 1.2). However, under normal 
conditions an intricate balance is maintained between the biosynthesis, utilization 
and transport of cholesterol, keeping its harmful effects to minimum. 
Lipids are transported through plasma compartment in lipoproteins, which 
are complex water soluble molecules consisting of a core of cholesteryl esters 
and TAG covered by a surface monolayer of phospholipids, free cholesterol and 
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Fig. 1.2. A model for plasma triacylglycerol and cholesterol transport. 
(Adapted from Biochemistry by D Voet and J G Voet, J Willey and sons. New York, 1990 
ed, p-306) 
apolipoproteins. In the last two decades, there have been major advances in our 
understanding of the role of plasma lipoproteins, apolipoproteins. lipolytic 
enzymes, and lipoprotein receptors in cholesterol and lipoprotein metabolism. 
This new information has provided major insights into the role of cholesterol and 
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classes of human plasma lipoproteins, these include chylomicrons, very low 
density lipoproteins (VLDL), intermediate density lipoprotein (IDL), low density 
lipoprotein (LDL), high density lipoprotein (HDL) and lipoprotein (a) [Lp(a)] 
(Gofman et al., 1954; Berg et al.. 1974). HDL can be further separated by hydrated 
density into HDL2 and HDL3. These lipoproteins are distinguished on the basis of 
their lipid content, ultracentrifugation size, electrophoretic mobility and surface 
proteins. 
Fourteen major human plasma apolipoproteins have been identified and 
their gene and protein structures determined (Brewer et ai, 1988). The five most 
clinically relevant apolipoproteins are A-I, B-lOO, B-48, C-II and E. The two 
major apolipoproteins on HDL are apoAI and apoAII (Oran et ai. 1983; Suzuki et 
ai, 1983). In human plasma apoB exist as two isoproteins designated apoB-100 
and apoB-48, with molecular weights of 512 and 250 kDa, respectively (Kane et 
ai, 1980; Kane, 1983). ApoB-48 and apoB-100 are the principal structural 
apolipoproteins on chylomicrons, VLDL, IDL and LDL. ApoB-100 is virtually the 
only apolipoprotein on LDL. 
Over the last decade three major physiological functions for the plasma 
apolipoproteins have been identified, (i) Apolipoproteins functions as structural 
proteins for the biosynthesis and secretion of plasma lipoproteins. ApoB-100 and 
apoB-48 are required for the secretion of TAG-rich lipoproteins from the liver and 
intestine. ApoA-I has been proposed to be an important structural protein for the 
biosynthesis of HDL. Individuals with an inability to synthesize and secrete apoA-I 
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have a virtual absence of plasma HDL (Narun et al., 1982; Schaefer et ai, 
1985).(ii) Apolipoproteins function as cofactors or activators of enzymes involved 
in lipid and lipoprotein metabolism. ApoC-II is required for the enzymatic activity 
of lipoprotein lipase, which is responsible for the perivascular hydrolysis of 
lipoprotein TAG to free fatty acids and monoacylglycerols (La Rosa et a!., 1970; 
Havel et al., 1970). Lipoprotein lipase is attached to the capillary endothelium by a 
heparin-like proteoglycan allowing direct interaction of the enzyme with the 
circulating TAG-rich lipoproteins. A deficiency of lipoprotein lipase or apoC-II 
results in defective TAG hydrolysis (Breckennidge et al., 1978). Clinically, 
patients have eruptive xanthomas. se\'ere hypertriglyceridemia and recurrent bouts 
of pancreatitis. ApoA-I activates lecithin: cholesterol acyltransferase, which 
catalyzes the esterification of plasma cholesterol to cholesteryl esters (Fielding et 
al., 1972). (iii) Apolipoproteins also play a critical role in lipoprotein metabolism 
as ligands on lipoprotein particles which interact with cellular receptors for 
specific lipoproteins. ApoB-100 interacts with the LDL receptor to initiate 
absorptive endocytosis and cellular uptake of LDL (Brown and Goldstein, 1986). 
ApoE has been proposed to interact with apoE receptor, which facilitates the 
hepatic removal of lipoprotein remnants secreted, by the intestine and liver 
(Davignane^a/., 1988; Hertz e/a/., 1988). 
The metabolic relationship of the major classes of lipoproteins containing 
apoB-48 and apoB-100 may be considered to consist of two major "apoB 
cascades". The first apoB cascade involves the stepwise delipidation of TAG-rich 
chylomicrons secreted by the intestine. These lipoproteins transport dietary 
cholesterol and TAG from the intestine to the liver and peripheral tissues. Shortly 
after secretion, chylomicrons acquire apolipoproteins C-Il and E primarily from 
HDL. As already outlined, apoC-lI activates lipoprotein lipase, which initiates 
TAG hydrolysis and remodeling of the lipoprotein particles. With TAG hydrolysis 
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of the hydrated density the chylomicrons increases and chylomicron remnants are 
generated with a hydrated density of VLDL and then IDL. Chylomicron remnants 
are removed primarily by a hepatic remnant receptor (Davignan et al., 1988). 
ApoE has been proposed to interact and initiate the hepatic uptake of the 
chylomicron remnants (Davignan el al.. 1988; Hertz et al., 1988). The second 
apoB cascade is a parallel cascade involving TAG rich VLDL containing apoB-
100 secreted by the liver. ApoC-II and apoE from HDL rapidly associate with the 
newly secreted hepatogenous VLDL. ApoC-11 activates lipoprotein lipase, which 
hydrolyzes VLDL triglycerides, and the VLDL is serially converted to smaller 
VLDL remnants, IDL. and finally LDL. During the conversion of VLDL to LDL 
approximately 50 per cent of VLDL remnants and IDL are removed directly from 
the plasma by interaction of apoE and apoB-100 with the remnant and LDL 
receptors. 
Another lipolytic enzyme, hepatic lipase and apoE have also been proposed 
to be necessary for the conversion of IDE to LDL. Hepatic lipase functions as both 
a triglyceryl hydrolase and phospholipase. LDL, the end product of the VLDL 
cascade, contains almost exclusively apoB-100 as its only protein constituent. 
ApoB-100 on LDL interacts with LDL receptor on the plasma membrane of cells 
in the liver, adrenal and peripheral cells, including smooth muscle cells and 
fibroblasts (Brown and Goldstein, 1986), where it supplies cholesterol to the 
intracellular cholesterol pool. The work of Brown and Goldstein (1979 & 1983) on 
the cellular metabolism of LDL elucidated the LDL Pathway. The high affinity 
receptors bind LDL particles and extract them from the fluid that bathes the cell. 
LDL is transported to lysosomes where the protein is degraded and the cholesterol 
is transferred to the intracellular cholesterol pool (Brown and Goldstein, 1986). 
The receptor displayed on the surface of the cells varies with the cellular demand 
for cholesterol. When the need is low. the cells make fewer receptors and take up 
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LDL at a reduced rate, this protects the cells excess cholesterol but at a higher 
price, the reduction in the number oi" receptors decreases the rate of removal of 
LDL from the circulation, blood level of LDL rises and atherogenesis is 
accelerated. LDL receptor plays an important role in the maintenance of plasma 
LDL-cholesterol levels. The serum concentration of LDL, therefore, depends on 
the rate that liver removes IDL from the circulation which in turn, depends on the 
number of functioning LDL receptors on the liver cell surface (Fig. 1.3a). High 
blood cholesterol which results from the overproduction and/or underutilization of 
LDL, is known to be caused by two metabolic irregularities (i) the genetic disease 
familial hypercholesterolemia (discussed in detail later); (ii) the consumption of 
high cholesterol diet. Familial hypercholesterolemia (FH) (Fig. 1.3b) is a dominant 
genetic defect that results in a deficiency of functional LDL receptors. FH 
homozygotes. therefore have plasma LDL-cholesterol levels three to five times 
higher than average. FH heterozygotes, which are far more common, have about 
one half of the normal number of functional receptors and plasma LDL-cholesterol 
levels of about twice the average. The ingestion of high cholesterol has an effect 
similar, although not as extreme, as FH (Fig. 1.3c). Excessive dietaiy cholesterol 
enters the liver cells in chylomicron remnants and represses the synthesis of 
LDL-receptor protein. The resulting insufficiency of LDL-receptors on the liver 
cell surface has consequenses similar to those of FH. In Watanable hereditable 
hyperlipidemic (WHHL) rabbits, with a genetic deficiency of LDL receptor 
function, extremely high plasma LDL cholesterol levels are observed with the 
development of atherosclerosis early in life (Brown and Goldstein, 1983). 
LDL receptor activity is under the metabolic regulation in vivo, such that 
receptor activit)' can be increased or decreased by appropriate interventions 
with diet and/or drugs (Mahley and Innerarity, 1983; Brown and Goldstein, 1983). 
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Nascent HDL, primarily in the form of piiospholipid-apolipoprotein A-I 
discs, are synthesized both in the human liver and intestine. The nascent HDL 
acquires cholesterol from tissues and the enzyme lecithin: cholesterol 
acyltransferase catalyzes the esterification of cholesterol to cholesteryl esters. With 
the increase in lipid content, the nascent HDL are converted to HDL3, these HDL^ 
lipoproteins are then converted to the larger HDL2 lipoproteins by the acquisition 
of lipids and apolipoproteins released during the stepwise delipidation and 
remodeling of the TAG rich chylomicrons and VLDL as well as the uptake of 
cholesterol from peripheral tissues. HDL2 is converted back to HDL3 by the 
removal of TAG and phospholipids by hepatic lipase as well as by the transfer of 
cholesteiyl esters into VLDL and LDL by the cholesteiyl ester exchange protein 
(or lipid transfer protein) as well as the transfer of cholesteiyl esters to the liver 
and other tissues. In this overall process. HDL are interconverted from HDL3 to 
HDL? and back to HDL3 as cholesterol is picked up and transferred from 
peripheral tissues to the liver (Fig. 1.4). This process is termed as reverse 
cholesterol transport (Brewer et ai, 1971; Eisenberg et al, 1984b). In this 
proposed model, HDL interacts with a putative HDL receptor (Oran et al, 1983; 
Suzuki et al, 1983; Schmitz et al, 1988) that facilitates the transfer of intracellular 
cholesterol to HDL. HDL transports this cholesterol in plasma and delivers it to the 
liver via the HDL receptor for removal from the body by direct secretion into bile 
or following conversion to bile acids. A variable portion of tissue cholesterol has 
been proposed to be transported to the liver by HDL particles containing apoE, 
which may interact with the hepatic remnant and LDL receptors (Eisenberg et al, 
1984b). 
Atherosclerosis, which is the most common form of arteriosclerosis 
(hardening of arteries), is characterized by the presence of atheromas. These 
atheromas or arterial thickenings exude a paste of yellow deposit of almost pure 
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cholesteiyl esters upon sectioning. Atherosclerosis is a progressive disease and 
results due to the deposition of intracellular lipids in the smooth muscle cells of the 
inner arterial wall. These lesions narrow and eventually block the arteries due to 
the formation of fibrous, calcified plaques. The rough arterial wall promotes the 
formation of blood clots, which may also block the artety. Due to the blocking of 
arteries, blood flow stops and causes the death of the deprived tissues. The 
stoppage of blood flow is known as an infarction. Atheromas mostly occur in the 
arteries supplying blood to the heart known as coronary arteries. This results in 
myocardial infarctions or heart attacks, which is the most common cause of death 
in Western man (Packer and Landvik. 1989). The earliest lesions of atherosclerosis 
can be found in young children and infants in the form of a lesion called the fatty 
streak, whereas the advanced lesion, the fibrous plaque, generally appears during 
early adulthood and progresses with age (Geer el al, 1961; Geer, 1965; Ghidoni 
and Oniel. 1967; Staiy. 1983: Stary et al. 1994; American Heart Association, 
1994). Fatty streaks were first observed by Stary (1983), he demonstrated that by 
the age of ten years, the fatty streaks consisted principally of lipid laden 
macrophages and smooth muscle cells and appears as yellow coloured area due to 
large amount of lipid filled foam cells. The bulk of lipid is generally formed by 
cholesteiyl esters, cholesterol derived from lipoproteins. 
Stary (1983) also studied fatty streaks in coronary arteries of children and 
young adults and observed that they were localized at same anatomical sites as the 
fibrous plaques did in older individuals. Based on this observation he concluded 
that the fatt}' streak with age advanced to form the mature fibrous plaque in adults. 
Chemical analysis of severe atherosclerotic plaques from humans and animal 
models indicate that on an average, fully developed atheromas are composed of 
about one half lipid and one half protein, including the cellular and extra cellular 
proteins, however, there may be great variations in these elements. 
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Two decades ago, atherosclerosis was considered to be a degenerative 
process because of the accumulation of lipid and necrotic debris in the advanced 
lesions, it is, however, now recognized that it is infact a multifactorial phenomena. 
The form and content of the advanced lesions of atherosclerosis demonstrates 
results of three fundamental biological processes; accumulation of intimal smooth 
muscle cells, together with variable numbers of macrophages and T-lymphocytes. 
formation of large amount of connective tissue matrix, including collagen, elastic 
fibers, and proteoglycans by the proliferated smooth muscle cells and 
accumulation of lipids, principally in the form of cholesteryl ester and free 
cholesterol within the cells as well as in the surrounding tissues (Ross and 
Glomset, 1973; Ross and Glomset. 1976; Fuster ef al., 1992; Ross and Fuster, 
1996). 
Jackson and Gotto (1976) have suggested that injuiy to endothelial cell 
membrane at arterial wall, may occur upon exposure to chronically elevated levels 
of LDL due to an increase in the number of cholesterol molecules in plasma 
membranes of cells, including endothelial cells. Elevation of the 
cholesterol/phospholipid ratio of endothelial cell plasma membrane can 
theoretically lead to an increase in the viscosity and decrease in the malleability of 
endothelial cell surface, which has a critical effect at particular anatomical sites, 
such as points of bifurcation in the arterial tree. This could lead to inter-endothelial 
cell separation and retraction particularly at the sites where the blood flow is 
modified due to the formation of fatty streaks, as has been found in 
hypercholesterolemic monkeys, swine and humans. 
Repeatedly, epidemiological studies have established a strong association 
between elevated blood cholesterol and CAD. Risk for CAD is increased with 
increasing plasma cholesterol levels and can be decreased by decreasing plasma 
cholesterol. One of the important observational study demonstrating a positive 
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relation between total cholesterol level and CAD mortality was "The Multiple Risk 
Factor Intervention Trial" (Stamler et al., 1986). It was observed that in Japan and 
some other Mediterranean countries, where the dietaiy intake of saturated fat and 
mean plasma cholesterol level was relatively low, the mortality rate for CAD was 
also low. As against this, countries like Finland and United States, with high 
average plasma cholesterol levels showed a higher CAD mortality rate (Keys, 
1970). An important interventional study on primary prevention of CAD was the 
Lipid Research Clinic Coronary Primary Prevention Trial. The 
hypercholesterolemic subjects of this study received either bile acid sequestrant, 
cholestyramine or a placebo (FRCP, 1984a). The cholestyramine group, showed 
significant reductions in LDL-cholesterol. Incidence of non-fatal myocardial 
infarction and CAD death was also reduced significantly (FRCP, 1984b) in this 
group. The results of Fipid Research Clinic Coronaiy Primary Prevention Trial 
provided the first major clinical substantiation to the lipid hypothesis, and were 
also the first to give rise to the rule of thumb that a 1% decrease in total cholesterol 
reduces the incidence of CAD events by 2 to 3%. 
Increased plasma levels of three lipoproteins, FDF (Gordon et al, 1977; 
Castelli et al, 1977), p-VFDF (Mahley, 1979; Brewer et a/., 1983) and Lp(a) (Berg 
et al, 1974; Kostner et al, 1981; Armstrong et al, 1986) and decreased levels of 
HDF (Castelli et al. 1977; Miller et al, 1977; Naito, 1980; Yaari et al, 1981) 
have been associated with the development of premature cardiovascular disease. 
Increased plasma levels of FDF may result from ingestion of excess dietaiy 
saturated fat and cholesterol as well as from primary and secondary 
hyperlipoproteinemias. p-VFDF are abnormal lipoprotein remnant particles 
present in patients with type-Ill hyperlipoproteinemia and animals fed a high 
cholesterol and fat diet (Mahley, 1979; Havel, 1982a; Brewer et al, 1983). p-
VFDF remnant lipoproteins have been proposed to be taken up by macrophages by 
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either the LDL receptor (Koo et al., 1988) or a specific macrophage P-VLDL 
receptor (Venlenter et al., 1983; Baker et al., 1984). Elevated levels of Lp(a) are 
genetically determined and associated with an increased risk of premature 
cardiovascular disease (Berg et al., 1974; Kostner et al.. 1981; Armstrong et al., 
1986). The mechanism for the potential cellular uptake of Lp(a) and the 
development of premature cardiovascular disease is not known. Over the past 30 
years a considerable body of evidence has accumulated to establish that an 
elevated concentration of the Lp(a) lipoprotein, commonly referred to as 
"lipoprotein little a" in plasma is an important independent risk factor for the 
development of premature cardiovascular disease (Berg et al., 1974; Kostner, 
1981; Armstrong et al., 1986). Lp(a) levels in plasma range from less than 1 to 
more than 100 mg/dl. Approximately 20 per cent of the populations have levels 
above 30 mg/dl; this is associated with a twofold increase in the relative risk of 
coronaiy atherosclerosis. With elevations of both Lp(a) and LDL, the relative risk 
of vascular disease increases to approximately fivefold (Armstrong et al., 1986). 
An inverse association has been established between HDL-cholesterol level 
and CAD incidence in numerous epidemiological studies. For example, in the 
Framingham Heart Study, men and women with HDL-cholesterol of 35 mg/dl or 
less had an eight fold increase in CAD incidence compared with men and women 
with HDL-cholesterol of 65 mg/dl or greater (Gordon et al., 1977). Women have 
significantly higher plasma levels of HDL2 than men (James and Pometta, 1990); 
increased levels of these larger, less dense particles may be partially responsible 
for the relative cardioprotection seen in premenopausal women. Each 1 mg/dl 
increase in HDL-cholesterol is estimated to decrease CAD risk 2 per cent in men 
and 3 per cent in women (Gordon et al., 1989). The low HDL in men with 
clinically significant CAD is due to a reduction in both HDL2 and HDL3; however, 
the reduction in HDL2 is greater than that in HDL3 (Miller et al., 1981; Laakso et 
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al, 1985; Wallentin and Sundin. 1985; Hamstcn et al, 1986). These studies 
support the concept that HDLT is a better predictor of coronary artery disease than 
is HDL3 (Drexel et a/.. 1992). The question, however, as to whether quantitation of 
HDL2 as a screening test is superior to total HDL-cholesterol has not been 
definitively ansv.'ered due to \ariabi!it>' in results of the individual reported studies. 
The results of the studies in which apoA-1 was evaluated as a discriminator 
for CAD also do not permit a definitive conclusion to be drawn as to whether 
apoA-I is a better discriminator than HDL-cholesterol. In the majority of patients 
with angiographically documented CAD or survivors of myocardial infarction, 
plasma apoA-1 concentrations were lower than control groups (Brunzell et a!.. 
1984; Miller, 1987; Alauporic et al, 1988). In some studies apoA-1 has been 
shown to be a better discriminator than lipids and lipoprotein cholesterol levels in 
identifying patients with CAD, while in other studies the apoB/apoA-I ratio 
appeared to be an even more powerful predictor than the individual lipoproteins 
(Brunzell et al, 1984; Miller. 1987; Alauporic et a!., 1988). However, in other 
studies HDL-cholesterol was found to be a better predictor than apoA-I (Brunzell 
etal., 1984; Miller, 1987; Alauporic e/o/.. 1988). 
The relation between plasma TAG and CAD is not as well established as 
the relation between plasma cholesterol and CAD.Epidemiological evidence, 
however, suggests that TAG plays an important role in determining CAD risk. In 
Helsinky Heart Study (Manninen et al.. 1992) it was established that the relative 
risk for cardiac events was significantl) more in the subgroup with a higher TAG 
and LDL cholesterol: HDL cholesterol ratio as compared to the subgroup with 
lower TAG and LDL cholesterol: HDL cholesterol ratio. Diabetes is frequently 
associated with hypertriglyceridemia, and is often combined with reduced HDL-
cholesterol (Haward. 1987). Recently, there has been increasing evidence of an 
association between TAG and increased risk of cardiovascular disease (Austin. 
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1991), a risk that is especially high in subjects with low HDL-cholesterol (Castelli, 
1986). One of the major causes of hypertriglyceridemia with low HDL-cholesterol 
in diabetes is the decrease in lipoprotein lipase activity, an enzyme that plays 
crucial role in both TAG removal and HDL-cholesterol production, due to insulin 
deficiency, because lipoprotein lipase is knov/n to be an insulin-dependent enzyme 
(Garfmkel et al, 1976; Murase et a/.. 1981). Elevated levels of plasma apoB and 
LDL cholesterol may be due to dietary excess, genetic hypercholesterolemias or 
other diseases. Approximately 10 per cent of the patients with 
hypercholesterolemia have a monogenic disease causing elevated plasma LDL 
levels. The monogenic disease, familial hypercholesterolemia, is an autosomal 
codominant disease characterized clinically by tendon and tuberous xanthomas, 
arcus, xanthelasma and premature cardiovascular disease (Brown and Goldstein, 
1986). The molecular defect in familial hypercholesterolemia is one of several 
mutations in the gene coding for the LDL receptor (Brown and Goldstein, 1986). 
The deficiency of the LDL receptor leads to a decreased rate of removal of plasma 
LDL. The reduction in the number of LDL receptors has been previously 
demonstrated to be proportional to the elevated levels of plasma LDL (Sprecher et 
al., 1985). The frequency of familial hypercholesterolemia is approximately 1 in 
500 and the heterozygotes and homozygotes have plasma LDL cholesterol levels 
>250 mg/dl and >750 mg/dl, respectively. Plasma apoB levels are usually greater 
than 140 mg/dl. The clinically important complication of familial 
hypercholesterolemia is premature atherosclerosis. In homozygous patients 
coronary and myocardial infarctions are frequent in young adults. For 
heterozygous men, the chance of having a myocardial infarction is approximately 5 
per cent by age of 30, 51 per cent by the age of 50 and 85 per cent by age of 60. 
Familial combined hyperlipidemia is probably the most frequent monogenic 
dyslipoproteinemia (frequency 1 in 300) in the population associated with an 
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increased risk of premature cardiovascular disease (Goldstein et al., 1973; Ross et 
a/., 1973). Clinically the patients may have arcus and xanthelasmas; however, 
tendon xanthomas are rare and this may be used as a diagnostic clue to distinguish 
these patients from patients with familial hypercholesterolemia. Plasma cholesterol 
and TAG levels are generally moderately elevated. A characteristic feature of 
combined hyperlipidemia is that the lipoprotein elevation is variable and may 
change from elevated LDL (phenotype Ha) to VLDL and LDL (phenotype lib) and 
VLDL (phenotype IV). In addition, several different phenotypes may be observed 
in a single family. In contrast to familial hypercholesterolemia, the cholesterol 
levels may not be elevated in childhood and the hyperlipidemia frequently is not 
expressed until after age 30. The molecular defect(s) in combined hyperlipidemia 
has not been elucidated. In the patients studied, the characteristic metabolic defect 
is the over production of apoB-containing lipoproteins (Tenz et al., 1986). The 
LDL present in patients with combined hyperlipidemia is abnormal in hydrated 
density and lipid composition. The "dense LDL" characteristic of combined 
hyperlipidemia has a hydrated density of approximately 1.055 gm/mi and has a 
ratio of LDL cholesterol to LDL apoB of < 1.3 as compared with a normal ratio of 
>1.3 (Sniderman et al., 1980; Krauss et al., 1988; Musliner and Krauss, 1988). The 
LDL apoB level in these patients is usually >120 mg/dl. The presence of "dense 
LDL" may be an important causative factor in the development of atherosclerosis 
observed in these patients. Elevated plasma level occur in type III 
hyperlipoproteinemia and in experimental animals fed diets high in cholesterol and 
saturated fat (Mahley, 1979; Havel, 1982a; Brewer et al., 1983). Epidemiological 
studies have established a correlation between the apoE phenotype and alterations 
in the plasma level of remnant lipoproteins, apoB and LDL cholesterol (Davignan 
etal., 1988). 
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Rabbits have been extensively utilized as an ideal model of atherosclerosis 
because of its size, easy manipulations and extra ordinaiy response to 
atherosclerosis. In mammalian nonprimate models rabbits and hares have been 
known to be best in dietary induction; lipoprotein metabolism (Watanable 
hyperlipoproteinemia strain); dictar>' and drug intervention; immune comiplexcs: 
clonal characteristic of lesion (Shore and Shore 1976). Although rabbit is the first 
and most frequently used animal at all point of atherosclerosis research (Shore and 
Shore 1976). but many investigators have expressed doubts as the usefulness of 
this animal model, because the lesions are result of extreme hyperlipidemic 
conditions. Recently, WHHL rabbit, an excellent model, which can serve as 
counterpart of homozygous familial hypercholesterolemia in humans, has become 
available (Watanabe, 1980; Havel et al, 1982b; Buja et a/., 1983). Hepatic 
cholesterol synthesis is found to be by far the highest in the rat. Whereas in the 
rabbit and man the rate of cholesterol synthesis was 20% and 16%, respectively, in 
comparison to the rat. Similarly, hepatic ACAT activities tend to be high in the rat. 
low in the rabbit and man (Suckling et al., 1986). Historically much of the work 
has used cholesterol fed rabbits, an approach that has received strong criticism 
(Stehbens et al., 1986). Cholesterol feeding in the rabbits leads to massive 
hypercholesterolemia characterized by a high VLDL concentration. In contrast, in 
the WHHL rabbits the hypercholesterolemia is due to increased LDL, as it is in 
many human hypercholesterolemics. However, feeding regimes have been advised 
that are less open to such concerns (Bocan et al., 1991). One of the problems of 
working with fat and cholesterol fed rabbits has been the high variability between 
individual animals, is not fully understood. The animals appear to maintain a low 
intracellular cholesterol flux even when on a high cholesterol diet. One study (La 
Ville et al., 1989), has shown that the HMG-CoA reductase inhibitor, lovastatin. 
can prevent the formation of atherosclerotic lesions in this animal. Some studies 
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have combined interest in atherosclerosis with diabetes, Arbeeny and Bergquist. 
1991, showed that alloxan diabetic rabbits fed on a diet containing casein and 
coconut oil developed hypercholesterolemia, which could be controlled by the 
HMG-CoA reductase inhibitor, provastatin. HMG-CoA reductase inhibitors have 
also been shown to be effecti\ e in controlling hypercholesterolemia in human type 
II diabetics. Rabbits have been widely used as a model for testing hypolipidemic 
and antiatherosclerotic drugs. In the past few years, drugs, some of which are not 
primarily hypolipidemics, have been tested in rabbits for antiatherosclerotic 
activity, for example calcium channel blockers, cholesterylamine and ACAT 
inhibitors (Weinstein and Heider, 1989: Suckling 1989; Subbiah et ai, 1987). 
Finally, report has appeared of a transgenic rabbit containing a human apoA-I on 
antisense gene intended as a model for the genetic direction of atherogenic 
disturbances of lipid metabolism (Perevozchikov et al, 1990). In all the animals 
containing the human gene the lipoprotein profile was shifted to an atherogenic 
phenotype with increase in plasma cholesterol and triglyceride concentration. 
Recent studies in nonhuman primates have demonstrated injury by free 
radicals as another possible mechanism of initiation of atherogenesis, which was 
protected by the antioxidant, probucol (Sasahara et al, 1994). The fact that 
probucol prevents the formation of fatty streaks and suppresses the inflammatoiy 
processes required for lesion development bears evidence to this effect. These 
studies have provided new insights into the role of oxidation and other chemical 
modifications of LDL. such as glycation in the process of atherogenesis. In 
particular, the oxidative modification of LDL enhances its atherogenecit}' 
(Steinberg, 1988; Duthie et ai. 1989: Palinski et al., 1989). The etiology of 
cardiovascular disease is complex and multifactorial, but there is substantial 
evidence that oxidized lipid in the diet play an important role in atherosclerosis 
(Staprans et al. 1998: Rong et al. 1999: Liu et al, 2000). Nearly all natural fats 
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oxidized wiien exposed to air. light, moisture, particularly warm temperature and 
develop an unpleasant odour and taste. This happens due to formation of peroxides 
at the double bonds of the unsaturated fatty acids. Peroxidation of lipids exposed to 
oxygen is responsible not only for deterioration of foods, oils, fats, but also for 
damage to tissues in vivo, where it may be the cause of atherosclerosis, cancer, 
inflammatory diseases and ageing etc. The deleterious effects are initiated by free 
radicals ROO', RO*. OH* produced during peroxide formation from fatty acids 
containing double bonds. Lipid peroxidation is a chain reaction providing a 
continuous supply of free radicals that initiates further peroxidation. Lipid 
peroxidation usually begins with the abstraction of a hydrogen atom from an 
unsaturated fatty acid resulting in the formation of a lipid radical (Poyer and 
Stanley, 1975). The rearrangement of the double bonds results in the formation of 
conjugated dienes. Attack by molecular oxygen produces a lipid peroxy radical. 
which can either abstract a hydrogen atom from an adjacent lipid to form a lipid 
hydroperoxide, or form a lipid endoperoxide. The formation of lipid endoperoxides 
in unsaturated fatty acids containing at least three methylene interrupted double 
bonds can lead to the formation of malondialdehyde as a breakdown product 
(Fig. L5). Microsomes isolated from liver have been shown to catalyze an 
NADPH-dependent peroxidation of endogenous unsaturated fatty acid in the 
presence of ferric ions and metal chelators such as ADP or pyrophosphates. 
Microsomal membranes are particularly susceptible to lipid peroxidation owing to 
the presence of high concentrations of polyunsaturated fatty acids. Poyer and 
McCay (1971). have demonstrated that both microsomal membranes and 
phosphate buffer contain sufllcient contaminating iron to facilitate NADPLI-
dependent microsomal lipid peroxidation. Free radicals are molecule that have lost 
an electron and try to replace by reacting with other molecules. Oxidative damage 
can occur when chemical processes within the body generate free radicals. Some 
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free radicals are highly reactive and can interact and damage functionally 
important molecules such as DNA, lipid membrane constituents, structural proteins 
and impairing our immune system. We are most often subjected to free radicals 
from air pollution, exposure to radiation and toxic chemicals, cigarette smoke, UV 
radiation, fried and burnt foods, food and water contaminants such as pesticides. 
Converting food or stored fats to energy generates free radicals in our body as 
well. Cigarette smoke contains vast amount of free radicals, that is, 10 free 
radicals per inhalation, which can directly or indirectly initiate and propagate the 
process of lipid peroxidation. 
It has been demonstrated earlier that oxidized fatty acids in the diet play a 
significant role in lipoprotein oxidation. In rodents (Staprans et al, 1993a; 
Staprans et al, 1993b; Staprans et al, 1996a) and humans (Staprans et al, 1994), 
oxidized fatty acids in the diet are absorbed by the small intestine and incoiporated 
into chylomicrons. In rodents, oxidized dietary fatty acids are also incorporated 
into the endogenous serum VLDL+LDL fraction (Staprans et al, 1993b). The 
levels of oxidized chylomicrons and VLDL+LDL directly correlated with the 
quantity of oxidized lipids in the diet. Furthermore, Staprans et al. have shown that 
oxidized lipids in the diet are delivered to the liver via chylomicrons, incorporated 
into VLDL, and resecreted into the circulation, thereby providing a mechanism by 
which dietary oxidized lipids can affect the oxidative state of endogeneous 
lipoprotiens (Staprans et al, 1996a). It has been demonstrated that oxidized lipids 
in the diet are atherogenic. Feeding a diet enriched in oxidized fatty acids to 
cholesterol fed rabbits resulted in a significant increase in fatty streak lesions in the 
aorta (Staprans et al., 1996b). Similar to fatt\' acids, cholesterol also undergoes 
free radical-mediated oxidation via hydroperoxide formation, resulting in the 
production of numerous oxygenated derivatives (oxidized cholesterol or 
oxysterols). There is growing evidence that cholesterol oxidation products 
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contribute to the development of atherosclerosis (Smith 1996; Staprans et al., 
1998; Rong et al., 1999). Studies specifically addressing this issue have shown that 
cholesterol oxidation products possess several characteristics that may promote 
atherosclerosis. These include cytotoxic/apoptotic potential to vascular cells such 
as fibrobasts (Sevanian and Peterson, 1986), endothelial cells (Sevanian et a!., 
1991; Sevanian et al., 1995; Palladini et al., 1996), and smooth muscle cells (Peng 
et al., 1979; Hughes et al., 1994; Nishio and Watanabe, 1996); impairment of 
vascular endothelial barrier function (Boissonneault et al., 1991a; Boissonneault et 
al.. 1991b); inhibition of endothelial NO release (Deckert et al., 1998) and arterial 
relaxation (Deckert et al., 1997); inhibition of cholesterol synthesis or utilization 
(Tamasawa et al., 1997; Taylor and Kandutsch,1985); perturbation of intracellular 
cholesterol trafficking (Kilsdonk et al., 1995; Fielding et al., 1997; Gelissen et al., 
1996); and activation of acyl CoA: cholesterol acyltransferase (ACAT) activity 
(Cheng et al., 1995; Brown et al., 1975). Cholesterol oxidation products are 
abundant in oxidatively modified LDL (Hodis et al., 1994) and high levels of 
circulating cholesterol oxidation products are found in rabbits fed a cholesterol 
containing diet (Hodis et al., 1991; Hodis et al., 1992). However, direct evidence 
linking circulating cholesterol oxidation products to early vascular lesion 
formation is only recently becoming available (Mahfouz et al, 1997; Staprans et 
al, 1998; Rong et al, 1999). These results demonstrate that diets containing 
oxidized fatty acids or oxidized cholesterol accelerate atherosclerotic leisons. It is 
well established that due to processing, heating, frying/deep frying or prolonged 
storage, the Indian as well as the Western diet contains large quantities of oxidized 
polyunsaturated fatty acids and oxidized cholesterol, that could constitute a risk 
factor for cardiovascular disease. Oxidized lipoproteins especially oxidized low 
density lipoprotiens have been involved in the pathogenesis of atherosclerosis and 
atherosclerotic lesions contain oxidized LDL (Steinberg et al, 1989; Witztum and 
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Steinberg, 1991; Esterbauer et al, 1992; Yla-Herttuala et al., 1989). The oxidation 
of LDL can be mediated by various cell types (Witztum and Steinberg, 1991; 
Esterbauer et al., 1992). Recently. Liu et al. (2000), have demonstrated that not 
only LDL but also VLDL and HDL were oxidatively modified in vivo in the 
patients with endogenous hypertriglyceridemia and in the rabbits fed with a high 
cholesterol diet. According to oxidative modification hypothesis, LDL initially 
accumulates in the extracellular subendothelial space of arteries and, through the 
action of resident vascular cells, is mildly oxidized to a form known as minimally 
modified LDL (Navab et al., 1996). This minimally modified LDL induces local 
vascular cells to produce monocyte chemotactic protein 1 and granulocyte and 
macrophage colony stimulating iactors. which stimulate monocyte recruitment and 
differentiation to macrophages in arterial walls (Parhami et al., 1993). The 
accumulating monocytes and macrophages stimulate further peroxidation of LDL 
(Fig. 1.6). The products of this reaction make the protien component of LDL 
(apolipoprotein B-lOO) more negatively charged. By virtue of its increased 
negative charge, this completely oxidized LDL is recognized by scavanger 
receptors on macrophages and internalized to form so called foam cells (Henriksen 
et al., 1981). In contrast to the uptake of unoxidized (native) LDL by the LDL 
receptor on macrophages, the uptake of oxidized LDL by the scavenger receptor 
pathway is not subject to negative feedback regulation and thus results in massive 
uptake of cholesterol (from oxidized LDL) by the macrophages. 
In addition to promoting the formation of foam cells, oxidized LDL has 
direct chemotactic activit}' for monocytes (Quinn et al., 1988), and stimulates the 
binding of monocytes to the endothelium (Frostegard et al., 1991). Once 
monocytes cross the endothelial layer, they become trapped in the subendothelial 
space, partly because oxidized LDL inhibits their egress from the arterial wall 
(Quinn et al., 1987). Oxidized LDL is also C}totoxic to vascular cells (Schwartz et 
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Fig. 1.6. Early events in atherogenesis 
(Adapted from The New England Journal of Medicine 1997, Vol.337, p.410) 
al, 1991; Cathcart et al, 1985), thus promoting the release of lipids and lysosomal 
enzymes into the intimal extracellular space and enhancing the progression of 
atherosclerotic lesions (Schwartz et al., 1991). The oxidative modification 
hypothesis is supported by evidence that LDL oxidation occurs in vivo and 
contributes to the clinical menifestations of atherosclerosis. Antibodies raised 
against oxidized LDL react with atherosclerotic lesions, but not with normal 
arterial segments (Palinski et al., 1989). LDL extracted from human 
atherosclerotic lesions, but not plasma-derived LDL. resembles LDL that has been 
oxidativeiy modified in vitro (Yla-Herttuala et al., 1989). Patients with carotid 
atherosclerosis have higher levels of autoantibodies to oxidized LDL than do age 
matched normal subjects (Salonen et a/., 1992). Plasma concentrations of 
immunoreactive oxidized LDL are higher in patients with acute myocardial 
infarction than in normal subjects (Holvoet et al., 1995). Thus, oxidative 
modification of LDL appears to have an important role in foam cell formation and 
atherogenesis (Fig. 1.6). This link between the oxidation of LDL and atherogenesis 
provides a convenient and simple rationale for the beneficial effect of antioxidants 
on the incidence of coronaiy artery disease. A number of clinical studies and 
studies in animals have explored this link between LDL oxidation and 
atherogenesis. Several studies have investigated the ability of various antioxidant 
compounds to prevent atherogenesis in animals. Probucol is a lipid soluble 
cholesterol lowering drug with potent antioxidant properties (Reaven et al., 1992). 
When fed to WHHL rabbits, it inhibits the formation of atherosclerotic lesions 
independently of its cholesterol lowering properties (Carew et al., 1987), and LDL 
derived from rabbits given probucol is more resistant to oxidation than LDL from 
control rabbits (Kita et al., 1987). These results support the concept that the 
antiatherogenic effect of probucol involves an antioxidant mechanism. Probucol 
also reduces the formation of atherosclerotic lesions in cholesterol fed monkeys. 
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and there is an inverse relation between the ibrmation of lesions and the resistance 
of isolated LDL to oxidation (Sasahara et al.. 1994). Similarly, cholesterol fed 
rabbits treated with N. N^-diphenyl-phenylenediamine, a synthetic antioxidant that 
is structurally distinct from probucol. have less atherosclerosis and LDL that is 
more resistant to oxidation than do untreated rabbits (Sparrow et a!., 1992). 
Vitamin E reduces atherosclerosis in WHHL rabbits (Williams et al., 1992) and in 
cholesterol fed hamster (Parker et al., 1995), although in WHHL rabbits this effect 
is confounded by a reduction in serum cholesterol concentrations (Williams et al., 
1992). Thus, a number of studies in animals have demonstrated that antioxidants 
inhibit the development of atherosclerosis, and in many of these studies, 
antioxidant treatment enhanced the resistance of LDL to oxidation. This 
association between reduced atherosclerosis and increased resistance of LDL to 
oxidation provides support for the oxidative modification hypothesis of 
atherosclerosis. Many clinical studies have investigated the effect of antioxidative 
supplementation in humans on LDL oxidation ex vivo (Keaney and Frei, 1994a). 
The administration of lipid soluble antioxidants such as a- tocopherol (Reaven et 
al., 1993) or probucol (Reaven et al., 1992) is associated with their incorporation 
into LDL and concomitant increase in the resistance of LDL to oxidative 
modification. In contrast, supplementation of p-carotene does not protect LDL 
from oxidation, despite its occumulation within the particle (Reaven et al., 1993; 
Gaziano et al., 1995). Even though a-tocopherol has been labelled as the most 
efficient chain breaking antioxidant, tocotrienols are known to be more potent 
antioxidant, than tocopherols (Kamat et al., 1997). Tocotrienols have been shown 
to have greater free radical scavanging properties as cell membrane constituents 
than tocopherols (Serbinova et al., 1991). Tomeo et al.(\995), reported that 
tocotrienols significantly decreased plasma lipid peroxidation in patients with 
hyperlipidemia and carotid atherosclerosis with no change in their lipid and 
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lipoprotein parameters. Ascorbic acid (vitamin C) also protects LDL against 
oxidation but is not incorporated into LDL, because it is water soluble (Retsky et 
al, 1993). In the majority of studies linking antioxidants with decreased 
atherosclerosis, the atherogenic diet and antioxidant therapy were introduced 
simultanously (Sasahara et al., 1994: Sparrow et a!., 1992; Williams et al, 1992), 
or at a very early stage (Carew et al., 1987, Kita et al, 1987). Such studies focus 
on the initiating events in atherogenesis, and the decrease in LDL oxidation by 
antioxidants could explain the reduction in early formation of foam cells and 
plaque. Although in humans supplementation with lipid soluble antioxidants 
protects LDL against ex vivo oxidation (Keaney and Frie, 1994a), prevention of the 
initiating events in atherosclerosis may not be the principal mechanism responsible 
for reduction in the clinical manifestations of atherosclerosis that has been linked 
to higher antioxidant intake (Fig. 1.7). 
Oxidized LDL is toxic to vascular cells (Morel et ai, 1983), and the 
cytotoxic potency of oxidized LDL has been linked to its content of lipid 
peroxidation products (Morel et al., 1983; Hughes et al., 1994). Inhibiting LDL 
oxidation should therefore decrease the cytotoxicity of LDL in arterial walls. In 
fact, oral supplementation with a-tocopherol increases the resistance of LDL to 
oxidation and lowers the cytotoxicity of this oxidized LDL toward endothelial cells 
(Belcher et al., 1993). Endothelial denudation induced by oxidized LDL may also 
be an important trigger of coronary thrombosis and acute coronaiy events (Faster 
et al., 1992). suggesting that improved resistance of LDL to oxidation will limit 
the oxidized LDL-mediated cytotoxicity that contributes to instability of lesions, 
rupture of plaques, and coronary thrombosis events. In the presence of 
oxidized LDL, the physiologic action of nitric oxide is impaired, which might 
contribute to plalelet adhesion and vasospasm that are involved in the pathogenesis 
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(Adapted from The New England Journal of Medicine. 1997.Vol. 337, p.414) 
of acute coronai-y syndromes (Levine et ai, 1995). Enhanced protection of LDL 
against oxidation is associated with a number of vascular effects that would be 
expected to reduce the clinical activity of coronaiy arteiy disease: reduced plaque 
rupture, platelet adhesion, and vasospasm (Fig. 1.7). In addition to improving the 
nitric oxide action by reducing the oxidation of LDL, antioxidants are beneficial to 
vascular function through other mechanisms. Cholesterol fed rabbits has reduced 
endothelium derived nitric oxide-mediated vascular relaxation. This reduction can 
be prevented by the administration of a-tocopherol (Keaney et al., 1993; 
Andersson et al., 1994; Steward-Lee et al.. 1994), p-carotene (Keaney et al., 
1993), or probucol (Keaney et al., 1995; Simon et al., 1993). One simple 
explanation for these observations would be that LDL oxidation is prevented in 
vivo. The aforementioned effects of antioxidants on vascular function (Keaney et 
al, 1993; Keaney et al., 1994; Keaney et al., 1995; Simon et al., 1993; Andersson 
et al., 1994; Steward-Lee et al., 1994) are most likely related to the presence of 
these compounds in the vascular wall, where they are known to accumulate. 
Monocytes and macrophages in atherosclerotic lesions express matrix 
metalloproteinases that degrade components of extracellular matrix (Galis et al., 
1995), thus weakening atherosclerotic plaques and increasing the likelihood of 
plaque rupture. Upto 98% of patients with acute coronary thrombosis have a 
thrombus in the arterial lumen in direct communication with macrophage rich 
regions of plaque (Friedman and Bovenkamp, 1966). The recruitment of 
monocytes and macrophages into these regions is regulated, in part, by endothelial 
cells through the selective expression of specific cellular adhesion molecules 
(Collins, 1993). Similarly, monocytes derived from subjects treated with a-
tocopherol adhere to activate endothelium to a lesser extent than do monocytes 
from normal subjects (Devaraj et al.. 1996). These data support the concept that 
direct cellular action of a-tocopherol has a role in inhibiting the adhesion of 
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monocytes to endothelium and in promoting plaque stability. The cellular content 
of antioxidants is an important determinant of cellular injury from oxidized LDL. 
Endothelial cells and macrophages exposed to oxidized LDL rapidly become 
necrotic (Kuzuya et al, 1991; Reid and Mitchinson, 1993). In contrast, endothelial 
cells and macrophages loaded with a-tocophero! or probuco! arc resistant to the 
cytotoxic effects of oxidized LDL (Kuzuya et al, 1991). Thus, cellular antioxidant 
status is an important determinant of the extent of cell injury resulting from 
oxidized LDL that contributes to plaque instability (Fig. 1.7). Platelets have an 
important role in the pathogenesis of atherosclerosis and coronary thrombosis 
(Schwartz et al, 1991). and there is now convincing evidences that supplemental 
concentrations of a-tocopherol inhibit plaletlet function. The administration of 
400 to 1200 lU of a-tocopherol per day for two weeks to normal subjects was 
associated with a marked reduction in the sensitivity of platelets to activation by 
platelet agonists such as arachidonic acid and phorbol ester (Freedman et al, 
1996). This effect of a-tocopherol is related to inhibition of protein kinase C 
stimulation rather than to its antioxidant activity (Freedman et al, 1996). Similarly, 
the inhibition of protein kinase C stimulation by a-tocopherol also prevents the 
proliferation of smooth muscles cells (Boscoboinik et al, 1991). Smooth muscle 
proliferation is a major component of restenosis after coronaiy artery balloon 
angioplasty, and recent evidence indicates that vascular antioxidant content may 
modulate this process. These results support the view that incorporation into 
tissues may be important in the therapeutic action of antioxidant. 
As humans evolved to use oxidative metabolism, many mechanisms have 
been developed to control this process and minimize random free radical 
oxidation. Firstl}'. oxidaii\e metabolism is compartmentalized for example, in the 
mitochondria. Secondly, molecular oxxgen and its reactive free radical species are 
tightly bound to enzymes, as in case of the cytochrome systems during oxidative 
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phosphorylation. Thirdly, in order to prevent Iree radical formation, transition 
metals like copper and iron, which in the free form catalyze free radical formation, 
are tightly bound to transport and storage proteins. Fourthly, several enzymes exist 
within the cells to neutralize free radicals. Superoxide dismutase catalyses the 
transformation of superoxide radicals to hydrogen peroxides. Similarly, catalase 
and glutathione dismutase neutralize hydrogen peroxide and fatty acid radicals. 
Finally, damage caused by oxidation can be repaired by specific enzymes. 
If, however, inspite of the availability of all the above mentioned protective 
mechanisms against oxidative damage, due to any reason, the free radical 
peroxidation of LDL lipids occurs, it results in numerous structural changes, ail 
depending on a common initiating event i.e.. peroxidation of polyunsaturated fatty 
acids on LDL (Jurjens et ai, 1987; Steinbrecher et a/., 1990). Also, all the major 
cells of arterial wall (endothelial cells, macrophages, smooth muscle cells) can 
oxidatively modify LDL. Both forms of oxidized LDL are taken up more avidly by 
the macrophages than the LDL itself and this aviditiy appear to be facilitated by 
scavenger receptor mechanism (.lurjens et al., 1987; Steinbrecher et ai, 1990). The 
biological effects of oxidized LDL reported to date could contribute to initiation 
and progression of atherosclerotic process. Oxidized and partially oxidized LDL 
itself or the oxidized products derived from it can have a number of deleterious 
effects, including chemotaxis for monoc)4es (Qureshi et al., 1991a), inhibition of 
nitric oxide mediated relaxation of coronary tone (Schaefer et ai, 1985). To 
summarize, recognition of uncontrolled uptake of oxidized LDL by macrophages 
leads to a chain of biochemical events, which can result in the formation of foam 
cells, fatty streaks and later atherosclerosis. 
Pharmacological control over cholesterol biosynthesis has long been sought 
as a means for regulating the amount of cholesterol in the blood and for the 
prevention and treatment of atherosclerosis (Kolata, 1983). Probucol has been 
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reported to effectively reduce plasma cholesterol in human and a number of animal 
species (Miettinen and Toinonen. 1975; Martz. 1979; Sunson et al, 1981). It also 
affects the composition and in vitro catabolism of LDL in Type Ha 
hypercholesterolemia (Baudet ef al.. 1986). It increases the activity of plasma 
lipoprotein lipase and decrease HDL- and LDL-cholesterol concentration in rats. 
Probucol prevents the de\elopment of macrophages into foam cells by inhibiting 
the lipid storage in macrophages (Yamamoto et al., 1986a). These observations 
probably accounts for the clinical findings that probucol causes a more marked 
regression of xanthomas than would be expected from the of lowering of LDL-
cholesterol levels alone. Probucol seems to act by increasing LDL removal from 
the plasma by an LDL receptor independent mechanism (Kasaniemi and Grundy, 
1984), as it causes moderate reduction in LDL-cholesterol in non-familial 
hypercholesterolemia (Sunson et al., 1981) and a smaller decrease in familial 
hypercholesterolemic patients (Durrington and Miller, 1985; Fellin, 1986). A 
marked decrease in cholesterol has been constant finding (Kasaniemi and Grundy, 
1984; Fellin. 1986) but circulating HDL-cholesterol in probucol treated patients is 
less than in controls (Yamamoto et al., 1986b), which minimizes the use of 
probucol as a hypocholesterolemic agent. 
Fibrates are orally active compounds with relative long plasma half life. 
Among fibrates, clofibrates, with combined maximal effectiveness and minimal 
toxicity in the initial screen, were widely used in the management of 
hyperlipoproteinemia in humans. More recently, however, due to questionable 
activity in the secondaiy prevention of atherosclerosis (Coronary Drug Project, 
1975) and to the observation of untoward effects in primary prevention 
(Committee of Principal Investigators, 1978), the use of clofibrates has become 
limited. Among side effects, proliferation of peroxisomes in rodents has been a key 
target for chemical and pharmacological studies. A number of clinical trials have 
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constantly shown that clotlbrate reduces plasma TAG levels substantially, 
affecting both VLDL and LDL associated TAG. This reduction is more evident in 
hypertriglyceridemic patients but less marked in normotriglyceridemic subjects 
(Hunninghake et ai, 1981; Grouse and Grundy, 1981). 
Halofenate, structurally related to ciotTbrate, is hypolipidemic and 
hypourecemic (Sirtory et al., 1972) and is effective in lowering serum TAG in rats 
(Kovanen et al., 1981). Bezafibrate, a fibric acid derivative, has been reported to 
lower plasma TAG in hypertriglyceridemic patients (Eisenberg et al., 1984b) and 
was effective in reversing most if not all, of the abnormalities in lipoprotein 
compositions, structure and function detected in these patients. Fenofibrate, 
another analogue, is more potent than the previously described compounds, being 
fully active at a daily dose of 300 mg (Rossner and Oro, 1981). It is markedly 
effective in patients with type II and IV hyperlipidemias (Franceschini et ai, 1985) 
as well as in subjects with familial combined hyperlipidemia (Weisweiler et al., 
1984) in decreasing total plasma cholesterol and TAG levels. However, HDL-
cholesterol levels were unchanged in t}'pe II and combined hyperlipidemia 
(Malmendier and Delcroise, 1985). The mechanism of hypolipidemic effect of 
fenofibrate is different from that of parent compound involving its effect on 
lipoproteins as seen in subjects with familial hypercholesterolemia as well as 
combined hyperlipidemia. 
Nicotinic acid is possibly the oldest lipid lowering drug. Large doses of this 
drug rapidly reduce plasma TAG by lowering VLDL in normal and sucrose diet 
fed mice (Oliver et al., 1988). The reduction in TAG was reported to be due to 
decreased production of VLDL (Grundy et al., 1981). To overcome the difficulty 
of obtaining adequate compliance with nicotinic acid treatment, because of drug's 
numerous side effects, several analogues and derivatives have been tested but no 
clear advantages have been gained over the parent drug (Cretaldi et al.. 1988). 
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An alternate approach to the control of cholesterol level is the use of bile 
sequestrant resin, such as cholestyramine. The mode of action of bile acid binding 
resin is apparently fairly simple: bile acids, which are bound to these resins in the 
intestinal lumen, are not reabsorbed, and are excreted with faeces. These 
sequestrant agents thus interfere with the enterohepatic circulation of bile acids, 
and since bile acids are synthesized in the liver from cholesterol, cholesterol 
catabolism is enhanced. After prolonged treatment hypocholesterolemia is 
observed. Homozygous type II patients are insensitive to cholestyramine inspite of 
increased level of faecal bile acids (Moutafis et al, 1971). The LDL pathway 
receptor plays a role in the action of bile acid binding resin (Shepherd et a/., 1980). 
An encouraging development in the treatment of hypercholesterolemia has 
been the introduction of a new class of fungal derived compounds that are potent 
competitive inhibitors of HMG-CoA reductase. These drugs are extremely 
effective in lowering plasma concentrations of LDL-cholesterol. The development 
of these specific inhibitors of HMG-CoA reductase has considerably widened the 
therapeutic opportunities in hypercholesterolemic patients. Compactin and 
lovastatin (mevinolin) are potent competitive inhibitors of HMG-CoA reductase. 
The molecular structures closely resemble the HMG moiety of HMG-CoA, and the 
enzyme HMG-CoA reductase binds both the compounds with high affinity 
(Paolletti and Poli, 1987). These drugs have been used to reduce plasma 
cholesterol levels in many animal species (Alberts et ai, 1980; Kovanen et al., 
1981; Tobert et al., 1982). In clinical studies, lovastatin and compactin effectively 
reduce plasma LDL in normal (Tobert et ai, 1982) as well as in subjects with 
heterozygous familial hypercholesterolemia (Bilheimer et al., 1983). A 
compensatory increase in the receptor mediated catabolism of LDL also occurs 
(Grundy and Bilheimer. 1984). In patients with type Ha and type lib 
hypercholesterolemia, reduction in serum cholesterol was reported after lovastatin 
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treatment. Goldstein and Brown (1984a) proposed that statins (compactin. 
lovastatin and simvastatin) lower plasma LDL cholesterol by inhibiting cholesterol 
biosynthesis and increasing the number of LDL receptors. Although an increase in 
HDL levels has also been reported in several studies (Hoeg et ai, 1986; Mol et al. 
1988), others (Mabuchi et a!., 1981; Iliingworth and Sextan, 1984) have found no 
change in HDL levels. 
The mechanism of action of lovastatin differs from that of probucol (Helve 
and Tikkanen, 1988). Lovastatin therapy resulted in the increase of both HDL and 
HDL2-cholesterol whereas with probucol HDL-cholesterol was markedly 
decreased mainly because of reduction in HDL2. Triacylglycerols remain unaltered 
during lovastatin treatment and no significant changes in lipase activity were 
observed indicating that these enzymes were not involved in its action. Recently, 
other forms of statins such as atorvastatin, pravastatin and fluvastatin have been 
introduced in the market as lipid lowering drugs. Out of these statins, including 
lovastatin and simvastatin, atorvastatin is most effective as a lipid lowering agent. 
Daily intake of 10 to 80 mg of atorvastatin by patients with primary 
hypercholesterolemia (heterozygous familial and nonfamilial) and mixed 
dyslipidemia was associated with a 39-60% decline of plasma LDL-C and 19-37% 
in TG levels. HDL-C level was increased by 5-9 %. However, all the statins known 
to exhibit host of side effects (Assmann etal, 1998; Haffner, 1998). 
3-Hydroxy-3-methylglutaric acid (HMG), which is formed by the 
hydrolysis of HMG-CoA catalysed by HMG-CoA hydrolase in liver, is also known 
to inhibit cholesterogenesis between HMG-CoA and mevalonate (Rabinowitz and 
Gurin, 1954) and competitively inhibit the enzyme HMG-CoA reductase 
(Fimognari and Rodwell, 1965). The hypolipidemic activity of HMG has been 
studied in rats (Yusufzai and Siddiqui, 1976a, 1977; Francesconi et al, 1987). 
rabbits (Lupien et al., 1973). hamster (Padova et a!., 1982) and humans (Lupien et 
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ai, 1973; Yusufzai and Siddiqui. 1976b). A support to the hypolipidemic action of 
HMG is also obtained from the observation that low incidence of CHD in Massai 
tribesman is related to their high consumption of cow's milk (Richardson, 1978), 
known to contain HMG (Man, 1977). 
Inhibitors of HMG-CoA reductase block synthesis of cholesterol in the 
liver, thereby triggering compensatory reactions that lead to a reduction in plasma 
LDL. Much of the information about the mechanism for this reduction comes from 
studies in cell culture and in experimental animals (Groot et a/., 1992). Cultured 
human fibroblasts respond to an inhibition of HMG-CoA reductase by 
accumulating increased amounts of the enzyme (Brown et al., 1978). The increase 
is attributable to an increase in the rate of transcription of the HMG-CoA reductase 
gene, an increase in the rate of translation of the mRNA, and a decrease in the rate 
of degradation of the protein. Through these compensator mechanisms, cultured 
cells can increase the amount of HMG-CoA reductase sufficiently to restore rates 
of cholesterol synthesis almost to normal, even in the presence of relatively high 
concentrations of the inhibitor. An increase in HMG-CoA reductase also occurs in 
the livers of rabbits, hamsters, and rats (Endo et al., 1979; Tanaka et ai, 1982) 
treated with these inhibitors. A similar adaptation is presumed to occur in humans. 
Hamster has been reported to respond to hypocholesterolemic drugs (Suckling et 
al.. 1991) and develop atherosclerosis under appropriate conditions (Nistor et al, 
1987; Sima et al., 1990), although differences between the hamster and man, 
which hamper the use of this species as a model for human atherosclerosis, have 
been noted (Nikkari et al., 1991). Rats also respond to hypocholesterolemic drugs 
but in a different way to hamsters. Rats are very capable of modulating their 
hepatic cholesterol synthesis and this is the first response to drugs such as bile acid 
sequeslrants and HMG-CoA reductase inhibitors. However, hyperlipidemia can be 
induced and in some cases this can lead to atherosclerosis (Russell et ai, 1990; 
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Vance and Russell. 1990; Russell et al.. 1991). Inhibition of mevalonate and 
cholesterol synthesis by inhibitors of HMG-CoA reductase such as mevastatin and 
lovastatin prevents farnesylation and blocks cells growth (Maltese and Robishaw, 
1990). It has been postulated that inhibitors of HMG-CoA reductase such as 
lovastatin used in the treatment of hypercholesterolemia, may also be useful for 
cancer chemotherapy (Schafer et al., 1989). HMG-CoA reductase inhibitors and/or 
inhibitors of Ras farnesyl protein transferase could prevent farnesylation of Ras 
proteins, inhibiting the growth of Ras-dependent tumour cells (Goldstein and 
Brown, 1990). Lovastatin and sodium phenylacetate, an inhibitor of isopentenyl 
pyrophosphate synthesis is in clinical trials for the treatment of malignant gliomas 
{Shack etal.. 1994). 
One of the areas, which have attracted a great deal of attention, is 
antioxidant nutrition in the control of degenerative diseases such as atherosclerosis 
and cancer (Ames, 1983; Ong and Packer, 1992). Peroxidation of the cellular 
membrane lipids is a basic reaction, which results in the deterioration of 
unsaturated fatty acids in the membrane. This process has been implicated in 
several human diseases and in the toxicit}' of xenobiotics (Yagi, 1982; Halliwell 
and Gutteridge, 1989; Sies, 1991). If lipid peroxidation is triggered, it can 
inactivate cellular components and its products can have serious consequences on 
almost all the crucial molecules leading to diseased conditions (Halliwell and 
Gutteridge, 1989; Sies, 1991). The peroxidation products can also cause the 
formation of 8-hydroxydeoxyguanosine whose presence in the genetic material can 
lead to mutagenesis and carcinogenesis (Kuchino et al., 1987; Park and Floyd, 
1992). The susceptibility of tissues to lipid peroxidation is influenced by the lipid 
and antioxidant composition of cellular membranes, which in turn may be 
controlled, by dietary composition (Clegg, 1973; Manorama and Rukmini, 1992). 
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The greater stability of \egetable oils versus animal fats under oxidative 
conditions is known to be due to the higher levels of natural antioxidants in the 
oils. An important and commonly occurring class of natural antioxidants in 
vegetable oils is tocopherols (f) of vitamin E family. There are 8 naturally 
occurring forms of vitamin E: a-. (3-, y-, 5-tocopherols and tocotrienols (T,). 
Tocotrienols are minor plant constituents especially abundant in cereal grains 
(such as barley, oat, wheat and r}e). rice bran, palm oil and latex (Kasparek, 
1980b). The vitamin E antioxidant property reflects the similarity in chemical 
structures of T and T3, which differ only in possessing a farnesyl or unsaturated 
phytyl side chain, respectively (Kasparek, 1980a) (Fig. 1.8). Tocopherols 
predominate in certain oils such as corn oil, soyabean oil and olive oil. Whereas, 
the T3 series predominates in rice bran oil (RBO), palm oil and barley oil. Small 
amounts of T3 are found in carrots, sweetcorn and germ oils (Shin and Godber, 
1994). Several lines of research ha\e established that populations, which consume 
large amounts of cereal grain and vegetable oils tend to have a lower incidence of 
cardiovascular disease (Sacks et al. 1975; Burstem et al, 1978; Gould et ai, 
1980). Furthermore, studies on cereal grains demonstrated that barley is 
particularly effective in lowering lipid levels in animal models (Qureshi et al, 
1980 a, b & c). The ability of barley extracts to lower lipids in vivo led to 
the purification and identification of biologically active compound tocotrienols 
(Qureshi et al, 1986). There are scattered reports that neither rice bran nor 
RBO lowered cholesterol levels. These findings may be explained by reports 
that some, but not all. rice cultivars contain tocotrienols, which exert a 
powerful hypocholesterolemic action (Qureshi et al, 1986; Qureshi et al, 1989). 
Qureshi et al (1986) have demonstrated the hypocholesterolemic effect of 
tocotrienols isolated from barle\'. oats, rice bran and palm oil in various animal 
models. Anticholesterol impact of tocotrienols has also been demonstrated in 
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Fig. 1.8. Structures of tocotrienois and tocopherols 
hypercholesterolemic subjects (Qurcshi el a/., 1995). Out of a-. (3-, y- and 5-1^,7 
and 5-T3 have been found to be most potent in terms of their HMG-CoA reductase 
inhibition as well as cholesterol lowering effects. The efficiency of 
hypocholesterolemic action as well as the degree of inhibition of HMG-CoA 
reductase activity mediated by a-T3 was substantially lower than y and 6- T3 
(Pearce ef al, 1992). p-form of T3 failed to exhibit any anticholesterol activity. 
Rice bran oil is the richest source of T3. whereas corn, groundnut, mustard, 
soyabean and coconut oils and butter fat contain only T, which have no lipid 
lowering effect. The T3 are highly effective in lowering total blood cholesterol and 
LDL-cholesterol apparently by reducing the HMG-CoA reductase activity. The T 
on the other hand does not inhibit cholesterol synthesis and thus do not lower 
serum cholesterol. A dose dependent effect of tocotrienol rich fraction (TRF) 
isolated from palm oil was observed for lowering the serum cholesterol and LDL-
cholesterol in normolipidemic and hypercholesterolemic swine, quail and chicken 
(Pearce etal., 1992; Qureshi and Qureshi. 1993). 
In several respects T3 appear to operate in similar manner to oxysterols. 
Certain oxysterols have been shown to regulate cholesterol biosynthesis by 
transcriptional down-regulation of reductase gene (Kandutsch et al, 1978; 
Schroepfer et al, 1979; Schroepfer et a/., 1981; Schroepfer et al, 1982; Miller et 
al, 1982). It has been postulated that endogenously produced oxysterols are 
natural regulators of cholesterol biosynthesis. These oxysterols are potent 
repressors of HMG-CoA reductase and bind strongly to cytosolic oxysterol binding 
protein (Spencer et al. 1985: Saucier et al, 1985). Since oxysterols, are natural 
regulators of cholesterol biosynthesis and act by suppressing HMG-CoA reductase 
gene, the T3 may have a similar function, but it acts at post-transcriptional level as 
has been experimentally demonstrated in HepG2 cells (Parker et al, 1993).The 
human hepatoma HepG2 cell culture model was employed to compare the intrinsic 
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activities of T3. In HepG2 ceils, inliibition of sterol synthesis correlates with rapid 
suppression of HMG-CoA reductase when incubated with T3. The recemic 
synthetic tocotrienols exhibit comparable biological activity to the natural 
tocotrienols in the cholesterol suppression activity. Gamma-Tocotrienol has been 
shown to mediate the suppression of enzymatic activity and protein mass of IIMG-
CoA reductase in HepG2 cells, through decreased synthesis (57% of control) and 
enhanced degradation (2.4 fold versus control) of the enzyme (Parker et ai, 1993). 
Thus, tocotrienols influence the mexalonate pathway in mammalian cells in vitro, 
by post-transcriptional suppression of HMG-CoA reductase, and appear to 
specifically modulate the intracellular mechanism for controlled degradation of the 
reductase protein (Parker et al. 1993). These activities of tocotrienols in HepG2 
cells mirror the actions of the putati\e nonsterol feedback regulators derived from 
mevalonate in cultured cells (Goldstein and Brown, 1990). hi contrast to the 
effects of 25-hydroxycholesterol. T3 does not suppress LDL receptor protein in 
HepG2 cell membranes as demonstrated by western blotting. 
Our laboratoiy has previously reported that feeding of TRF or purified TRF, 
isolated from refined edible grade RBO, to normal rats for two weeks was 
associated with a significant decline in plasma TG, TC, LDL-C, including apoB 
levels. HDL3-C, which is considered as strong predictor of the presence and extent 
of CAD was significantly increased in TRF, treated normolipidemic rats. TRF 
feeding to rats along with an atherogenic diet for three weeks significantly 
prevented the rise in plasma TG. TC. LDL-C, apoB, HDL-C, apoA-1 and HDL3-C 
levels in comparison to rats fed atherogenic diet alone. Five and seven days after 
the withdrawal of atherogenic diet, plasma and lipoprotein lipid levels including 
apoB and apoA-1 were reduced. Treatment of hyperlipidemic rats with purified 
TRF resulted in a further significant reduction in the above parameters indicating 
the efficacy of TRF in the treatment of experimental hyperlipidemia. The 
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minimum dose of TRF or puiitled TRF required lo exert the maximum 
iiypolipidemic effect in normolipidemic and hyperlipidemic rats has been found to 
be 8 mg TRF or 5.2 mg puriiled TtlF/day/Kg body weight. It has also been 
demonstrated that cholesterol lowering property of tocotrienols in normolipidemic 
and hyperlipidemic rats is due to suppression of enzymatic activity and protein 
mass of HMG-CoA reductase. (Minhajuddin, Ph.D. thesis, 1999; Minhajuddin et 
a/., 1999). Administration of TRF enriched with tocotrienols and tocopherols, 
resulted in a significant decline in microsomal lipid peroxidation (TBARS) and 
plasma LDL oxidation (conjugated dienes) in normolipidemic as well as in 
response to oxidative stress, evoked in experimental hyperlipidemia in rats 
(Minhajuddin et al, 1999). Our results also demonstrate a differential 
hypolipidemic impact of purified TRF isolated from four cultivars of rice, raw 
Basmati. Saket-4, Sarju-52. and Mansuri, due to the difference in their y- and 5-T3 
content, in hyperlipidemic rats. Based on total content of y- and 5 -T3 present in 
the purified TRF of each cultivar. hypolipidemic efficacies at an equivalent dose of 
3 and 6 mg TRF/day/Kg body weight (calculated on the basis of combined content 
of y- and 5 -T3 present in 3 and 6 mg of TRF) caused a dose-dependent decline in 
plasma and lipoprotein lipids including apoB, HMG-CoA reductase activity and 
it's protein mass, formation of TBARS and conjugated dienes of plasma LDL (Beg 
et al, 2000a ; Beg et al, 2000b) 
Our laboratory has also demonstrated a long-term therapy of a FH patient 
with severe xanthomas. Treatment at a dose of 8 mg TRF/day/Kg body weight for 
20 weeks caused a significant reduction in plasma TG, TC, LDL-C, and apoB 
levels with a substantial increase in the levels of HDL-C, HDL2-C and apoA-1. 
TRF also caused a substantial improvement in the ratios of LDL-C/HDL-C, 
apoB/apoA-1 and HDL-C/TC. indicating the normalization of lipid parameters. 
Consistent with reduction in lipid parameters, after TRF treatment rapid growth of 
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skin xanthomas was arrested. In addition, a significant regression of xantliomas on 
buttocks extending to thigiis, elbows and knee was observed (Beg et a/., 1997; 
Minhajuddin, PhD Thesis, 1999). 
Based on strong hypochoiesteroleniic and antioxidant properties of 
tocotrienois. our laboratory has also investigated antitumour activity of tocotrienols 
in experimental carcinogenesis of mammary gland and liver. The carcinogen, 7,12-
dimethylbenz (a) anthracene (DMBA), which is known to induce both mammaiy 
carcinogenesis and hypercholesterolemia in rats, was utilized. As expected, six 
months after administration of DMBA. a significant increase in plasma TG, TC, 
LDL-C. including apoB. HMG-CoA reductase activity, microsomal lipid peroxides 
(TBARS). conjugated dienes of LDL oxidation, plasma, liver and mammary gland 
alkaline phosphatase and glutathione-S-transferase levels. DMBA treatment also 
resulted in the formation of neoplastic nodules as multiple tumours on mammaiy 
glands and greyish white patches on the livers of rats. Feeding of TRF to rats, 
during pre-and post-intiation stages, was associated with a significant decline in 
the above parameters. In addition, examination of gross morphology and histology 
suggested that dietaiy TRF did offer a significant protection and did reduce the 
severity and extent of neoplastic transformation during both initiation and/or 
promotion in both mammary glands and livers of carcinogenic rats. TRF treatment, 
in addition to its anticancer and antioxidant impacts also exerted a strong 
hypochoiesteroleniic action, indicating a linkage between atherosclerosis and 
cancer. The dual chemopreventive actions of TRF in atherosclerosis and cancer are 
apparentl)- mediated by reducing HMG-CoA reductase, thus limiting the 
availabilit)' of mevalonate derived products required for cholesterol production and 
tumour growth (Iqbal. Ph.D. thesis. 1999). 
Our laboratory has also reported a strong hypolipidemic action of TRF, 
when administered to type 2 diabetic patients with hyperlipidemia. In particular TC 
50 
and LDL-C. which are positively associated with CHD, were significantly reduced 
to normal levels (Baliarsingh. M.D thesis, 2001; Baiiarsingh et al, 2002). 
During the past few years, two novel tocotrienols were isolated from 
stabilized and heated rice bran, apart from the known a-, (3-, y-, and 8-, tocopherols 
and tocotrienols. These new tocotrienols were separated by HPLC, using a normal 
phase silica column. Their structures were determined by ultravoilet, infrared, 
nuclear magnetic resonance, circular dichroism, and high resolution mass 
spectroscopies and established as desmethyl tocotrienol and didesmethyl 
tocotrienol. These tocotrienols significantly lowered serum total and LDL 
cholesterol levels and inhibited HMG-CoA reductase activity in chickens. They 
had much greater in vitro antioxidant activities and greater suppression of B16 
melanoma cell proliferation than a-tocopherol and known tocotrienols. These 
results indicated that the number and position of methyl substituents in tocotrienols 
affect their hypocholesterolemic. antioxidant and antitumour properties (Qureshi et 
al., 2000). Feeding of these two novel tocotrienols to hereditaiy 
hypercholesterolemic swines for 6 weeks caused a significant reduction in TG, TC. 
LDL-C, apoB. platelet factor 4. thromboxane B2 and hepatic HMG-CoA reductase 
activity (Qureshi et al, 2001a). These results are consistent with the 
hypocholesterolemic effects of these two novel tocotrienols in chickens (Qureshi et 
al, 2000). The reduction in cholesterol level may be due to inhibition of 
cholesterol biosynthesis at the level of HMG-CoA reductase through a post-
transcriptional mechanism involving protein degradation as shown earlier for other 
tocotrienols (Parker et al, 1993). Desmethyl tocotrienol and didesmethyl 
tocotrienol also mediated a significant decrease in serum TG, TC, LDL-C, apoB, 
Lp(a), platelet factor 4 and thromboxane B2 levels of hypercholesterolemic humans 
after a double blind, 12-week study (Qureshi et al, 1997). It is interesting to note 
that these two newly discovered tocotrienols are more effective in terms of 
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cholesterol lowering activity than a-, y- and 5-tocotrienols (Qureshi et al., 2000; 
Qureshi et al., 2001a). Recently, a dose-dependent effect of tocotrienol rich 
fraction containing mixture of the novel desmethyl- and didesmethyl tocotrienols 
(TRF25) has been investigated in hypercholesterolemic humans (Qureshi ef al., 
2002). The results showed that intake of a dose of 100 mg/day of TRF25 for 35 
days caused maximum decrease in serum TC, LDL-C, apoB and TG levels when 
compared to baseline values (Qureshi et al, 2002). The synergestic effect of 
TRF25 has been reported in hjpercholesterolemic humans. Administration of TRF 
in combination with lovastatin to hypercholesterolemic humans for 35 days exerted 
a synergestic lipid lowering effect, when compared to values obtained from 
subjects given TRF25 or lovastatin alone (Qureshi et al, 2001b). Administration 
of a 4-week dietary supplement of either 58 mg y-Ts or mixture of tocotrienols as 
TRF (29.5% a-T3, 3.3% p-Tj. 41.4% y-T3 and 0.1% 5-T3) per day per Kg body 
weight to hamsters receiving a high fat diet revealed that y-T3 was more potent 
hypocholesterolemic agent than TRF (Raederstorff e/a/., 2002). 
Since the discoveiy of vitamin E, in Berkeley by H.M. Evans in 1992, when 
it was first described as antisterility agent, many scientists and physicians have 
sought to elucidate its biochemistry, health benefits and clinical applications 
(Lester, 1992). Vitamin E has been well accepted as nature's most effective lipid 
soluble, chain-breaking antioxidant. It is the first line of defence against lipid 
peroxidation protecting polyunsaturated fatty acids in cell membranes through its 
free radical quenching activit)' in biomembranes at an early stage of free radical 
attack (Horwitt. 1986). After being oxidized in this process and before being 
decomposed, vitamin E can be re-reduced by ascorbic acid and glutathione. This 
reaction is dependent on the concentration of these substances and/or the enzymes 
that maintain them in their reduced form. 
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The antioxidant activity of T and T3 is mainly due to their ability to donate 
their phenolic hydrogens to lipid free radicals (Burton and Ingold, 1986; Pokorny, 
1987; Burton and Ingold. 1988: Burton and Traber, 1990). The mechanism for the 
inhibition of lipid peroxidation in biological membranes by T and T3 can be 
outlined as follows: The peroxidation proceeds in 3 phases; initiation, propagation 
and termination (Burton and Traber, 1990). In the initiation phase a carbon 
centered lipid radical R* is produced from a polyunsaturated fatty acid RH. This R* 
reacts with molecular oxygen in the propagation phase to form ROO', which reacts 
with other RH forming a hydroperoxide. ROOH. 
R* + 02 -^ ROO* 
ROO* f RH -^ ROOH + R* 
This propagation process continues and consumes the valuable polyunsaturated 
fatty acids. In the termination phase, the chain reaction stops when a peroxyl 
radical (ROO*) combines with another ROO*. 
ROO* + ROO* -^ Inactive product 
However, tocotrienols (T3-OH) and tocopherols (T-OH) can intercept the peroxyl 
radical more rapidly than can polyunsaturated fatty acids by the following 
reactions: 
TrOl 1 + ROO* -^ TrO* + ROOH 
TrO* + ROO* -> Inactive product 
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The T3-O* radical is unable to continue the chain and reacts with the peroxyl to 
form inactive product. 
Although, it is generally agreed that the relative antioxidant activity of T in 
vivo is in the order of a>P>y>5 (Dillard et ai. 1983; Burton and Ingold, 1986; 
Burton and Traber. 1990: Verlangieri and Bush 1992), there is a wide spread 
confusion concerning their relative potency in vitro (Burton and Ingold, 1981). 
The chemical structures of T and T3 support hydrogen donating power in the order 
of a>P>Y>5 (Pokorny. 1987). This order also was obtained when the activity of the 
four T was compared in a homogenous solution in dichlorobenzene (Burton and 
Ingold, 1981). but a reverse order (5>Y=P>a) was obtained when the relative 
antioxidant properties were compared in fats, oils and lipoproteins in vitro (Lea 
and Ward. 1959; Olcott and Van Der Ven. 1968; Parkhurst et ai, 1968; Koskas et 
al., 1984; Esterbauer et ai. 1989; Gottstein and Grosch, 1990). The reason behind 
this order is not yet clearly understood. Several studies have demonstrated the 
ability of tocopherols to prevent ex vivo and in vitro LDL-C oxidation and 
significantly reduce the development of atherosclerotic lesions (Carew et ai, 1987; 
Esterbauer et al., 1991; Mao et al., 1991), risk of coronary heart disease (CHD) 
(Rimm et al., 1993; Stampfer et al., 1993) and ischemic heart disease (Gey, 1995). 
Even though. a-T has been labeled as the most efficient chain breaking 
antioxidant, tocotrienols are known to be more potent antioxidant than tocopherols 
(Suarna et al.. 1993; Kamat and Devasagayan, 1995; Kamat et al., 1997). 
Tocotrienols have been shown to ha\e greater free radical scavenging properties as 
cell membrane constituents than T (Yamaoka and Carrillo, 1990; Serbinova et al., 
1991). Recently, it was shown that compared to a-T, a-T3 possesses a 40-60 times 
higher antioxidant activity against Fe'^ + ascorbate- and Fe'^ + NADPH-induced 
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lipid peroxidation in rat liver microsomal membranes and 6.5 times greater 
protection of cytochrome P-450 against oxidative damage (Serbinova et al. 1991). 
This higher antioxidant potency of a-T3 as compared to a-T is attributed to the 
combined effects of three properties; its higher recycling efficiency from 
chromanoxyl radical, its more uniform distribution in membrane bi layer, and its 
stronger disordering of membrane lipids which makes interaction of chromanols 
with lipid radicals more efficient. 
Several animal studies have been conducted to test the hypothesis that 
antioxidants delay atherosclerosis. Wojcicki reported a statistically significant 25 
per cent reduction in aortic atherosclerotic lesions in hypercholesterolemic 
mongrel rabbits fed 10 mg/kg/da\ of \itamin E compared to controls (Wojcicki et 
al.. 1991) and Verlangieri reported a 54 per cent lesion reduction in monkeys fed 
108 lU of vitamin E per day compared to controls (Verlangieri and Bush. 1992). 
Qureshi et al. (1991a & b) have reported a reduction in both total and LDL-
cholesterol in human hyperlipidemics and pigs supplemented with T3. 
Supplementation of y-T3 along with an atherogenic diet to rats for six weeks has 
been shown to lead to decreased plasma lipid and lipoprotein concentrations. In 
addition, a decrease in the plasma lipid peroxidation was shown (Watkins et al., 
1993). Similar observations were reported in hypercholesterolemic rabbits by Teoh 
et al. (1994). Wahlquist et al. (1992), however, observed a differential response to 
T and T3 supplementation in human subjects without any change in serum lipids. 
Tomeo et al. (1995) also reported that T3 significantly decreased plasma lipid 
peroxidation in patients with h>perlipidemia and carotid stenosis with no change in 
their lipid and lipoprotein parameters. Similarly, Mensink et al. (1999) recently 
reported that T3 had no markedl}' favourable effects on the serum lipoprotein 
profile in men with slightly elexated lipid concentrations. Experiments involving 
the effects of T3 on apoB (LDL) and apoA-I (HDL) and apoB/apoA-I ratio has 
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been reported in chickens, swine and humans. The apoB/apoA-1 ratio, considered 
being a better indicator than LDL/HDL ratio, for assessment of CHD, was reduced 
in T3 treated subjects (Qureshi et al.. 1991a&b). Recently, the mechanism of action 
of T3 on apoB metabolism in HepG2 cells has been investigated (Wang e/ al., 
1998;Theriaulte/a/.. 1999b). 
For a long time now it has been shown that dietary regimen in conjunction 
with exercise favourably alter the lipid parameters in hypercholesterolemic 
individuals. Based on the current knowledge dietary recommendations to optimize 
plasma lipid profiles and thus reduce the risk of coronary heart disease are 
currently focused on the total fat content, the fatty acid profile, and the cholesterol 
content of the diet (Dietary Guidelines, 1988). Public health programmes for 
prevention of CAD in developed countries recommend changes in dietary habit 
and patterns of various components of diets, especially dietary fat. Recently a 
reduction in dietary intake of total fat. particularly animal fat with a limited amount 
of saturated fatty acid and polyunsaturated fatt>' acid, has been suggested (Lesserre 
et al., 1985). The American Heart Association (1982) recommends that total fat 
content of the diet should not exceed 30% of total calories, saturated fatty acid 
should not exceed 10%, monounsaturated fatty acid should not exceed 10%) and 
polyunsaturated fatty acid should not exceed 10% of calories. Lesserre et al. 
(1985) reported that linolenic acid (18:3) should provide 0.5-1.0%) of total calories. 
Polyunsaturated fatty acids are abundantly available in vegetable oils like 
safflower oil. sunflower oil and corn oil which were found to lower blood total and 
LDL-cholesterol levels, as revealed by epidemiological studies (Berkson and 
Stamler. 1981). A number of studies in humans and animals have shown that RBO 
is as effective as other vegetable oils in lowering plasma cholesterol levels 
(Rukmini and Raghuram. 1991; Lichtenstein et al, 1994). In some cases. RBO 
lowered plasma cholesterol more effecti\ely than other commonly used vegetable 
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oils rich in linoleic acid (Rukmini and Raghuram. 1991); this effect was attributed 
to the presence of T and T;, in the RBO (Nicolosi el a!.. 1991). However, Qureshi 
et al. (1991a&b), confirmed the impact of tocotrienols on cholesterol, specifically 
the LDL-choIesterol. in animal and human studies. The tocopherols on the other 
hand do not lower serum cholesterol (Qureshi ef a!.. 1989). Recently, biological 
properties of tocotrienols such as h\polipidemic. antioxidant and antitumour, have 
been reviewed in detail (Theriault et a/., 1999a). 
57 
1.1 Objectives of the present investigation 
Based on the above discussion, in the first part of the thesis we have investigated 
the hypolipidemic, antioxidant and antiatherosclerotic impacts of tocotrienol rich 
fraction. TRF (isolated from purified edible grade RBO), and a commercial 
preparation of purified tocotrienol rich fraction, Tocomin (isolated from palm oil), 
when fed together with 0.33% cholesterol rich diet to rabbits for 22.4 weeks and 
compared with hypeiiipidemic control. The efficacy of 16.2 mg% TRF and 6.97 
mg% Tocomin in preventing the increase in plasma TG, TC, VLDL-C, LDL-C. 
HDL-C, and lipid peroxide levels in h\perlipidemic rabbits was investigated. In 
addition, we have investigated the impact of TRF and Tocomin on ex vivo and in 
vitro LDL oxidation, and on the formation of fatty streak lesions in the aortas. The 
second part of the thesis deals with the investigations related to the role of dietaiy 
0.33% nonoxidized cholesterol or the same diet containing 0.33% cholesterol of 
which 5% was oxidized, in experimental hyperlipidemia; plasma and liver lipid 
peroxidases; ex vivo and in vitro oxidative modification of LDL. In addition, this 
part also deals with the hypolipidemic, antioxidant and antiatherosclerotic impacts 
of dietaiy tocotrienols (TRF) fed to rabbits for 10 weeks together with a diet 
containing 0.33%) nonoxidized cholesterol or the same diet containing 0.33%) 
cholesterol of which 5% was oxidized. Effect of feeding 50 mg%) TRF (25 mg%o 
TRF plus 25 mg%) Tocomin), mixed with either nonoxidized cholesterol rich diet 
or a 95% nonoxidized and 5% oxidized cholesterol rich diet on liver TC, plasma 
TG, TC including FC and EC, VLDL-C. LDL-C, HDL-C, HDL3-C and HDL2-C, 
and plasma as well as liver lipid peroxidases was investigated. Moreover, 
antioxidant impacts of TRF on baseline levels of ex vivo diene conjugation of 
LDL, rates of conjugated diene formation in LDL, TBARS contents of LDL, and 
lag phase lime of copper-induced oxidation in LDL, isolated from plasma of 
rabbits in each group was undertaken. We have also examined the role of oxidized 
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cholesterol in (he acceleration of fatt} streak lesions in the aorta in comparison to 
rabbits fed only nonoxidized cholesterol. Similarly, efficacy of tocotrienols-
mediated protection against the formation of early atherosclerotic lesions in aortas 
of hyperlipidemic rabbits in both groups was also investigated. 
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Experimental 
MATERIALS 
2.1.1 Chemicals 
The chemicals were obtained from various sources listed below. 
Chemical 
Bovine Serum Albumin 
Cholesterol (Extra pure) 
Commassie Brilliant Blue G250 
Dextran Sulfate 
Digitonin 
Ferric Chloride 
Heparin Sodium 
Rabbit Chow 
Refined Edible Grade Rice Bran Oil 
Sodium Dodecyl Sulfate 
Sudan IV (Oil red IV) 
Thiobarbituric Acid 
(±)-a-Tocopherol 
Source 
Miles Ltd. Inc., USA 
SRL Ltd., India 
Polvsciences Inc., USA 
Sochibo s.a. France 
CDH Ltd., India 
Loba Chemie. India 
Fisher Scientific. USA 
Amrut Feed Co., India 
Dabur Ltd., India 
Sigma Chemical Co., USA 
HiMedia Labs. Ltd., India 
Sigma Chemical Co., USA 
Sigma Chemical Co., USA 
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We acknowledge our immense gratitude to Dr. Illona Staprans, Lipid Research 
Laboratoiy, VA Medical Center, San Francisco, CA 94121, USA, for kindly 
providing oxidized cholesterol. Fifty percent oil suspension of tocotrienol rich 
fraction (TRF) marketed as Tocomin was a gift from CAROTECH Sdn. BHD, 
Chemor, Malaysia. Tocomin is a reddish vegetable oil suspension of naturally 
occuring mixture of tocotrienols extracted and concentrated from palm oil. 
Tocomin suspension (500 mg / g) contained 44% d-y- tocotrienol, 11% d-5-
tocotrienol. 23% d-a-tocotrienol and 23% d-a-tocopherol. 
All other chemicals and reagents used were of analytical grade. 
2.1.2 Animals 
Male white rabbits (body weight 1.4-1.8 kg) were procured from a local supplier. 
Rabbits were individually housed in cages at central animal house facility of J.N. 
Medical College. The rabbits were acclimatized to animal house conditions for 
four weeks and were given powdered rabbit chow and water ad libitum. 
2.1.3 Diet preparation 
Cholesterol and oxidized cholesterol rich diets with and without TRF, Tocomin, 
TRF plus Tocomin were prepared by dissolving weighed amounts of cholesterol, 
oxidized cholesterol, TRF, Tocomin or TRF plus Tocomin in diethyl ether and 
thoroughly mixing with respective powdered diets in a commercial auto food 
mixer. In experimental group no. 2, the cholesterol enriched diet of HLP|-C and 
HLP2-C rabbits also contained the same amount of a-tocopherol as present in the 
diet of HLP|-T and HLP2-T groups, that is. 25 mg % TRF plus 25 mg % Tocomin. 
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METHODS 
2.2.1 Preparation of Oxidized Cholesterol 
Oxidized cholesterol used in our lest diet was prepared by Dr. Staprans of VA 
Medical Center, San Francisco. California, USA, by heating at 100°C for 8 hours 
as described by Kim and Navvar (1993). The composition of cholesterol oxidation 
products is highly dependent on the oxidizing conditions, and under these 
conditions, approximately 95% of the cholesterol was not altered and 5% was 
oxidized, yielding numerous oxidation products. Typically, the oxidized 
cholesterol had the following cholesterol oxidation products that were identified 
as: 7% cholest-5-ene-3p, 7a- diol (7a-hydroxycholesterol), 20% cholest-5-ene-3p, 
7p-diol (7p-hydroxycholesterol), 16% 5,6 p-epoxy-5p-cholestan - 3p-oi (p-
epoxy-cholesterol), 12%) 5. 6a-epoxy-5a-cholestan-3p-ol (a-
epoxycholesterol), 42%) 3p-hydroxycholest-5-ene-7-one (7-ketocholesterol), and 
3%) cholest-5-ene-3p, 25-diol (25 p-hydroxycholesterol). The area for these six 
oxysterols accounted for 52%) of the total. 
2.2.2 Isolation and Purification of Tocotrienol Rich Fraction from Refined 
Edible Grade Rice Bran Oil 
Tocotrienol rich fraction (TRF) from refined rice bran oil (RBO) was extracted in 
methanol by stirring in a container for 1 h. The minimum amount of methanol 
essential for extraction of maximum amount of TRF had been worked out to be 7 
ml per gram of RBO. Methanol layer containing TRF was evaporated at 65"C 
under vacuum in a rotary evaporator and TRF was recovered. Concentrated TRF 
suspension was analyzed by HPLC for percent content of tocotrienols and 
tocopherols (Beg, et ai. 1996). The results were calculated from each peak area of 
the chromatogram of HPLC and are representative of the percent of the amount of 
TRF loaded. A typical TRF preparation contained 6.2 mg%) y- tocotrienol, 6.2 
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mg% 5-tocotnenol, 14.6 mg% a- tocotrienol. 2.2 mg% p-tocotrienol and 14.7 
mg% a- tocopherol. 
2.2.3 Experimental Design 
2,2.3.1 Experimental Group No.l 
For investigating the hypolipidemic and antioxidant effect of TRF or Tocomin. 
rabbits, based on their body weight and daily diet consumption, were divided in the 
following groups. 
r:j> Normolipidemic Control (NLP-C) 
Four rabbits were fed powdered rabbit chow for 22. 4 weeks. 
=> Hyperlipidemic Control (HLP-C) 
Three rabbits in this group were given an atherogenic diet containing 0.33% 
cholesterol for 22. 4 weeks. 
=:> Hyperlipidemic Treated (HLP-Ti) 
Four rabbits were fed the above atherogenic diet (HLP-C) containing 0.33% 
cholesterol and 16. 2 mg%o TRF for 22. 4 weeks. 
=> Hyperlipidemic Treated (HLP-T2) 
Three rabbits in this group were given the above atherogenic diet (HLP-C) 
containing 0.33%) cholesterol and 6.97 mg % Tocomin for 22.4 weeks. 
2.2.3.2 Experimental Group No.2 
Seventeen rabbits were fed a powdered diet containing 0.33%) cholesterol for 3 
weeks. At the end of treatment blood was drawn from the central ear artery of each 
rabbit and plasma total cholesterol was determined. The mean (mg/dl) + SD 
plasma total cholesterol value of seventeen rabbits was 545 ± 155. Based on 
63 
similar cholesterol values, twelve rabbits having a mean TC level of 464 ± 69 
mg/dl, were divided into 4 groups of 3 each. 
=> Normolipidemic Control (NLP-C) 
Three rabbits in this group were fed a powdered control diet for 10 weeks. 
•=^ Hyperlipidemic-1 Control (HLPj-C) 
Three rabbits in this group were given an atherogenic diet containing 0.33% 
cholesterol for 10 weeks. 
•=^ Hyperlipidemic-1 Treated (HLPi-T) 
Three rabbits in this group were fed a diet containing 0.33% cholesterol and 25 
mg%o TRF plus 25 mg% Tocomin for 10 weeks. 
•=^ Hyperlipidemic-2 Control (HLPi-C) 
Three rabbits in this group were given a diet containing 0.33% cholesterol of 
which 5%) was oxidized for 10 weeks. 
=> Hyperlipidemic-2 Treated (HLPj-T) 
Three rabbits in this group were fed an atherogenic diet containing 0.33% 
cholesterol of which 5% was oxidized and 25 mg% TRF plus 25 mg% Tocomin 
for 10 weeks. 
2.2.4 Analytical Procedures 
2.2.4.1 Collection of blood 
In experimental group no. 2, at the end of 5 weeks of treatment blood was drawn 
from the central ear arteiy of each rabbit. At the end of 22.4 or 10 weeks of 
treatment, the rabbits in experimental group no.l and 2 after an overnight fast were 
anaesthetized and blood was collected by cardiac puncture in tubes containing 
iieparin. Blood was mixed gently b}' inversion 2-3 limes and immediately cooled to 
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4 C in a refrigerator. Plasma was separated from blood by centrifugation at 2,500 
rpm for 30 min. aliquoted and stored at -20 C for future use. 
2.2.4.2 Isolation and quantification of lesional area in aorta 
At the end of 22.4 and 10 weeks of treatment for experimental group no.l and 2. 
respectively, rabbits were anaesthetized and after laparotomy, the aortas were 
removed. The aorta was dissected from the aortic valve to the iliac bifurcation and 
the adventitia was removed as much as possible to prevent errors resulting from 
staining of the vessel. Each aorta was fixed in 10% phosphate buffered saline (pH 
7.4) and stained as described (Lamb et al.. 2001). At the time of staining, the aorta 
was opened longitudinally, rinsed in 80% isopropanol and stained for 90 seconds 
in 80%) isopropanol containing 2% (w/\) Sudan IV. Aorta was rinsed in 80%) 
isopropanol, restained for further 90 seconds in 80% isopropanol containing 2%) 
(w/v) Sudan IV. and destained in 80% isopropanol and PBS. The aorta was pinned 
flat on a styrofoam surface and photographed. Lipid deposition in aorta was 
determined by morphological assessment of the percentage of the aorta covered by 
lesions visualized by fat staining of the region between the aortic root and 
bifurcation. The fatty streak lesions in the enlarged photographs were traced on a 
digital tablet and the areas of the lesions were measured by pixel-based analysis 
software developed by Mr. Alsaad Ishaq and Mr. V.S. Sharma, Department of 
Computer Engineering, AMU, Aligarh, India. 
2.2.4.3 Preparation of liver homogenate 
At the end of treatment of rabbits in experimental group no.l and 2, liver from 
each rabbit was promptly excised and chilled in ice cold saline. After washing with 
saline, livers were blotted and weighed. Each liver was cut into pieces, mixed and 
20 g of wet tissue was homogenized with 80 ml of chilled 1.15% KCl in a waring 
blender. The volume of each homogenate was recorded and centrifuged at 600xg 
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for 10 min at 4"C. After centrilligation the homogenate was aliquoted and stored at 
-20"C. 
2.2.4.4 Fractionation of plasma lipoproteins 
Lipoproteins were fractionated from plasma by precipitation as described by 
Kastener (1976). Isolation of lIDL-cholesterol and VLDL-cholesterol + LDL-
cholestevol was done by using phosphotungstate and magnesium chloride. The 
following solutions were used: 
• 9.7 niM phosphotungstic acid 
• 0.4 M magnesium chloride 
• 0.2 volume of 1:1 mixture of phosphotungstic acid and magnesium chloride 
was added to 1 volume of plasma. The samples were mixed immediately, allowed 
to stand for 5 min at room temperature and then centrifuged for 10 min at 12,000 
rpm at room temperature. The clear supernatant was used for the analysis of HDL-
cholesterol as well as for the fractionation of HDL3-cholesterol and HDL2-
cholesterol. The precipitate was dissolved in 1 volume of freshly prepared 0.1 M 
sodium citrate and used for the analysis of VLDL-cholesterol + LDL-cholesterol. 
Fractionation of HDL-cholesterol subfraction and VLDL-cholesterol was done by 
precipitation method described by Bachorik and Albers (1986). The following 
solutions were used for the fractionation of HDL-cholesterol: 
• Dextran sulfate (Mr 50.000) 40 gm/L. pH 7.0. 
• MgCl2.6H20, 2 M, pH 7.0. 
• Reagent 'X' was prepared by mixing 1 volume of 40gm/L dextran sulfate with 
3 volumes of 2 M MgCl2.6I-l20. 
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For HDL-cholesterol fractionation, 0.1 volume of reagent 'X' was added to 1 
volume of HDL-cholesterol sample and mixed immediately. The samples were 
allowed to stand at room temperature for 15 min and then centrifuged at 5,000 rpm 
for 30 min at 4 °C. Aliquots of clear supernatant were used for HDLrcholesterol 
analysis. HDL2-cholesterol was then calculated as the difference between IIDL-
eholesterol and HDL3-cholesterol. 
For the isolation of VLDL, 0.075 volume of 10% SDS solution was added to 1 
volume of plasma. After mixing them well, the samples were incubated for 2 h al 
37 °C. These were then centrifuged at 10.000 rpm for 10 minutes at room 
temperature. The VLDL pellicle lloats at the top of the tube. The subnatant was 
carefully removed with a hypodermic syringe and discarded. The pellicle residue 
was dissolved in 1 volume of 1 % SDS by warming at 37 °C for 15 min. 
2.2.4.5 Deter min at ion of c/i olesterol 
Total, free and esterified cholesterol were estimated in plasma and lipoproteins as 
described by Annino and Giese (1976). To glass centrifuge tubes, containing 4.8 
ml of isopropanol, were added 0.2 ml of the test sample or 0.2 ml of the standard 
cholesterol (200 mg/100 ml isopropanol). The contents were mixed, allowed to 
stand for 5 min and centrifuged at 3,000 rpm for 10 min. 
For the determination of cholesterol in plasma and subfractions, 1.0 ml of the 
supernatant was taken in glass lest tubes and treated with 2.0 ml of ferric chloride 
reagent (70 mg of ferric chloride hexahydrate/100 ml of glacial acetic acid), mixed 
immediately, followed by the addition of 2.0 ml of sulphuric acid with thorough 
mixing. For reagent blank, 1.0 ml of isopropanol was used instead of supernatant. 
After 5 min, the absorbance was read at 550 nm in a Beckman DU 640 
spectrophotometer. 
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For the determination of free cholesterol and cholesterol ester, 1.0 ml of the above 
supernatant was treated with 2.0 ml of acetone and 1.0 ml of digitonin solution 
(1.0 g of digitonin dissolved in 60ml of absolute ethanol, diluted to 100 ml with 
distilled water and mixed well). The tubes were allowed to stand in an ice bath for 
30 min and then centrifuged for 10 min at 4.000 rpm. The supernatant was 
decanted completely. The precipitate was again washed with 3.0 ml of acetone and 
dissolved in 1.0 ml of isopropanol. At the same time, 1.0 ml isopropanol was taken 
in a clean tube to serve as blank. To all the tubes. 2.0 ml of ferric chloride reagent 
and 2.0 ml sulphuric acid were added and the contents were mixed well. After 5 
min, the absorbance was read at 550 nm in a Beckman DU 640 spectrophotometer. 
Calculations: Total, free and eslerified cholesterol were calculated as follows: 
Absorbance of test sample 
Total cholesteroKmg/dl) = >i 200 
Absorbance of standard 
Absorbance of test sample 
Free cholesterol (mg/dl) = x 200 
Absorbance of standard 
Cholesterol ester (mg/dl) = Total cholesterol - Free cholesterol 
2.2.4.6 Determination of triglycerides 
Triglycerides were determined by using enz)matic kit purchased from Bayers 
Diagnostics Ltd.. India. The method uses a modified Trinder colour reaction to 
produce a fast, linear, end point reaction (Trinder. 1969). 
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Principle: 
Lipase 
Triglycerides • Glycerol + Fatty acids 
Glycerol kinase 
• 
Glycerol + ATP G3P + ADP 
Glycerophosphate oxidase 
G3P + 0 , ^ DAP + H2O2 
Peroxidase 
H2O2 + 4-AAP + TBHB « • Quinoneimine Dye +2H2O 
Triglycerides in the sample are hydrolyzed by lipase to glycerol and fatty acids. 
The glycerol is then phosphorylated by adenosine-5-triphosphate (ATP) to 
glycerol-3-phosphate (G3P) and adenosine-5-diphosphate (ADP) in a reaction 
catalyzed by glycerol kinase. Glycerol-3-phosphate is then converted to 
dihydroxyacetone phosphate (DAP) and hydrogen peroxide (H2O2) by 
glycerophosphate oxidase. The hydrogen peroxide then reacts with 4-aniino-
antipyrine (4-AAP) and 3-hydroxy-2.4,6-tribromobenzoic acid (TBHB) in a 
reaction catalyzed by peroxidase to yield a red coloured quinoneimine dye. The 
intensity of the colour produced after incubation is directly proportional to the 
concentration of triglycerides in the sample when measured at 540 nm. 
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Calculations: Triglycerides in a plasma sample were calculated as follows: 
OD Sample 
Triglycerides (mg/dl) = x n 
OD Standard 
2.2.4.7 Determination of lipid peroxide levels in plasma 
Lipid peroxide content in plasma was assayed as described by Yagi (1987). 
Hundred microliter of plasma was mixed with 4.0 ml of N/12 H2SO4. To this 
mixture. 0.5 ml of 10% phosphotungstic acid was added and mixed. After standing 
at room temperature for 5 min. the mixture is centrifuged at 3000 rpm for 10 min. 
The supernatant is discarded, and the sediment is mixed with 2.0 ml of N/12 
H2SO4 and 0.3 ml of 10% phosphotungstic acid. The mixture is centrifuged at 
3000 rpm for 10 min. the sediment is suspended in 4.0 ml of distilled water, and 
1.0 ml of thiobarbituric acid (TBA) reagent (a mixture of equal volumes of 0.67%) 
TBA aqueous solution and glacial acetic acid) is added. The reaction mixture is 
heated at 95°C for 60 min in a shaking water bath. After cooling, the precipitate 
formed was removed by centrifugation at 3000 rpm for 10 min. The absorbance of 
the sample was determined at 532 nm against a blank that contained all the 
reagents minus the plasma.The values were calculated on the basis of molar 
extinction coefficient of malondialdehyde (1.56x10^ M"'cm"'). 
2.2.4.8 Assay of lipid peroxide levels in rabbit liver homogenates by 
thiobarbituric acid reaction 
Lipid peroxides in liver homogenates were determined by the method of Ohkawa 
et al. (1979). To 200 microliter of 10%o (w/v) liver homogenate sample were added 
0.2 ml of 8.1% SDS, 1.5 ml of 20% acetic acid solution adjusted to pH 3.5 with 
NaOH, and 1.5 ml of 0.8%o aqueous solution of TBA. The mixture was made up to 
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4.0 ml with distilled water, and then heated in a water bath at 95 C for 60 min. 
After cooling with tap water, the precipitate formed was removed by centrifugation 
at 1000 rpm for 5 min. The absorbance of the samples and the experimental blank 
containing 200 microlitre of liver homogenate and other ingredients except TBA 
was read against the reagent blan.k, at 532 nm. The TBAR values were calculated 
by utilizing molar extinction coefficient of malondialdehyde (1.56x10'^  M" cm" ) 
and the values were expressed as nmole of equivalent malondialdehyde formed. 
2.2.4.9 Determination of plasma LDL oxidation 
2.2.4.9.1 Isolation of LDL from plasma 
Plasma LDL was isolated by a precipitation method as described by Wieland and 
Seidel (1983). The precipitation buffer consisted of 64 mM trisodium citrate 
adjusted to pH 5.05 with 5 N HCl. and contained 50,000 lU/L heparin. Before 
precipitation of LDL, plasma samples and precipitation reagents were allowed to 
equilibrate to room temperature. One milliliter of the sample was added to 7.0 ml 
of the heparin-citrate buffer. After mixing with a vortex mixer, the suspension was 
allowed to stand for 10 min at room temperature. The insoluble lipoproteins were 
then sedimented by centrifugation at 1,000 g for 10 min. The pellet was 
resuspended in 1.0 ml of 0.1 M Na-phosphate buffer, pH 7.4, containing 0.9% of 
NaCl. 
2.2.4.9.2 Measurement of the resistance of LDL to oxidative modification 
This was performed as described by Esterbauer et al. (1989). The formation of 
conjugated dienes {in vivo status) was measured by incubating 100 microgram of 
LDL protein with 5 micromole per liter Cu^ ^ in 1 ml of PBS (pH 7.0) at 37 C. The 
reaction was stopped by the addition of 50 millimolar EDTA (pH 7.4). The 
absorbance at 234 nm was measured in a Beckman DU 640 spectrophotometer. 
The base line levels of diene conjugation, lag phase and rates of conjugated diene 
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formation in LDL were calculated by using an extinction coefficient of 
malondialdeh>de (2.52x10"^ M''cm''). The values were expressed in terms of 
nmole of equivalent malondialdehyde formed. The above LDL aliquotes were used 
for the measurement of thiobarbituric acid reactive substances (TEARS) by 
employing the method of Niehaus and Sarnuelsson (1968). Briefly, 0.3 ml of LDL 
mixture, in triplicate, was thoroughly mixed with 2ml of TCA -TBA-HCl reagent 
containing 15% trichloroacetic acid. 0.375% thiobarbituric acid and 0.25N 
hydrochloric acid. The solution is heated for 15 min in a boiling water bath. After 
cooling, the flocculent precipitate is removed by centrifugation at 1000 rpm for 10 
min. The absorbance of the sample is determined at 535 nm against a blank that 
contains all the reagents minus the LDL. The malondialdehyde concentration of 
the samples was calculated by using an extinction coefficient (1.56x10'^ M" cm" ). 
2.2.4.10 Protein estimation 
The protein was determined by the method of Bradford (1976), using Bovine 
serum albumin as standard. Aliquots of liver homogenates and LDL fractions were 
first precipitated with 20%) trichloroacetic acid. The protein pellets were dissolved 
in IN NaOH and suitable aliquots were used for protein determination. 
2.2.4.11 Statistical analysis 
Statistical analysis of data was done by employing two tailed student t-test (Bennet 
and Franklin. 1967). P values less than 0.05 were considered significant. 
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3.1 Average Body Weight of Rabbits, Consumption of a Diet Containing 
0.33% Cholesterol, 0.33% Cholesterol Plus 16.2 mg% Tocotrienol Rich 
Fraction and 0.33% Cholesterol Plus 6.97 mgVo Tocomin Per Rabbit 
Per Day During 22.4 Weeks of Feeding 
As shown in Table 1. after 22.4 weeks of (ceding a control diet (NLP-C). a 
diet containing 0.33% cholesterol (HLP-C). a diet containing 0.33% cholesterol 
plus 16.2 mg% tocotrienol rich fraction, TRF (HLP-T|) and the cholesterol rich 
diet containing 6.97 mg%) Tocomin (HLP-T2), the average consumption per rabbit 
per day was 106.0, 105.2. 104.8 and 108.1 g. respectively. Based on the diet 
consumption, average weight of cholesterol consumed per rabbit per day in HLP-
C, HLP-T| and HLP-T2 groups \Nas 347.2. 345.8 and 357.3 mg, respectively, 
whereas, consumption of TRF and Tocomin per rabbit per day was 16.97 and 7.54 
mg. respectively, for HLP-Ti and HLP-T2 animals. 
3.2 Impact of Tocotrienol Rich Fraction and Tocomin on Plasma Lipids, 
Plasma Lipoprotein Lipids, Plasma Lipid Peroxides and Plasma LDL 
Oxidation in Hyperlipidemic Rabbits Treated For 22.4 Weeks 
In the experiments described below the efficacy of TRF (16.2 mg%)) and 
Tocomin (6.97 nig%) in preventing the increase in lipid parameters, lipid 
peroxidation and LDL oxidation was investigated in hyperlipidemic rabbits, after 
22.4 weeks of feeding along with a 0.33 % cholesterol rich diet. 
3.2.1 Impact on plasma lipids 
As seen in Table 2, in comparison to normolipidemic control rabbits (NLP-
C). plasma TG and TC levels were increased by 1667%) and 1283%o. respectively, 
after leeding a cholesterol rich diet for 22.4 weeks (HLP-C). Supplementation of 
TRF (HLP-T|) or Tocomin (HLP-T2) along with cholesterol rich diet 
was associated with a decline of 27% and 28%) in plasma TG levels. Whereas, a 
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TABLE I 
AVERAGE BODY WEIGHT OF RABBITS, CONSUMPTION OF A DIET 
CONTAINING CHOLESTEROL, CHOLESTEROL + TRF AND 
CHOLESTEROL + TOCOMIN AFTER 22.4 WEEKS OF FEEDING 
Paranieters NLP-C HLP-C HLP-T, HLP-T, 
Average body weight L60±0.02 1.68±0.08 I.50±0.17 L53±0.11 
(kg) 
Average diet 
consunied/rabbit/day 106.0±n.87" 105.2±10.08^ 104.8±10.53' 108.1±n.27'^ 
(g) 
Average cholesterol 
consumed/rabbit/day _ 347.24±14.23 345.84+34.76 357.28+37.19 
(mg) 
Average TRF 
consumed/rabbit/day 16.97±L71 — 
(mg) 
Average Tocomin 
consumed / rabbit/day 
(mg) 7.54±0.79 
"Values are mean ± SD of 4 rabbits in NLP-C and HLP-T,. 
^Values are mean ± SD of 3 rabbits in HLP-C and HLP-Tj. 
NLP-C, normolipidemic control; HLP-C, fed a diet containing 0.33 % 
cholesterol for 22.4 weeks; HLP-T| and HLP-T?, fed a diet containing 0.33 % 
cholesterol as well as 16.2 mg % TRF and 6.97 mg % Tocomin, respectively, 
for 22.4 weeks. 
TABLE 2 
IMPACT OF TRF AND TOCOMIN ON TRIGLYCERIDES AND TOTAL 
CHOLESTEROL IN PLASMA OF RABBITS FED CHOLESTEROL FOR 
22.4 WEEKS 
Group Triglycerides Total Cholesterol 
NLP-C 73±12' 112±9 
HLP-C 1290±46' 1549177 
HLP-T, 
HLP-T, 
946±37 
(-27 % ) " 
932±280^ 
(-28 % ) ' 
1070±140 
(-31 % ) ' ' 
1318±93 
(-15 % ) " ! 
Values are mean (nig/dl) ± SD from plasma of 4 individual rabbits in NLP-C 
and HLP-T,. 
Values are mean (mg/dl) ± SD from plasma of 3 individual rabbits in HLP-C 
and HLP- Tj. 
NLP-C, normolipidemic control; HLP-C, fed a diet containing 0.33 % 
cholesterol for 22.4 weeks; HLP-Ti and HLP-T2, fed a diet containing 0.33 
% cholesterol as well as 16.2 mg % TRF and 6.97 mg % Tocomin, 
respectively, for 22.4 weeks. 
Significantly different from HLP-C at ''p<0.001, ''p<0.05, 'not significant & 
'p<0.01. 
significant decrease of 31% and 15% was seen in plasma TC levels in HLP-T| and 
HLP-T2 rabbits, respectively, when compared to HLP-C values. 
3.2.2 Effect on plasma lipoprotein lipids 
Data presented in Table 3, demonstrate that plasma VLDL-C, LDL-C and 
HDL-C levels were significantly increased in HLP-C rabbits in comparison to 
NLP-C values. The percent increase was 1275%. 1372% and 1166% for VLDL-C, 
LDL-C and HDL-C levels, respectively. Treatment with TRF or Tocomin 
mediated a significant decline of 34% and 19%) in VLDL-C, and 37% and 18%o in 
LDL-C levels of HLP-Ti and HLP-T2 rabbits in comparison to respective HLP-C 
values. No significant effect of tocotrienols was seen on plasma HDL-C or it's 
subfractions. 
3.2.3 Impact on the ratios of HDL-C/TC, HDL-C/LDL-C, TC/HDL-C and 
LDL-C/HDL-C 
As shown in Table 4, HDL-C/ TC and HDL-C/ LDL-C ratios in TRF and 
Tocomin-treated rabbits were positively increased, whereas TC/ HDL-C and LDL-
C/ HDL-C ratios were significantly decreased. 
3.2.4 Impact on plasma lipid peroxide levels 
The data summarized in Table 5, demonstrate the antioxidant impact of 
tocotrienols on plasma lipid peroxidation. Feeding of cholesterol rich diet to 
rabbits for 22.4 weeks caused a 190%) increase in plasma peroxide levels when 
compared to NLP-C values. Supplementation of tocotrienols in the diet of HLP-T| 
and HLP-T2 rabbits significantly blocked the rise in lipid peroxide levels to 42%o 
and 65%). It is interesting to note that decline in plasma lipid peroxides in TRF-
treated rabbits was significantly higher (4.52-fold) than Tocomin-treated rabbits 
(2.92-fold) when compared to hyperlipidemic control values. 
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1 ABLE 3 
IMPACT OF TRF AND TOCOMIN ON PLASMA VLDL-C, LDL-C, HDL-
C, HDL3-C AND HDL2-C IN HYPERLIPIDEMIC RABBITS AFTER 22.4 
WEEKS OF TREATMENT 
Parameters Ni p . r HLP-T, IILP-T. 
VLDL-cholesterol 16±2 220+18^ 146+23 
(-34 %)" 
179±10^ 
(-19 %)" 
LDL-cholesterol 61±6 898±30 564±29 
(-37 %)' ' 
740+12 
(-18 % ) ' 
HDL-choIesterol 32±6 405±23 390±16 373±62 
HDLi-choIestcrol 22±4 222±39 223±24 214±65 
HDLTcholesterol 10+3 183119 167131 159118 
Values are mean 1 SD from plasma of 4 individual rabbits in NLP-C and 
HLP-T,. 
^Values are mean 1 SD from plasma of 3 individual rabbits in HLP-C and 
HLP-T2. 
NLP-C, normolipidemic control; HLP-C, fed a diet containing 0.33 % 
cholesterol for 22.4 weeks; HLP-T] and HLP-Ti, fed a diet containing 0.33 
% cholesterol as well as 16.2 mg % TRF and 6.97 mg % Tocomin, 
respectively, for 22.4 weeks. 
Significantly different from HLP-C at ''p<0.05, "p<0.001 & 'p<0.01. 
^! 
"""fim UuivciS}^)--
TABLE 4 
IMPACT OF TRF AND TOCOMIN ON THE RATIOS OF HDL-C/TC, 
HDL-C/LDL-C, TC/HDL-C AND LDL-C/HDL-C IN HYPERLIPIDEMIC 
RABBITS AFTER 22.4 WEEKS OF TREATMENT 
Group 
Ratio' 
HDL-C/TC HDL-C/LDL-C TC/HDL-C LDL-C/HDL-C 
NLP-C 0.284 ±0.033 0.526±0.034 3.514+0.130 1.923+0.010 
HLP-C 0.253±0.004^ 0.437±0.0I5 3.946±0.069 2.289±0.082 
HLP-T, 0.386±0.023" 
(+53%)' 
0.708+0.013 
(+62%)' 
2.594±0.033 
(-34%)' 
1.4U+0.026 
(-38%>)''' 
HLP-T. 0.282±0.037^ 
(+12%)" 
0.502±0.075 
(+15%)' 
3.58110.454 
(-9%,)'' 
2.01610.278 
(-12%)'' 
For the calculation of ratios, data is taken from table 2 and 3. 
Values are mean ± SD from 4 individual rabbits in NLP-C and HLP-Ti. 
^Values are mean ± SD from 3 individual rabbits in HLP-C and HLP-T?. 
NLP-C, normolipidemic control; HLP-C, fed a diet containing 0.33 % 
cholesterol for 22.4 weeks; HLP-Ti and HLP-T., fed a diet containing 0.33 
% cholesterol as well as 16.2 mg % TRF and 6.97 mg % Tocomin, 
respectively, for 22.4 weeks. 
Significantly different from HLP-C at 'p<0.001, ''p is not significant & 
'p<0.01. 
TABLES 
IMPACT OF TRF AND TOCOMIN ON PLASMA LIPID PEROXIDE 
LEVELS IN HYPERLIPIDEMIC RABBITS AFTER 22.4 WEEKS OF 
TREATMENT 
Group Lipid peroxide level' Percent increase with 
(Percent decrease witii respect to NLP-C 
respect to HLP-C) 
NLP-C L39110.L30' 
HLP-C 4.029±0.266^ 190' 
HLP-T, L979±0322'^ 42" 
(-51%)" (4.52) 
HLP-T, 2.289±0.444^ 65' 
(-43%)' (2.92) 
Expressed in terms of malondialdehyde (nmole/ml plasma). 
Values are mean ± SD from plasma of 4 individual rabbits in NLP-C and HLP-
T,. 
^Values are mean ± SD from plasma of 3 individual rabbits in HLP-C and HLP-
Ti. 
NLP-C, normolipidemic control; HLP-C, fed a diet containing 0.33 % 
cholesterol for 22.4 weeks; HLP-Ti and HLP-T,, fed a diet containing 16.2 mg "/o 
TRF and 6.97 mg % Tocomin, respectively, for 22.4 weeks. 
''Fold decline with respect to HLP-C in HLP-T| and HLP-T2, respectively. 
Significantly different from NLP-C at 'p<0.001, ''p<0.05 & 'p<O.OL 
Significantly different from HLP-C at ''p<0.001 & 'p<0.01. 
3.2.5 Effect on ex vivo and in vitro LDL oxidation 
As shown in Table 6, feeding of cholesterol rich diet to rabbits for 22.4 
weeks caused a substantial increase in plasma LDL oxidation due to oxidative 
stress. Base line levels of diene conjugation (BDC) of LDL, as modified in vivo, 
were 293% higher in HLP-C rabbits in comparison to NLP-C values. However, 
tocotrienols, being potent antioxidants, significantly reduced the BDC value to 
133% and 164%. respectively, for HLP-T, and HLP-T2 rabbits. Similarly, 
hyperlipidemia significantly reduced the lag phase time of LDL oxidation in vitro 
from 75 min to 30 min. Supplementation of TRF or Tocomin with cholesterol rich 
diet significantly blocked the LDL oxidation and restored the lag phase time to 60 
min and 45 min, respectively, for HLP-T 1 and HLP-T2 rabbits. The rate of LDL 
oxidation for HLP-C was increased by 181% in comparison to values from control 
rabbits. Treatment with tocotrienols significantly blocked the rate of LDL 
oxidation to 77% and 106% for HLP-T, and HLP-T, rabbits. 
3.3 Impact of Tocotrienol Rich Fraction and Tocomin on Fatty Streak 
Lesions in the Aortas of Hyperlipidemic Rabbits Treated For 22.4 
Weeks 
Figure 3.1, depicts the comparison of the percent fatty streak lesion areas in 
aortas of three groups of rabbits fed for 22.4 weeks a cholesterol rich diet (HLP-C) 
or the same diet containing either 16.2 mg%) TRF (HLP-T|) or 6.97 nig% Tocomin 
(HLP-T2). The fatty streak lesion areas in HLP-C rabbits was 21.5 %>, whereas 
TRF and Tocomin supplemented groups revealed an average lesion areas of 10.3%) 
and 13.3%, respectively. Therefore, feeding of dietary TRF or Tocomin mixed 
with cholesterol rich diet to HLP-T, and HLP-T2 rabbits was associated with a 
significant reduction in the formation of fatty streak lesions in the aortas by 
approximately 2.1-and 1.6-fold, respectively, when compared to hyperlipidemic 
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TABLE 6 
ANTIOXIDANT IMPACT OF TRF AND TOCOMIN ON EX VIVO AND IN 
VITRO PLASMA LDL OXIDATION IN HYPERLIPIDEMIC RABBITS 
TREATED FOR 22.4 WEEKS 
Parameters 
BDC 
Lag phase 
(min)' 
NLP-C HLP-C HLP-T, HLP-T. 
45 177^ 105 119^ 
(+293%)' (+133%)' (+164%)' 
75 30 60 45 
Rate 
,§ 262 736 464 540 (MAD/hr)^ (+181%) (+77%) (+106%) 
Values are representative of two different experiments of isolated LDL from 
pooled plasma samples of 4 rabbits in NLP-C and HLP-Tj. 
Values are representative of two different experiments of isolated LDL from 
pooled plasma samples of 3 rabbits in HLP-C and HLP-T2. 
•The lag phase is defined as the interval between the intercept of the tangent of 
the slope of the curve with the time expressed in minutes. 
^Rate of conjugated diene formation is defined as maximum change in the 
absorbance at 234 nm/niin., which Is expressed in terms of nniole 
malondialdehyde (MAD) per hour. 
NLP-C, normolipidemic control; HLP-C, fed a diet containing 0.33 
cholesterol for 22.4 weeks; HLP-Ti and HLP-Ti, fed a diet containing 0.33 
cholesterol as well as 16.2 mg %> TRF and 6.97 mg % Tocomin, respectively, fo 
22.4 weeks. 
" Percent increase with respect to NLP-C values. 
c 
o 
ifl 
ss 
20 ^ 
15 -
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0 - i 
HLP-C HLP-Ti 
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HLP-T2 
Fig. 3.1 Percent aortic area covered by fatty streaks in rabbits. HLP-C, fed a 
diet containing 0.33 Vo cholesterol for 22.4 weeks; HLP-Ti and HLP-
T2, fed a diet containing 0.33 Vo cholesterol as well as 16.2 mg % TRF 
and 6.97 mg % Tocomin, respectively, for 22.4 weeks. 
control values. These results demonstrate that tocotrienols mediated a significant 
protection against fatty streak lesion formation in rabbit aortas in both groups. 
3,4 Effect of Dietary Oxidized Cholesterol in the Acceleration of Aortic 
Atherosclerosis in Cholesterol Fed Rabbits: Hypolipidemic, 
Antioxidant and Antiatherosclerotic Impacts of Dietary Tocotrienols 
Fed to Rabbits For 10 Weeks 
Earlier reports indicate that oxidative modification of LDL is a prerequisite 
for rapid accumulation of LDL in macrophages and for the formation of foam 
cells. Cholesterol oxidation products are abundant in oxidatively modified LDL 
and high levels of circulating cholesterol oxidation products are found in rabbits 
fed a cholesterol containing diet. However, direct in vivo evidence linking 
circulating cholesterol oxidation products to early vascular lesion formation is only 
recently becoming available. It has also been reported that oxidized cholesterol in 
the serum of rabbits is both produced endogenously and derived from food. It is 
well known that Indian diet may contain good concentrations of cholesterol 
oxidation products. Food processing, heating, fiying/ deep frying or prolonged 
storage, particularly at room temperature, induces cholesterol oxidation. Oxidized 
cholesterol is present in various food products, including dairy products, eggs, 
meat, fish and deepfried nuts. Many bakery products due to the presence of butter 
and eggs also contain oxidized cholesterol products. Therefore, dietaiy oxidized 
cholesterol may be a risk factor for atherogenesis. In the experiments described 
below, the hypolipidemic, antioxidant and antiatherosclerotic impacts of dietary 
tocotrienols fed to rabbits for 10 weeks along with a diet containing 0.33% 
nonoxidized cholesterol or the same diet containing 0.33% cholesterol of which 
5% was oxidized, was investigated. 
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In order to find out the differential effect of oxidized cholesterol in the 
acceleration of fatty streak lesions in the aorta, in comparison to nonoxidized 
cholesterol, it was essential that all animals had a similar food intake. Similar 
amount of food consumption per rabbit per day would provide an almost equal 
overall exposure of nonoxidized cholesterol, 95% nonoxidized cholesterol 
containing 5% oxidized cholesterol and tocotrienols to each rabbit in respective 
groups during the 10-week feeding period. This aim was achieved first by feeding 
to twenty two rabbits a powdered rabbit chow for several weeks and monitoring 
their food intake on daily basis. Secondly, seventeen rabbits were then fed a diet 
containing 0.33% cholesterol for 3 weeks. At the end of treatment, blood was 
drawn from the main ear artery of each rabbit and plasma total cholesterol level 
was determined. The mean (mg/ dl) ± SD plasma TC value for 17 rabbits was 
545 ± 155. Twelve rabbits having similar body weight (1.60 to 1.87 kg), diet 
consumption (97.86 to 99.56 g/ rabbit/ day) and plasma TC levels, with a mean 
value of 464 ± 69, were divided into four groups of three each: NLP-C, 
normolipidemic control; HLPpC and HLP|-T, received 033% cholesterol rich diet 
without and with 50 mg% tocotrienol rich fraction (TRP), respectively, for 10 
weeks; HLP2-C and HLP2-T, fed oxidized cholesterol diet containing 0.33%) 
cholesterol of which 5% was oxidized, except HLP2-T rabbits also received 50 mg 
%TRF for 10 weeks. 
3.4.1 Average body weight 
The average body weight of rabbits at the end of 3, 5 and 10 weeks of 
feeding is summarized in Table 7. The data demonstrate that average body weight 
of rabbits in the five groups is quite similar. 
84 
til J 
ca 
< 
z 
Q 
fa 
o 
< 
f^ 7 
fa 
O 
a 
z 
fa 
fa 
X 
H 
H 
< 
H 
M 
fa 
O 
H 
K 
O 
HH 
fa 
Q 
O 
ca 
fa 
O 
fa 
> 
t 
C H 
fa 
U 
fa 
H 1 
cC fa 
U 
pZ" fa 
U 
1 
fa 
z 
;/3 
I . 
o 
£ 
IT; 
o 
o 
+1 
0 0 
«N 
o 
o 
+1 
<^  r-
T f 
i-H 
o 
+1 
o 
o 
+1 
o 
0 0 
rr 
o 
o 
+1 
•^^ 
R 
I . 
> • 
< 
o 
o 
+1 0 0 
0 0 
- t 
^ 
+1 
( N 
0 0 
( N 
o 
o 
+1 
^^  
o 
o 
+1 
IT; 
t ^ 
O 
d 
+1 
IT; 
'H* 
'o 
o 
> 
< 
U-; 
d 
+1 
00 
^ 
^ 
Ti 
(^ ; 00 
'^ 
1—^ 
^ 
+1 0 0 
^ 
+i 
00 
o 
d 
- * - » 
o ? 
^ o 
> 
< 
^ 
«^ 
H 
'V. 
" y 
u 
> • ^ 
f^/ 
,o 
"" 
o 
'— 
d 
"p 
"o 
•a 
c 
o 
u 
s 
3t 
W H 
o 
3 
/-\ 
IT; 
+1 
"/", 
-^ i r , 
.r. 
> 
:/; 
C^  
c 
> 
c 
o 
• * 
^ 
1 
1 
c 
£ 
if, 
n 
"E. 
+1 
"5 
> £ 
£ 
+-* *-• . c 
3 W ^ 
.1= "o £ 
^ h o 
^ ^ yri 
" ^ T ! " l i 
!J W 5 
rs 'Z rs 9 
> o^ -a ^ 
« ® "S ^ 
>• — ^ -^ 
4-1 a> C N <-< 
Zl "T; fa "^  
'^ 2 ^ fa 
Tf ^ _ fa 
^ 
£ H 3 .2 
- oT •-.'2 
i i fa — o 
2 fa O c« 
o -0 " > 
^ fa . " "cj 
c fa ^ : 5 
H "^ -^ ^ c^-
« fat. ^ _ -
c o g « ,^ 
> ex) w ^ -S 
5 "^  « fa S 
•^ •« "S C^  "o 
:s -5 .-2 -^  =:  . 
•2 « .£-- ^ ^ 
.« ^ H = ^' ^ 
<y 3 2 "^ ^ fcJJS 
^ ' i f U - ^ . H . 2 
. i o fa _ ^ fa 
? .= Z « o H 
' • • • -< 
o 
c/5 
c 
U 
o 
l l - l 
J2 J 2 
r* 
u 
^^H 
o 
t/3 
_c 
'3 
> 
B- 5 
3 o 
2 £ 
ei C 
« > 
C « 
J2 S 
— « 
« ^ 
•— o 
s; o 
c , 
^ 5^  
+1 -
^ f a 
6 H 
« ° i^  
O « QJ 
« « H 
rt ^ 2 
« I . C. 
^ 4 ; - N 
« «:2 
3.4.2 Average consumption of diet, cholesterol, oxidized cholesterol and TRF 
after 5 weeks of feeding 
As seen in Table 8, the average weight of diet consumed per rabbit per day 
in each group was quite similar. The lowest amount consumed by HLP2-C rabbits 
was 97.66 g, whereas, highest amount was 99.86 g consumed by NLP-C rabbits. 
As a result, average weight of nonoxidized cholesterol consumed per rabbit per 
day for HLPpC and HLFpT groups was 324.94 mg and 326.26 mg, respectively, 
whereas for HLP2-C and HLP2-T rabbits it was 306.17 and 312.10 mg, 
respectively, during 5 weeks of feeding. Similarly, the amount of oxidized 
cholesterol intake for HLP2-C rabbits was 16.1 Img, whereas for HLP2-T rabbits it 
was 16.42 mg. The amount of TRF consumed was 49.4Img and 49.78 mg per 
rabbit per day for HLPpT and HLP2-T groups, respectively. 
As shown in Table 9, after 10 weeks of feeding, the average weight of diet 
consumed per rabbit per day varied between 97.89 g to 99.80 g, which is quite 
similar. Based on the diet consumption, daily intake of nonoxidized cholesterol per 
rabbit per day in HLPpC and HLPpT groups was 323.03 mg and 323.40 mg, 
respectively, whereas for HLP2-C and HLP2-T rabbits, the consumption of 
nonoxidized cholesterol was 313.08 mg and 311.30 mg, respectively. The average 
consumption of oxidized cholesterol per rabbit per day in HLP2-C and HLP2-T 
groups was 16.47 mg and 16.38 mg, respectively, whereas TRF consumption for 
these two groups was 48.96 mg and 49.65 mg, respectively, during 10 weeks of 
feeding. 
3.4.3 Impact on plasma and lipoprotein lipids after 5 weeks of treatment 
As seen in Table 10, feeding of nonoxidized and oxidized cholesterol rich 
diet to rabbits for 5 weeks was associated with an increase of TC level to 1211 
and 1200 mg/ dl from an initial value of 11 Img/ dl. Supplementation of TRF to the 
86 
< 
U 
b & 
ci Q 
H W 
+ 
^ 
0 
2^  
a H 
U) 
td 
O 
nc u 
J 0 
a: 
w 
w fe 
O 
C/!) 
;^ 
u a 
^ 
i n 
ci 
, td 
H 
fe 
< 
fc 
H Ci 
in 
ta 
J 
o 
a 
u 
u 
z H ^ 
z 
< 
H 
H 
+ 
J 
O 
Ci 
w H 
!/) 
u J 
o 
E 
Z U 
O 
U 
H 
Q 
Q 
W 
N 
5 
>< 
< O 
to 
O 
z 
o 
a. 
in 
Z 
0 
u 
Q 
Z 
<: 
J 
o 
t/5 
a J 
0 
a 
w u 
o 
< 
r / 
s 
> 
< 
r\ 
Vx 
N 
5 
>< 
-1 
u 
U 
I 
CM 
Z 
c: 
u 
c: 
30 
+1 
J 
E 
H 
L 
CM 
-5 
E 
+1 
K 
CN 
IT/ 
o 
+1 \ 5 
30 
0 0 
© 
+1 
00 
o 
+1 
00 
ON 
• 3 
tn 
00 
00 
+1 
o 
>—I 
+1 
o 
o 
+1 
CN 
IT; 
+1 
'^ 
o 
•a p 
o *: 
o 
+1 
o 
O 
+1 
OO 
OO 
O 
+1 
o 
o 
•a ^^ 
• > < > > 
O C! 
. 1 ^ 
"3 >-
^ 
u 
DX) 
c: 
o 
< 
J2 
u 
•a 
u 
S p 
IT) 
C o 
o 
Tc 
'S j : 
u 
6i3 
1^ 
< 
Si 
u 
• ^ 
u 
£ 
3 
C 
C 
biD 
•a 
o 
ex) 3 
C 
O 
u 
s 
3 
o 
ex) ? 
.S ^ 
fa 
•-= — =^  
I I r 
— -5 " O • - O 
U •< u:: 
« "= •? 
O 
•a 
O U 
Kg:" 
i E 
c E 
u 
X5 
« 
3 
73 
• ^ O 
re 
U 
I 
E 
•a 
s*« 
Q S 
•^ o 
o 
o 
fa — 
5 o H «i 
o 
E 
CI 
re 
u 
_3 
re 
> 
o 
s 
U 
I 
z 
irj ^ 
^ d 
< 
a 
SI 
Cri 
H 
+ 
O 
H 
o 
u 
o 
ci 
-J 
o 
U 
o 
o 
Z 
o 
u 
H 
5 
< 
+ 
O 
S 
O 
•r 
U 
s 
-: a 
< 
O 
z 
o 
Pu 
Z 
o 
u 
u 
o 
Q 
z 
< 
o 
J 
O 
X 
u 
u 
I 
U 
I 
u 
-J 
z 
+i 
o 
o 
+1 
o 
00 
0 \ 
00 
0 0 
o 
+1 
o 
o 
Q6 
ON 
0 0 
0^ 
ON 
1—1 
+1 
CM 
© 
© 
I5t 
o - i 
« 3 
< 2 
IT/ 
+1 
rT) 
in 
+1 
oc 
o 
O 
+1 
- r 
+1 
o 
o ^ 
i i S 
o ^ 
o *2 
'i- ^ 
o « 
2 = 
o 
+1 
00 
IT) 
o 
+1 
"o 
Si 
u 
4> OX) 
•^ E 
O K 
o ^ 
^1 
bxi-S 
o 
+1 
IT; 
© 
+1 
0 0 
t5X) 
o ^ 
2 = 
« c 
bn vo 
s ^ 
© ^ 
•t: bx) 
S= .S 
"^ .S 
£ K t/5 
'=' "£ ^  
13 O S 
2 " ^ 
• I - a> o 
.y i i H 
u o 
- '^ ?> 
O o « 
-a 
c «> 3 2i 
o '^ 
biH 
u 
c: 
"R 3 
c 
« 
U 
in ^ 
.t: o 
X! "S 
2 ^ 
J H 
K J. 
c J 
u -S. 
l - I U 
CM 
K 
'> "o 
C C 
— o 
Q i 
'-a T3 
(« N 
^ o 
2 « 
o ^ 
^ in 
+1 .£< r •? 
I i 
o 
Si = 
TABLE 10 
IMPACT OF TRF ON PLASMA TOTAL CHOLESTEROL, VLDL-C, LDL-
C AND HDL-C IN HYPERLIPIDEMIC RABBITS AFTER 5 WEEKS OF 
TREATMENT 
Parameters NLP-C HLPrC HLP,-T HLP.-C HLP,-T 
Total cholesterol 111116* 
VLDL-cholesteroI 13±2 
1211±13 
125±15 
968±39 
(-20%)" 
93+8 
(-26 % ) " 
1200±102 
141±11 
9761129 
(-19%)" 
100±8 
(-29 %f 
LDL-cholesterol 65±5 716135 548162 
(-23 %)" 
702+36 50612 
(-28 %)" 
HDL-choIesterol 3618 363144 337147 363132 361111 
Values are mean (mg/dl) 1 SD from plasma of 3 individual rabbits in each group. 
NLP-C, normolipidemic control; HLP|-C and HLPi-T, fed a diet containing 0.33 % 
cholesterol without and with 50mg % TRF, respectively, for 10 weeks; HLP2-C and HLP2-T, 
fed oxidized cholesterol diet containing 0.33 % cholesterol of which 5 %> was oxidized, except 
HLP2-T rabbits also received 50mg % TRF for 10 weeks. 
Significantly different from HLP,-C at ''p<0.001 & V<0.05. 
Significantly different from HLP2-C at "p<0.001 & 'p<0.01. 
above diets caused a significant decrease in TC levels by 20% and 19%, 
respectively. Similarly, VLDL-C and LDL-C levels were increased by 862% and 
908% in HLPi-C and HLP2-C, respectively, when compared to control values. 
Treatment with TRF caused a significant decline of VLDL-C levels by 26% and 
29%), whereas, LDL-C was reduced by 23% and 28%, respectively, forHLP|-T 
and HLP2-T rabbits in comparison to respective hyperlipidemic controls. 
Although, HDL-C levels were increased by 908% in HLP,-C and HLP2-C, when 
compared to NLP-C values, no significant effect of TRF was seen. 
As shown in Table 11, HDL-C/TC and HDL-C/LDL-C ratios of HLP|-T 
and HLP2-T rabbits were significantly increased in comparison to ratios from 
respective hyperlipidemic controls. TC/HDL-C and LDL-C/HDL-C ratios were 
decreased in tocotrienol treated rabbits when compared to ratios of HLPpC and 
HLP2-C. 
3.4.4 Effect on plasma and lipoprotein lipids after 10 weeks of treatment 
Table 12, shows the effect of TRF on plasma lipids of hyperlipidemic 
rabbits treated for 10 weeks, hi comparison to a TG value of 104 mg/dl in NLP-C, 
HLPi-C and HLP2-C values were increased to 1397 mg/dl and 1399 mg/dl, 
respectively. Supplementation of TRF mediated a decline of 21% and 29%, 
respectively, for HLPpT and HLP2-T TG values. Plasma TC levels in HLPpC and 
HLP2-C animals were increased by 1161% and 1099% respectively, when 
compared to NLP-C values, hi comparison to HLPpC and HLP2-C TC values, 
treatment with TRF was associated with a significant decline of 22% and 23% for 
HLPi-T and HLP2-T rabbits, respectively. Both free and esterifled cholesterol 
levels were significantly reduced in TRF-treated rabbits (Table 12). 
As seen in Table 13, both plasma VLDL-C and LDL-C levels were 
substantially increased after 10-week feeding of either a nonoxidized cholesterol 
90 
J 
5 J 
r\ 
Z. 
< 
u 1 
Q 
I 
D f— 
u 1 
J 
u 
j Q 
X 
u j 
Q 
a 
Z 
i^ 
S 
u« 
< 
fcj 
b. 
O 
c/) 
V 
s 
> 
^ 
ir, 
Q/ 
s 
< 
iTi 
h 
5 CO 
< 
o 
c/:i 
O 
H 
U 
^E 
H 
o 
H 
u. 
O 
H 
U 
< 
G 
oi 
a. 
z 
u 
I 
-3 
C 
33 
U 
u 
I 
Q 
U 
I 
-3 
Q 
J 
U 
I 
-J Q 
U 
H 
U 
I 
J 
u 
I 
J 
Q 
X 
u 
u 
I 
J 
Q 
3 p 
H c-
00 
^ M 
r<^  
o 
+1 
«N 
^ M 
00 
rs 
TT 
o 
o 
+1 
ro 00 
0^ 
o 
rn 
o 
+1 
o 
o 
o 
+1 
o 
o 
+1 
r-
o 
U 
I p 
J 
Z 
• o 
o 
+1 
00 
<N 
o 
I 
A 
<N 
+1 ^  
+1. 
o 
IT; 
d d 
+i ^ 
00 + 
1 
<r/ 
r-
^^  d 
+1 
>o 
f^-
CN 
r<"/ 
<N 
^ • ^ ,,*"s 
d -^  
+1 ^ 
^ ^. 
— <N 
Tf w 
0 0 
o 
n 
d 
+1 0 0 
o 
IT/ 
<^ ' 
C^ 
r-
«N > ^ 
d s= 
+1 €^  \r, ^ \o T 
a: w 
<N 
^ O 
-^ 
d 
+1 t^ 
f<"/ 
TT 
r^, 
+1 
IT/ 
d 
o 
d 
+1 
d NO 
00 t^  
00 w 
— (N 
<N — 
O O 
d i5 
+1 Xo 
d 
d ^ 
o o 
Cm 
d 
u 
0 
C3 
0 
c 
^ 
i»> 
0 
c 
0 
*^  
3 
0 
+ -
U 
0 
C 
3 
0 
0 
u 
_c 
J2 
C3 
3 
> 
•5 
ro 
0 
Q 
in 
+1 
c 
£ 
P 
tfi 
u 
_3 
K 
> 
d 
OH 
OJD T 3 
c 
0 
•5 
:S 
r s 
1 
J 
K 
U 
1 
"0 
c 
0 
£ 
2 
'c-
B-MT 
0 
£ 
L. 
0 
3 
U 
£1< 
Z 
3 
u 
1 
E 
0 
> 
1/^ 
^ 
<s 
_> 
fa 
Di3 
£ 
0 
IT) 
j -
•a 
c 
c: 
3 
0 
^ 
^ 
"o 
(« u 
" 0 
"o 
•0" 
u 
^ 
0 
IT; 
«^  0 
IZl 
u 
"o 
»^  
d 
c 
0 
u 
"3 
0 
CI 
IZJ 
0 
"o 
•a 
j5 
'^ 0 
T3 
t * ^ 5+iM 
"o 
0 
IT; 
;2 
fa (2! 
bX) 
£ 
© 
-o 
' 0 
u 
0 
0 
»5 
!c X i 
H 
1 
C^ ' 
J 
E 
0 
d 
V 
• 4 - * 
c: 
1 — < 
0 
0 
d 
V 
c 
u 
•a 
c 
0 d 
V 
c 
u u 
1 1 
— r i 
M ffi 
£ 
0 
•^^ 8 
0 
( M 
•5 
>^  
3 
C 
"s 
.2f 
C^ 
1 
• w 
c 
01 
c> 
•a 
i:> 
C 
s 
c 
'B 
_M 
C^ 
< 
S 5 [V, 2 
H 
Q 
Z o 
r. O 
H 
O 
H 
03 
Pi a 
o 
b. 
O 
H 
u 
< 
= o 
o 
w 
U 
I 
-J 
-J 
U 
I 
z 
c: 
1 
J 
T" 
4-1 
o 
o 
~^„^ 
• ^ 
CN 
(N 
+i 
•-*' r^, 
^ 
00 
+1 
t-^ 
(N 
:::< 
00 
t 
00 
+1 
2; (N r4 
-
(N 
1 
+1 
O 
^ 
iri 
1 
t^ 
CN 
+1 
t^ 
a\ 
r^y 
r-
c% 
+1 
C^ 
r^  
m r^i 
+1 
o 
+1 
U 
o 
bS) 
o 
p 
V3 
fa 
+i 
O 
ON 
o 
c\ 
+1 
C\ 
<^> 
r^  00 
+1 
^ 
-t 
r-
+1 
^^  
O 
^ 
+1 
— 
+1 
ON 
IT; 
r^ i 
+1 
•o 
"^  
C--
"* 
^ H 
+1 
ro ON 
^^  
+1 
r^ iTl 
rr) 
+1 
ON 
VO 
"o 
•D 
01 
ON 
•o "S ^ 
O O " ^ 
I—( 
o =r; -a 
" - 1 ?> N 
"5 -i 
o 
C/3 
C! .= §u 
t« w ^ s: 
."2 *- a, "^  
— • - M J NT 
^ - ^ — C^ 
^ ^ ^ JS 
•r H ^ f 
w ^ ^^ (*^ 
.5 J u ® . 
r^ " ^ SM O . : i 
««. - a ^ I . o 
c: c: «j s^ f 
E u •=: -I o 
— ^ « y l -
Q i g d s= 
^.S £ 
.5 o 
V 
o ^ 
1^ 
o o 
d d V V 
c c. 
= -^ exj.S o 
5- S £ ?« "^  
o 
s s 
5 £ C « u^  
y3 I/-1 ^ «J c ."2 "^ o 9 
i 2 > I g 
!- c K ? T: 
c s 
« J S 2-5 ^ " j t : "o j 2 
> z f o 2 
"3 -a 
C S 
'c 'c 
_6JD _6J3 
t i l 
J 
< 
U 
I 
J 
Q 
Q 
H 
H 
< 
Q 
a 
u 
Q 
X 
H 
O 
V2 
Q 
> 
< 
Z 
o 
H 
o 
H 
U 
< 
0-
en 
H 
Q 
H 
I 
U 
I 
r i 
- J 
u 
Z 
+) 
0 0 
o 
+1 
ON 
o 
+1 
o u 
Q 
> 
:s: 
00 
+1 
=^  in 
+1 
IT) 
0 0 
+1 
oc 
m 
+1 
0 0 
0 0 
oo 
+1 
0 0 
IT; 
IT/ 
+1 
p 
1/2 
^ 
IT) 
+1 
r-1 
+1 
+1 
IT) 
+1 
p 
o 
J 
Q 
X 
o 
OS 
+1 
+1 
O 
+1 
00 (S 
+1 
0 0 
o 
u o 
Q 
+1 
o 
+1 
ON 
+1 
+1 
+1 
so 
O 
CI 
o 
u 
I 
n 
Q 
^ 2 J 
4 ^x 
p o J 
^ c 
~ 'c "^  
o ~ f! 
e c u 
•-" O 1 
^ " cC' 
. - -h- ^ 
X! .« -J 
^ T3 E 
u 
;«; 
o 
•a 
u 
N 
73 ^ K 
o f 
•a 
:> H 
" ^ Q ~ ' " ' '•*-
— 1-1 p 
m o 
o o 
•d d 
V V 
- ^ ^ = < J 
I « > 
« ;_ « 
+1 o ^ 
:a .Si S 
M S 
_ -a wo 
c "H,^ 
3 "o '" 
? o c 
c: c ^ 
"^  r r 3 
^ n • — 
> Z ^^  
p 
o 
O 
o o d d 
V V 
E i ' ® 
i •-
ftD 
_c 
£ 
'« 
C 
o 
u 
CJ 
•5 
'o 
;. 
o 
-^^ C/5 
o 
,£ 
u 
bD 
B 
o 
irj 
-a Q 
> 
U 
CI 
;. 
o 
1/3 
"K 
1/3 
, 0 
c: 
u 
u u 
I I 
— r^  
S S 
o o 
c s 
o o 
c c 
u u 
C C 
"c "c 
rich diet or a 95% nonoxidized and 5% oxidized cholesterol rich diet. 
Supplementation of TRF to these diets caused a 48% and 52% decline in VLDL-C 
levels, whereas, LDL-C levels were reduced by 25% and 13% in HLPpT and 
HLP2-T rabbits, respectively. Plasma HDL-C levels including it's subfractions, 
HDL3-C and HDL2-C, were substantially increased following feeding of a 
cholesterol rich diet. However. TRF treatment did not significantly affect their 
levels. 
As shown in Table 14. HDL-C/ TC and HDL-C/ LDL-C ratios, calculated 
from the data in Table 12 and 13. were increased in TRF-treated rabbits in 
comparison to respective hyperlipidemic controls. Similarly, TC/ HDL-C and 
LDL-C/ HDL-C ratios in HLPpT and HLP2-T groups were reduced, when 
compared to corresponding ratios of HLPpC and HLP2-C rabbits. The combined 
results demonstrate that increase in plasma and lipoprotein lipids following 10-
week feeding of a diet containing 0.33% nonoxidized cholesterol without and with 
5% oxidized cholesterol was similar, hi addition, supplementation of TRF to 
HLP|-C and HLP2-C diets, mediated a significant decrease in plasma lipid levels. 
3.4.5 Hypocholesterolemic impact on liver TC after 10 weeks of treatment 
The data related to hypocholesterolemic effect of TRF on hepatic TC is 
summarized in Table 15. Feeding of a diet containing nonoxidized cholesterol 
(HLPi-C) caused an increase of 224% in liver TC content expressed as per 100 mg 
liver protein. Feeding of the same diet containing 5% oxidized cholesterol 
(HLP2-C) was associated with a significantly higher increase (323%) in TC level. 
In addition, the decline in hepatic TC level mediated by tocotrienols in HLP2-T 
animals was 45%, which is two-fold higher, when compared to a decline of 22% in 
HLPpT rabbits. These results demonstrate that unlike plasma TC, liver TC was 
increased to a higher level in oxidized cholesterol fed rabbits than nonoxidized 
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cholesterol fed animals. In addition, the hypocholesterolemic effect of tocotrienols 
in oxidized cholesterol fed rabbits was significantly more pronounced. 
3.4.6 Antioxidant effect on plasma lipid peroxide levels 
As shown in Table 16, plasma lipid peroxides were increased by 170% and 
216% in HLPi-C and HLP2-C rabbits, respectively, when compared to NLP-C 
values. Treatment with TRF significantly blocked the rise in lipid peroxides in 
hyperlipidemic animals. In HLPpT it was reduced to 88%, whereas, in HLP2-T to 
80% level. It is interesting to note that both increase in plasma lipid peroxides in 
HLP2-C and its decline in HLP2-T rabbits was significantly higher than HLPpC 
and HLP)-T rabbits. The TRF-mediated decline in lipid peroxides in HLP2-T and 
HLPpT was 43% and 30%, respectively. 
3.4.7 Impact on hepatic peroxidase level 
As seen in Table 17, after feeding a nonoxidized cholesterol rich diet or the 
same diet containing 5% oxidized cholesterol for 10 weeks, liver peroxide levels 
were significantly increased by 197% and 279%, respectively. Similar to plasma, 
the TRF- mediated block in the rise of hepatic lipid peroxidases was significant in 
both groups, when compared to respective hyperlipidemic control values. 
3.4.8 Antioxidant impact on base line levels of diene conjugation, lag phase 
and rates of conjugated diene formation in LDL 
As seen in Table 18, the ex vivo base line level of diene conjugation (BDC) 
of LDL isolated from plasma of hypercholesterolemic rabbits fed a nonoxidized 
cholesterol diet for 10 weeks was increased by 229%) in comparison to NLP-C 
value. The increase in BDC level of LDL from HLP2-C rabbits was 271%. 
Supplementation of TRF in HLPpT and HLP2-T diets significantly blocked the in 
vivo LDL oxidation and reduced the BDC levels to 95% and 173%, respectively. 
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TABLE 16 
ANTIOXIDANT EFFECT OF TRF ON PLASMA LIPID 
PEROXIDE LEVELS IN HYPERLIPIDEMIC RABBITS AFTER 
10 WEEKS OF TREATMENT 
Group 
NLP-C 
HLP,-C 
HLP|-T 
HLP2-C 
HLP2-T 
Lipid peroxide level 
(Percent decrease 
with respect to 
respective HLP-C) 
1.33110.303* 
3.592+0.268 
2.505+0.122 
(-30 %)" 
4.207+0.179 
2.399+0.116 
(-43 %)" 
Percent increase with 
respect to NLP-C 
— 
170" 
88" 
(1.93)^ 
216" 
80" 
(2.70)*' 
Expressed in terms of maiondialdehyde (nmoie/ml plasma). 
Values are mean ± SD from plasma of three individual rabbits in 
each group. 
NLP-C, normolipidemic control; HLP|-C and HLPpT, fed a diet 
containing 0.33 % cholesterol without and with 50 mg% TRF, 
respectively, for 10 weeks; HLP2-C and HLP2-T, fed oxidized 
cholesterol diet containing 0.33 % cholesterol of which 5% was 
oxidized, except HLP2-T rabbits also received 50 mg% TRF 
for 10 weeks. 
%old decline with respect to HLP,-C and HLP2-C in HLPi-T and 
HLP2-T, respectively. 
Significantly different from NLP-C at "p<0.001 & ''p<0.01. 
Significantly different from HLP,-C and HLP.-C at "p<0.001 & 
"p<0.01. 
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when compared to control values. The lag phase time of HLP|-C and HLP2-C 
rabbits was reduced to 30 min and 15 min, respectively, in comparison to a lag 
phase of 75 min in NLP-C. TRF supplementation in HLPpT and HLP2-T diets 
restored the lag phase time to 60 min and 70 min, respectively, which is closer to 
normal control value. In comparison to the rate of in vitro LDL oxidation of 
NLP-C rabbits, feeding of cholesterol or oxidized cholesterol rich diet was 
associated with an increase of 144% and 221%, respectively. The rise in rate of 
conjugated diene formation was significantly blocked to 95%) and 126%) in HLPpT 
and HLP2-T animals, respectively. These results establish in vivo and in vitro 
tocotrienol-mediated resistance of LDL to oxidation. 
As shown in Table 19. the baseline levels of TBARS in LDL were 
significantly higher in HLPpC and HLP2-C rabbits than untreated NLP-C group by 
242%) and 287%, respectively. Supplementation of TRF blocked the in vivo 
increase in TBARS contents of LDL in HLP|-T and HLP2-T rabbits, and the 
increase in comparison to control group was reduced to 148%o and 182%, 
respectively. Maximal in vitro copper-induced oxidation of the above LDL isolated 
from plasma of rabbits in each group was achieved after 24h of incubation. The 
TBARS content of LDL in NLP-C group was increased by 543%o, when compared 
to baseline value. In comparison to basal values, the LDL TBARS levels in HLPp 
C and HLP2-C rabbits increased by 99%o and 108%), respectively, whereas, in 
HLPpT and HLP2-T rabbits, due to feeding of TRF along with 
cholesterol/oxidized cholesterol rich diet, the maximal increase in TBARS of LDL 
was only 39% and 58%. respectively. These results demonstrate that similar to 
baseline levels of conjugated dienes in LDL (Table 18), basal TBARS contents in 
LDL, were significantly increased after 10 weeks of feeding of dietary cholesterol 
to rabbits. In addition, tocotrienols significantly blocked the increase in TBARS 
levels. 
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TABLE 19 
ANTIOXIDANT EFFECT OF TRF ON THE CONTENTS AND COPPER-
INDUCED GENERATION OF TBARS IN PLASMA LDL OF HYPERLIPIDEMIC 
RABBITS AFTER 10 WEEKS OF TREATMENT 
TBARS contents in LDL^ 
Group T^ 
Basal Maximal oxidation of LDL by Cu' 
NLP-C 3.39±0.96 21.7910.20" 
(+543%)' 
HLP,-C n.60±0.07 43.33±0.33 
(+242%/ (+99%)' 
HLP,-T 8.39+0.08 30.19±0.21 
(+148%) (+39%)^ 
HLP2-C 13.12+0.04 45.38±0.02 
(+287%) (+108%)' 
HLP2-T 9,57+0.20 34.44±0.35 
(+182%) (+58%)^ 
The TBARS contents in LDL are expressed as nmol nialondialdehyde (MDA) 
equivalents per mg protein. Basal TBARS represent the status of oxidized LDL 
in vivo in five groups of animals. Maximal /// vitro oxidation of LDL was achieved 
after 24 h incubation with CUSO4 in each group of rabbits. 
Values are mean + SD of 3 separate assay from pooled plasma samples of 3 
rabbits in each group. 
NLP-C, normolipidemic control; HLPpC and HLP|-T, fed a diet containing 
0.33% cholesterol without and with 50 mg % TRF, respectively, for 10 weeks; 
HLP2-T, fed oxidized cholesterol diet containing 0.33% cholesterol of which 5% 
was oxidized, except HLP:-T rabbits also received 50 mg % TRF for 10 weeks. 
"Percent increase with respect to NLP-C values. 
Percent increase with respect to baseline TBARS levels of HLPpC and HLPj-C 
group. 
^Percent increase with respect to basal TBARS levels of HLPi-T and HLPi-T rabbits. 
3.4.9 Impact of TRF on aortic fatty streak lesions 
As shown in Figure 3.2. feeding of a diet containing 0.33% nonoxidized 
cholesterol to HLP]-C rabbits for 10 weeks was associated with an average 14.3% 
aortic area covered by fatty streaks. Whereas, HLP2-C rabbits fed oxidized 
cholesterol diet containing 0.33% cholesterol of which 5% was oxidized had an 
average fatty streak lesion area of 27.7%, which shows an increase in fatty streak 
lesions by approximately 100% in comparison to HLPpC rabbits. Feeding of 
dietaiy TRF along with nonoxidized cholesterol rich diet blocked the formation of 
fatty streak lesions in the aortas of HLP|-T rabbits to an average value of 6.0 %, 
which is approximately 2.4-fold lower when compared to HLP|-C values. In 
oxidized cholesterol plus TRP fed rabbits (HLP2-T), the average area of fatty 
streak lesions in the aortas was reduced to 6.7%, which is 4.1- fold lower than 
HLP2-C values. These results demonstrate that tocotrienols offered a significant 
protection against fatty streak lesions in aortas of hyperlipidemic rabbits in both 
groups. However, the effect was more pronounced in oxidized cholesterol fed 
rabbits. 
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Fig. 3.2 Percent aortic area covered by fatt>' streaks in rabbits. HLPpC 
and HLPi-T, received nonoxidized cholesterol (0.33 %) rich diet 
without and with 50 mg % TRF, respectively, for 10 weeks; 
HLP2-C and HLP2-T, rabbits fed oxidized cholesterol diet 
containing 0.33 % cholesterol, of which 5 Vo was oxidized, except 
HLP2-T rabbits also received 50 rag % TRF for 10 weeks. 
(Discussion 
Diet induced hypercholesterolemia in rabbits has been a widely used model 
system for the development of human atherosclerosis (Clarkson et al, 1993). In 
order to achieve rapid lesion development, exceedingly high plasma cholesterol 
levels (>1500 mg/dl) have been produced by feeding a high cholesterol diet 
(>0.5% of diet, by weight) or by other dietaiy methods (Parker et al, 1966; 
Newman and Zilversmit, 1964). As a consequence, the lesions that are usually 
produced are topographically and morphologically dissimilar to those seen in 
humans (Jokinen et al, 1985). This dissimilarit}' is due in part to the fact that 
humans usually do not ingest such large quantities of cholesterol; do not, in 
general, have plasma cholesterol levels higher than 800 mg/dl (Evan and Myers, 
1994); and process and tolerate cholesterol intake better than rabbits. However, 
recent studies employing low levels of dietaiy cholesterol (<0.5% by diet weight) 
produced moderate hypercholesterolemia (Holvoet and Collen, 1997; Adams et al, 
1982; Feldman et al, 1991) with gradual lesion formation that more closely 
resembles early atherosclerosis in humans (Adams et al, 1982; Daley et al, 1994a; 
Bocan et al, 1991). Moreover, a number of studies have attempted to define the 
relationship between atherosclerotic lesion formation and diet induced 
hypercholesterolemia in rabbits fed low levels of cholesterol (Daley et al, 1994a; 
Bocan et al, 1993; Daley et al, 1994b, Kolodgie et al, 1996). A total plasma 
cholesterol exposure (cumulative plasma cholesterol levels over time) can be used 
to establish a threshold below which aortic lesions are minimal but above which 
the extent of aortic lesion formation is correlated positively with total plasma 
cholesterol exposure (Bocan et al, 1993: Kolodgie et al, 1996). Consistent with 
these findings, we have used a low, 0.33% cholesterol containing diet for inducing 
hypercholesterolemia and formation of early fatty streak lesions in the aorta of 
rabbits. The other problem working with cholesterol fed rabbits has been the high 
variability between individual animals. Therefore, it was pertinent that all the 
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animals had a similar food intake and thus exposed to similar amounts of 
cholesterol. As our results demonstrate we have divided the rabbits in four groups 
based on similar body weight and food consumption on per day basis. After 22.4 
weeks of feeding 0.33% cholesterol rich diet with and without TRF or Tocomin. 
the total intake of cholesterol was 54.R6, S4.64 and 56.45 g, respectively, for HLP-
C, HLP-T| and HLP-TT rabbits. From these results it is clear that although each 
rabbit has consumed similar amount of dietary cholesterol over a period of 22.4 
weeks, the plasma cholesterol and TG levels in certain rabbits did show a fair 
amount of variation. These results are consistent with earlier reports that a wide 
biological variability occurs among rabbits with respect to individual 
responsiveness to dietary cholesterol and that the severity of arterial lesions 
correlates with the plasma cholesterol concentration (Kolodgie et al., 1996; 
Collens, 1957;Stapranse/a/., 1996a; Staprans era/., 1998; Rong era/., 1999). 
Supplementation of TRF or Tocomin with cholesterol rich diet was 
associated with a significant decline in plasma TG (insignificant decrease in 
Tocomin treated HLP-Tj rabbits), TC. VLDL-C, and LDL-C levels. Although 22.4 
weeks of cholesterol feeding caused a substantial increase in plasma HDL-C and 
it's subfractions, HDL3-C and HDL2-C levels, TRF or Tocomin treatment did not 
significantly prevent the increase in these levels. TRF feeding also caused a 
significant improvement in the ratios of HDL-C/TC, HDL-C/LDL-C, TC/HDL-C 
and LDL-C/HDL-C, indicating the normalization of lipid parameters. 
In order to overcome this problem, in the second part of the investigation, 
rabbits were grouped based on similar total plasma cholesterol level before the 
initiation of experiments. This objective was achieved by feeding a diet containing 
0.33% cholesterol to rabbits for 3 weeks and only those animals having a similar 
elevated plasma TC levels were included in a 10-week study. Since in these 
experiments role of dietary oxidized cholesterol (5%)) in the acceleration of fatty 
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streak lesions in the aorta in comparison to nonoxidized cholesterol was 
investigated, it was essential that rabbits in different groups have almost the same 
plasma cholesterol concentration, otherwise one could not see the difference in 
aortic lesions. Similarly, the therapeutic impact of tocotrienols fed along with 
cholesterol or oxidized cholesterol rich diet would be difficult to assess. Our 
results demonstrate that average weight of nonoxidized cholesterol consumed per 
rabbit per day in HLPpC and HLPpT groups was 323.03 and 323.40 mg, 
respectively, whereas for HLP2-C and HLP2-T rabbits, the consumption of 
nonoxidized cholesterol was 313.08 and 311.30 mg, respectively. The average 
consumption of oxidized cholesterol per rabbit per day in HLP2-C and HLP2-T 
groups was 16.47 and 16.38 mg. respective!}-, whereas TRP consumption for these 
two groups was 48.96 and 49.65 mg, respectively, during 10 weeks of feeding. 
Because of the above manipulations, at the end of treatment, average plasma TC 
level in HLPpC and HLP2-C rabbits was 1539±97 and 1463±82 mg/dl, 
respectively, whereas in HLPpT and HLP2-T groups the TC level was reduced to 
1201±64 and 1134±17 mg/dl. respectively. These results suggest that a total 
plasma cholesterol exposure, that is, cumulative plasma cholesterol levels over 
time in rabbits of above four groups was apparently quite similar, thus causing a 
minimal variation in average TC values. These results are in agreement with the 
findings of others where a diet rich in 0.33% nonoxidized cholesterol or the same 
diet containing 0.33% cholesterol of which 5% was oxidized was fed to rabbits for 
12 weeks (Staprans et ai, 1998) or injections of cholesterol oxidation products 
mixture was given to cholesterol fed rabbits (Rong et a!., 1999). However, in these 
studies therapeutic interventions were not reported. 
Feeding of a cholesterol rich diet to rabbits either for 22.4 or 10 weeks 
caused a substantial increase in plasma TG. TC. VLDL-C, LDL-C and HDL-C and 
it's subfractions. HDL3-C and HDLo-C levels. Supplementation of TRF or tocomin 
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to the above cholesterol rich diet was associated with a significant decline in 
plasma TG (insignificant decrease in tocomin treated HLP-T2 rabbits), TC, VLDL-
C and LDL-C levels. However. 22.4 weeks of TRF or Tocomin treatment or 10 
weeks of TRF treatment did not significantly prevent the increase in HDL-C, 
HDL3-C and HDL2-C levels, v.'hen compared to respective hyperlipidemic control 
values. It has been shown in rodents (Staprans et al., 1993a; Staprans et ai, 1993b; 
Staprans et al, 1996a) and humans (Staprans et al, 1994) that oxidized fatty acids 
in the diet are incorporated into the serum chylomicron fraction. In rodents 
oxidized fatty acids are also incorporated into the endogenous VLDL fraction 
(Staprans et al, 1993b; Staprans et al, 1996a). Moreover, the above laboratory has 
demonstrated that oxidized fatt>' acids in the diet accelerate atherosclerosis in 
cholesterol fed rabbits (Staprans et al, 1996b). Recent studies demonstrate that 
oxidized cholesterol in the serum of rabbits is both synthesized endogenously and 
derived from food (Staprans et al, 1998; Rong et al, 1999). The evidence for 
endogenously produced oxidized cholesterol products is the observation that after 
feeding to rabbits a diet containing 0.33% nonoxidized cholesterol that contains no 
detectable levels of oxidized cholesterol, cholesterol oxidation products were 
identified in serum VLDL and LDL. However, their level in serum VLDL and 
LDL was significantly lower in comparison to rabbits fed the same diet containing 
0.33% nonoxidized cholesterol of which 5% was oxidized (Staprans et al, 1998). 
Similar results were found when injections of oxidized cholesterol were given to 
cholesterol fed rabbits (Rong et al, 1999). The exact source of endogenous 
oxidized cholesterol products is not clear, but it could be produced by enzymatic 
and/ or nonenzymatic processes (Addis et ai, 1996; Smith and Johnson, 1989). 
Enzymatic oxidation mainly occurs in liver and steroidegenic tissues, and several 
cholesterol oxides are produced in the liver in the course of enzymatic oxidation of 
cholesterol for the production of bile acids (Bjorkhem, 1972). Furthermore, the 
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elevated oxidized cholesterol could also retlect cholesterol peroxidation through 
free radical-mediated nonenzyniatic processes. The radical species responsible for 
cholesterol oxidation are derived from activated oxygen, which could occur in a 
variet}' of tissues (Morin and Peng, 1992), or within the artery cell wall, as 
suggested by several investigators (Steinberg. 1997; Sevanian and McLeod. 1987; 
Morel et ai, 1984; Parthasarathy et al, 1986). Such endogenously produced 
cholesterol oxidation products in rabbit serum have been described previously 
(Hodis et al.. 1991). In vivo formation of oxidized serum cholesterol has been 
shown by Breuer and Bjorkliem (1995) using an O2 inhalation technique. 
Our results demonstrate that feeding of cholesterol rich diet containing 5% 
oxidized cholesterol (HLP2-C) did not significantly alter the plasma cholesterol 
concentrations in comparison to values obtained from nonoxidized cholesterol fed 
rabbits (HLP|-C). In both the groups, at the end of 10-week experiment, the 
average plasma TG, TC, including FC and EC. VLDL-C, LDL-C, HDL-C, HDL3-
C and HDL2-C levels were markedly increased to a similar extent. In addition, 
more than 70% of plasma cholesterol was found in the VLDL plus LDL fraction 
and no significant differences in cholesterol distribution among lipoprotein 
particles were detected between the two experimental groups. These results are 
consistent with the results of others (Staprans et al., 1996b; Mahley, 1978). 
Feeding of either a nonoxidized cholesterol rich diet or the same diet 
containing 5% oxidized cholesterol supplemented with 50 mg % dietary TRF for 
10 weeks caused a similar but significant decrease in plasma TG, TC including FC 
and EC, VLDL-C and LDL-C levels, when compared to respective hyperlipidemic 
controls. Plasma HDL-C and it's subfractions. HDL-j-C and HDL2-C levels, were 
substantially increased to a similar extent in both the groups after 10 weeks of 
cholesterol feeding. Dietary TRF treatment to cholesterol fed rabbits (HLPpT) 
failed to suppress the increase in HDL-C levels. However, the increase in plasma 
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HDL-C levels of oxidized cholesterol led rabbits together with TRF (HLP2-T) was 
associated with a 19% decline, which was insignificant. These results are 
consistent with the dietary TRF and purified tocotrienols from palm oil, Tocomin. 
mediated decline of plasma and lipoprotein lipids in the above long-term (22.4 
weeks) experiment. In genera!, the combined results are in agreement with our 
previous findings and reports from other laboratories indicating a strong 
hypolipidemic effect of TRF or purified tocotrienols in normolipidemic and 
hyperlipidemic rats (Beg et al, 1996b; Minhajuddin el al, 1999; Sharma and 
Rukmini. 1986 & 1987; Seetharamaiah and Chandrasekhara, 1989; Watkins et al, 
1993), normolipidemic and genetically hyperlipidemic swines and chickens 
(Qureshi et al, 1991c: Qureshi and Qureshi, 1993; Qureshi et al, 2000), 
hyperlipidemic rabbits (Teoh et al, 1994), normolipidemic and hyperlipidemic 
humans (Khan et al, 1994: Beg et al, 1995 and 1996b, Beg et al, 1997; 
Minhajuddin et al, 1999; Tan et al, 1991; Qureshi et al, 1991a, Qureshi et al, 
1997; Qureshi et al, 2001b: Qureshi et al, 2002) and hyperlipidemic hamsters 
(Raederstorff e/ al, 2002). Treatment of patients with hyperlipidemia and carotid 
stenosis with TRF for 12 months revealed a significant carotid atherosclerotic 
regression with no change in serum TG, TC, LDL-C and HDL-C (Tomeo et al, 
1995). 
Intervention with repeated coronaiy arteriographies to monitor disease 
progession have consistently shown that ratios of LDL-C/HDL-C, apoB/ apoA and 
HDL-C/ TC are independently associated with growth of atherosclerotic lesion 
(Levy et al, 1984; Arntzenius et al, 1985; Nikkila et al, 1984). In addition, it has 
been established that LDL-C/ HDL-C and HDL-C/ TC ratios are good predictors 
for the presence and se\erity of CAD. Consistent with these findings our results in 
cholesterol (HLPpC) and oxidized cholesterol (HLP2-C) fed rabbits demonstrate 
that the ratios of HDL-C to TC and HDL-C to LDL-C were decreased by 26%. 
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39%, 29% and 37%, respectively, when compared to corresponding ratios of NLP-
C rabbits. However, in HLFpT and HLP2-T groups, treated with TRF. a 
significant increase in ratios by 32%. 39%, 14% and 10%, respectively, was 
observed, when compared to ratios of respective hyperlipidemic control rabbits. 
Similarly, the ratios of TC/ HDL-C and LDL-C/ HDL-C in Hf-Pi-C and HLP.-C 
rabbits were increased by 35%. 63%, 41% and 59%, respectively, in comparison to 
ratios in control group (NLP-C). In comparison to these ratios in two 
hyperlipidemic groups. TRF-trealed rabbits exhibited a significant decline of 24%. 
28%. 12% and 9%. respectively. Consistent with the above reported findings in 
humans, a FH patient (Beg et al., 1997) and hereditary hypercholesterolemic 
swines (Qureshi et al., 2001a), 10 weeks of TRF treatment demonstrated that the 
above ratios have been substantially improved indicating the normalization of lipid 
parameters. However, it is interesting to note that these ratios in TRF treated 
rabbits fed 0.33% nonoxidized cholesterol (HLP|-T) were restored close to ratio 
values of normal rabbits (NLP-C). Whereas, in oxidized cholesterol plus TRF fed 
rabbits (HLP2-T) due to less decrease in LDL-C and more decline in HDL-C 
(Table 9), in comparison to HLP|-T rabbits, the positive improvement in ratios was 
far less than ratio values of HLPpT groups, when compared to normal ratios of 
NLP-C rabbits. 
It has been previously reported that similar to the serum P-VLDL fraction, 
oxidized cholesterol products were also observed in the livers of animals fed a 
cholesterol diet containing no detectable oxidation products (Staprans et al., 1998). 
However, there was a significant increase in 7 (3-hydroxycholesterol, (3-
epoxycholesterol and 7-ketocholesterol in the liver after feeding the 0.33% 
cholesterol containing 5% oxidized cholesterol (Staprans et al., 1998). In 
previously published reports liver has been suggested to be the main site of 
oxidized cholesterol accumulation subsequent to feeding (Addis et al., 1993; 
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Watabe et al.. 1980). It is likely that this increase is secondary to the absorption of 
oxidized cholesterol from the diet. Thus, these findings suggest that similar to 
oxidized fatty acids, cholesterol oxidation products, when present in the diet, are 
absorbed by the small intestine, incorporated into serum lipoproteins, and 
delivered to the liver. However. 7-ketocholestcrol. the major cholesterol oxidation 
product in the oxidized cholesterol rich diet, was not increased in the serum P-
VLDL or LDL fraction but was greatly increased in the liver (Staprans et al, 
1998). This finding supports a previous observation by Addis and coworkers 
suggesting that serum albumin may be one of the carriers of oxidized cholesterol to 
the liver (Addis et al, 1993). This could account for the absence of a large 
increase of 7-ketocholesterol in the serum lipoproteins after feeding the 0.33% 
cholesterol rich diet of which 5% was oxidized cholesterol (Staprans et al, 1998). 
Since our experimental protocols were similar to one used by Staprans and 
coworkers and oxidized cholesterol was procured from them (Staprans et al, 
1998), one would expect a similar pattern in the distribution of cholesterol 
oxidation products in the serum and the liver. Our results demonstrate that unlike 
plasma TC, hepatic TC content was increased to a significantly higher level in 
oxidized cholesterol fed rabbits (HLP2-C) than nonoxidized cholesterol fed 
animals (HLPpC). In addition, unlike plasma, dietaiy tocotrienols (TRF) mixed 
with 0.33% cholesterol rich diet of which 5% was oxidized, mediated a 100%) 
higher decrease in liver TC, when compared to the TC values of HLP|-T rabbits 
fed 0.33%) nonoxidized cholesterol rich diet containing TRF. Although, in our 
investigations, plasma and liver cholesterol oxidation products were not measured, 
the above results are in complete agreement with the findings of Staprans et al 
(1998). However, in their study cholesterol lowering agent was not used. 
Our combined results demonstrate a strong hypolipidemic action of dietary 
tocotrienols, when administered as TRF or Tocomin to rabbits together with 0.33%) 
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cholesterol rich diet for 22.4 or 10 weeks. In addition, TRF was highly effective in 
lowering plasma and lipoprotein lipids in rabbits fed together with the diet 
containing 0.33% nonoxidized cholesterol or the same diet containing 0.33% 
cholesterol of which 5% was oxidized, for 10 weeks. In both the experiments, TC 
and LDL-C, which are positively associated with CHD, were significantly reduced 
Levels of plasma HDL-C and it's subfractions. HDL3-C and HDL2-C, which are 
considered as antiatherogenic were not significantly influenced in hyperlipidemic 
rabbits treated with TRF and/ or Tocomin either for 22.4 or 10 weeks. Several 
epidemiological studies have demonstrated that elevated TG level is associated 
with increased risk of CHD (Albrink and Man. 1959; Hulley et al.. 1980; Aberg et 
al., 1985; Freedman et al., 1988; Austin. 1991; Haffner et a!., 1998; Assmann et 
al., 1999), a risk that is especially high in subjects with low HDL-C (Castelli, 
1986). However, the status of TG as an independent risk for CAD continues to be 
controversial. In our investigations, TRF or Tocomin also mediated a significant 
decline in plasma TG levels in rabbits in both experiments. Although we have not 
investigated the mechanism of hypocholesterolemic action of tocotrienols in 
rabbits, it may involve reduction in HMG-CoA reductase activit}' by reducing it's 
protein mass as shown by our laboratoiy in normolipidemic and hyperlipidemic 
rats (Minhajuddin et al., 1999). The decline in protein mass may be achieved by 
inhibition of HMG-CoA reductase synthesis and/or enhanced degradation. Similar 
to our in vivo results (Minhajuddin et al, 1999), y-tocotrienol has been shown to 
mediate the suppression of enzymatic activity and protein mass of HMG-CoA 
reductase in HepG2 cells, through decreased synthesis and enhanced degradation 
of the enzyme (Parker et al., 1993). TRF-mediated in vivo mechanism of inhibition 
of enzymatic activity and it"s protein mass of HMG-CoA reductase in 
normolipidemic and hyperlipidemic rats and in hyperlipidemic rabbits may be 
analogous to the mechanism shown in HepG2 cells (Parker et al, 1993). 
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Administration of tocotrienols (TRF or Tocomin) to hyperlipidemic rabbits will 
reduce HMG-CoA reductase, which in turn will reduce the synthesis of 
cholesterol. Reduced formation of cholesterol will decrease VLDL production, 
thereby reducing the con\'ersion of VLDL to LDL, which will reduce TC, LDL-C 
and TG concentrations in plasma. Based on the findings of Parker et al. (1993), an 
increase in LDL-receptor protein in HepG2 cells following incubation of y-Tj. an 
additional mechanism for decreased TC, LDL-C and TG levels may involve 
upregulation of LDL receptors by TRF which in turn would increase the removal 
and catabolism of LDL. 
In recent years a growing body of evidence has linked processes involving 
oxygen- derived free radicals with the initiation and propagation of atherosclerosis 
and formation of atheromatous plaques. In particular, the oxidative modification of 
low density lipoproteins \'ia free radical mechanisms by endothelial cells, smooth 
muscle cells and monoc\tes/macrophages (Parthasarathy et al., 1992; Diaz ef al., 
1997). Oxidative modification of LDL is a prerequisite for rapid accumulation of 
LDL in macrophages and for the formation of foam cells. LDL isolated from 
atherosclerotic lesions resembles oxidized LDL in it's physical, chemical and 
immunological properties and these lesions contain immunoglobulins that 
recognize oxidized LDL (Diaz et al., 1997; Carew et al., 1987; Kita et al., 1987). 
Since in some human diseases, such as atherosclerosis, lipid peroxides are 
increased in various organs or tissues and leak into the bloodstream. Thus, the 
increased level obvioush' indicates the occurrence of some membrane damage in 
cells of some organ or tissue provoked by oxidative stress. Accordingly, the blood 
lipid peroxide level often indicates severity of the disease. The increase in lipid 
peroxide in the blood, attacks the blood vessels. Even slight injury to the 
endothelial cells of the artery initiate atherogenesis (Yagi, 1987). The increase in 
lipid peroxide level in the blood can be due to either exogenous cause (mainly 
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dietary) and/or endogenous. Recent studies have demonstrated that oxidized lipids, 
especially oxidized fatty acids and cholesterol in the diet are atherogenic (Staprans 
et al., 1996b; Staprans et al.. 1998; Rong et ai, 1999). An inadequate intake of 
foods containing antioxidant vitamins could result in the oxidation of LDL. In 
addition, antioxidants including vitamin E (tocopherols) and piobucol have been 
shown to inhibit LDL oxidation (Reaven et al., 1993; Parthasarathy et al., 1986; 
Diaz et al.. 1997) and retard the development of atherosclerotic lesions (Carew et 
al.. 1987; Cheng et al.. 1995: Williams et al., 1992). risk of CHD (Rimm et al.. 
1993; Stampfer et al.. 1993; Diaz et al., 1997) and ischemic heart disease (Gey, 
1995). Therefore, it is concei\able that agents that reduce the oxidant stress in 
hyperlipidemia might reduce the susceptibility of LDL to oxidation and the 
development of atherosclerosis. The TRF and Tocomin are enriched with 
tocotrienols and some tocopherols, and tocotrienols are known to be more potent 
antioxidant than tocopherols (Suarna et al., 1993; Kamat and Devasagayan, 1995; 
Kamat et al., 1997; Qureshi et al, 2000). In addition, tocotrienols have been 
shown to have greater free radical scavenging properties as a cell membrane 
constituent than tocopherols (Yamaoka and Carrillo, 1990; Serbinova et al, 1991). 
Based on the above discussion, and the fact that tocotrienols (TRF or Tocomin) 
exhibit a strong cholesterol lowering and antioxidant property, we have 
investigated the antioxidant impacts of TRF or Tocomin on plasma and liver lipid 
peroxide levels, ex vivo and in vitro oxidation of LDL from plasma of rabbits fed a 
cholesterol rich diet for 22.4 or 10 weeks; or the same diet containing 5% oxidized 
cholesterol fed for 10 weeks. The plasma lipid peroxide levels in rabbits fed 
cholesterol for either 22.4 or 10 weeks was increased by 190% and 170%, 
respectively, when compared to control (NLP-C) values. Supplementation of TRF 
or Tocomin together with cholesterol rich diet fed for 22.4 weeks significantly 
blocked the increase in lipid peroxide level by 4.52- and 2.92-fold, respectively. 
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compared to increase in HLP-C rabbits. As expected increase in plasma lipid 
peroxide levels in rabbits fed oxidized cholesterol containing cholesterol rich diet 
for 10 weeks was significantly higher (216%) than nonoxidized cholesterol fed 
(HLP|-C) animals (170%), when compared to control (NLP-C) values. The decline 
in lipid peroxides in cholesterol plus TRF fed rabbits (HLP|-T) was 1.93-fold, in 
comparison to hyperlipidemic control (HLPpC) values, whereas, in oxidized 
cholesterol plus TRF treated animals (HLP2-T) the decline was significantly higher 
(2.70-fold), when compared to corresponding hyperlipidemic control rabbits 
(HLP2-C). Similar to plasma, hepatic peroxide levels in oxidized cholesterol fed 
rabbit was significantly higher than only nonoxidized cholesterol fed group (HLP|-
C). Similarly, the decrease mediated by TRF supplementation along with oxidized 
cholesterol was also higher (32%) than HLPpT rabbits (19%), in comparison to 
respective hyperlipidemic control values. The combined results are consistent with 
the contention that feeding of a cholesterol rich diet to rabbits increases the 
oxidative stress, which is reflected by an increased formation of lipid peroxides in 
liver and plasma. Feeding of the same cholesterol rich diet containing 5% oxidized 
cholesterol, which is rich in cholesterol oxidation products, caused a further 
increase in oxidative stress, which in turn was responsible for an additional 
increase in hepatic and -plasma lipid peroxides. It is important to mention that 
tocotrienols (TRF) being potent antioxidants, mediated a higher degree of 
inhibition of increasing lipid peroxides in liver and plasma in rabbits fed a 
cholesterol rich diet containing 5% oxidized cholesterol than nonoxidized 
cholesterol fed animals. 
Because of the increasing interest in the role of LDL oxidation in 
pathogenesis of atherosclerosis, several methods (.lialal and Devaraj. 1996; Diaz et 
ai, 1997) were developed to evaluate ex vivo and in vitro LDL oxidation. The 
most widely used methods for monitoring LDL oxidation in vitro has been the 
116 
measurement of conjugated dienes, TBARS and relative electrophoretic mobility. 
These parameters appear to be the best index of LDL oxidizability (Jialal and 
Devaraj, 1996; Diaz et al., 1997). The present study indicate that LDL was 
substantially oxidized in vivo in hypercholesterolemic rabbits.The base line levels 
of diene conjugation (BDC). rates of conjugated diene formation and TRARS 
contents of LDL isolated from plasma of hypercholesterolemic rabbits were 
significantly higher than that of the control (NLP-C) values. Consistent with this 
was the observation that the lag phases of copper-induced conjugated diene 
formation, a measure of the susceptibilit} in vivo, was significantly reduced, when 
compared to control (NLP-C) \alues. It is important to mention that BDC, rates of 
conjugated diene formation and TBARS contents of LDL isolated from plasma of 
rabbits fed a cholesterol rich diet for 22.4 weeks were higher than the values 
obtained from animals fed the same cholesterol rich diet for 10 weeks. In addition, 
these values, as expected, were higher in rabbits fed a 0.33% cholesterol rich diet 
of which 5% was oxidized (HLP2-C) in comparison to 0.33% nonoxidized 
cholesterol fed group (HLPpC). In the long-term (22.4 weeks) cholesterol feeding 
experiment, supplementation of TRF or Tocomin was associated with a significant 
decrease of 41% and 33% in the ex vivo BDC levels, respectively. Whereas, 
decline in the rates of conjugated diene formation in LDL was 37% and 27%, 
respectively, in comparison to hyperlipidemic control values. Consistent with a 
strong in vivo antioxidant effect of TRF or Tocomin on oxidation of LDL, the 
resistance of isolated plasma LDL to in vitro oxidative modification, expressed as 
the lag time required for conjugated diene formation, was significantly increased. 
In comparison to 75 min lag phase of control (NLP-C) rabbits, under oxidative 
stress of 22.4 weeks of cholesterol feeding, it was reduced to 30 min. 
Supplementation of TRF or Tocomin together with cholesterol rich diet increased 
the lag time to 60 and 45 min, respecti\'ely. The higher efficacy of dietary TRF 
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expressed in terms of ifs cholcsleiol lowering property, greater inhibition of 
plasma lipid peroxides, ex vivo BDC and in vitro copper-induced oxidation of 
LDL, as measured by lag time for conjugated diene formation, was due to higher 
concentration of TRF (16.2 mg%) than Tocomin (6.97 mg%) used in the above 
long-term feeding experiments. 
In the second experiment, after 10 weeks of treatment, TRF (50 mg%) 
significantly blocked the in vivo oxidation of LDL. as measured by ex vivo BDC, 
by 41% and 26% in cholesterol and oxidized cholesterol fed rabbits, respectively. 
\vhen compared to corresponding h}'perlipidemic controls. Feeding of TRF 
together with cholesterol (HLPi-I) or oxidized cholesterol (HLP7-T) rich diet 
significantly increased the resistance of LDL to oxidative modification, as shown 
by an increase in the lag time required for conjugated diene formation, which was 
substantially reduced under extreme oxidative stress induced by hyperlipidemia. In 
cholesterol fed animals the lag phase was reduced to 30 min from a normal control 
(NLP-C) value of 75 min. TRF treatment significantly increased the lag time 
required for conjugated diene formation to 60 min, a value 80% closer to normal 
value. In oxidized cholesterol (5%) fed rabbits (HLP2-C) the lag time was reduced 
to 15 min in comparison to a control value of 75 min, which is a decline of 80%. In 
TRF plus oxidized cholesterol fed rabbits (HLP2-T) the lag time was restored to 70 
min (93% increase), which is very close to normal value. Similarly, the rates of 
conjugated diene formation was significantly higher in oxidized cholesterol fed 
rabbits (221%o) than nonoxidized cholesterol fed animals (144%)), in comparison to 
control (NLP-C) values. In addition. TRF supplementation reduced this value by 
20% and 30%, respectively, when compared to respective hyperlipidemic control 
groups. The combined results demonstrate that the presence of only 5% cholesterol 
oxidation products in a 95% nonoxidized cholesterol rich diet, fed to rabbits for 10 
weeks, was associated with a significantly higher magnitude of the oxidative 
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effects on plasma and liver peroxides, liver TC and LDL isolated from plasma, 
when compared to the values obtained from 100% nonoxidized cholesterol fed 
rabbits. In addition, the antioxidant effect of TRF was also more pronounced, 
when fed together with an oxidized cholesterol diet than TRF plus nonoxidized 
cholesterol fed group. Based on these results it can be inferred that oxidized 
cholesterol will be more atherogenic than nonoxidized cholesterol. In general, our 
results are consistent with se\eral other reports showing increased ex vivo and in 
vitro plasma LDL oxidation in hyperlipidemic animals and humans. In the year 
2000, it has been reported thai not only LDL but also VLDL and HDL were 
oxidatively modified in vivo in the patients with endogenous hypertriglyceridemia 
and in the rabbits fed on high cholesterol diet (Liu et al., 2000). The oxidation of 
HDL in vivo in turn could result in the impairment of reverse cholesterol transport 
from peripheral tissues and other biological functions, which reduce the protective 
effects of HDL against atherosclerosis. However, the mechanisms of lipoproteins 
oxidation in vivo in hyperlipidemia are yet to be established (Liu et al., 2000). 
The combined results demonstrate that strong hypolipidemic impacts of 
TRF and Toconiin in conjunction with a potent antioxidant property can provide 
additional therapeutic benefit in the prevention and treatment of atherogenesis. 
Furthermore, the additional increase in oxidative stress, evoked in experimental 
hyperlipidemia in rabbits fed a cholesterol rich diet containing 5% oxidized 
cholesterol, was blocked more effectively by TRF represents an initial 
demonstration. Our results indicating a strong antioxidant impacts of TRF in 
hyperlipidemic rabbits are in agreement with earlier findings from our laboratory 
in normolipidemic and hyperlipidemic rats (Beg et al., 2000a; Beg et al., 2000b) 
and other reports indicating an inhibition in the formation of TBARS and 
conjugated dienes by TRF or individual tocotrienols and tocopherols when fed to 
rats along with an atherogenic diet. These results also indicate that y-TS exerts a 
119 
significantly more potent antioxidant impact as compared to a-T (Watkins et al, 
1993). Support to our results is also obtained from another study where feeding of 
a mixture of tocotrienols along with an atherogenic diet to rabbits was associated 
with a significant reduction in the formation of serum lipid peroxides (Teoh et al., 
1994). TRF treatment of patients with hyperlipidemia and carotid stenosis caused a 
significant decrease in TBARS. an ex vivo indicator of maximal platelet 
peroxidation (Tomeo et al., 1995; Theriault et al., 1999a). The antioxidant activity 
of the a-tocoterienol (T3) homolgue has been shown to be more than 3-fold 
greater than that of a-tocopherol (T) (Packer. 1995). Using an in vitro liposome 
system, antioxidant activities for several tocotrienols were 4-33-fold higher than 
that for a-T. The order of activity was d-P25-T3>d-P2lTT3>TRF25>5-T3>y-
T3>a-T3>a-T (Qureshi et al, 2000). These results indicate that in intact 
membranes, including LDL particles, tocotrienols may have a significantly greater 
antioxidant effect than tocopherols and they may provide greater protection against 
CAD. D-P25-T3 is the most potent homologue of all natural forms of unsaturated 
(T3) and saturated (T) vitamin E tested. These findings were further confirmed by 
determining the antioxidant activities involving coupled autoxidation of p-carotene 
and linoleic acid. The antioxidant activities of known a-, y- and 5-tocotrienols and 
TRF25 (prepared from stabilized and heated rice bran with 6% a-T) were 22%, 
27%, 32% and 24% better than a-T, respectively (Qureshi et al., 2000). The 
possible mechanism for this superior efficacy of tocotrienols compared to 
tocopherols has been reported elsewhere (Packer, 1995; Packer et al., 2001). 
Differences in the transport and tissue uptake of the saturated (T) and unsaturated 
(T3) tocols have been reported b}' other investigators (Kayden and Traber, 1993: 
Pearson and Barnes, 1970). A hepatic binding protein with high specificity for a-T 
in the liver results in the subsequent enrichment of this tocol in the VLDL moiety 
and as a consequence, the LDL moiety. The tocotrienols on the other hand are 
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transported non specifically like other lipid soluble compounds (Kayden and 
Traber, 1993; Pearson and Barnes. 1970; Suarna et al., 1993). It has been 
previously reported that treatment of hypercholesterolemic humans with TRF25 
resulted in substantial increases in the levels of LDL-bound antioxidants, 
especially tocotrienols. which are known to have significantly greater antioxidant 
activity than tocopherols (Qureshi et al., 1997). Therefore, it appears that 
tocotrienols as TRP or Tocomin exert their antioxidant effect on plasma LDL 
oxidation while being attached to LDL particle. 
Rabbits fed a low cholesterol containing diet (<0.5% by weight) have been 
studied more frequently in recent years as an atherosclerotic animal model (Adams 
et al, 1982; Daley et al, 1994a; Bocan et al, 1991). In this model, plasma 
cholesterol levels comparable to those found in human hypercholesterolemia can 
be achieved (Holvoet and Coilen, 1997: Adams et al, 1982; Feldman et al, 1991). 
The early foam ceil lesions more closely resemble the human fatty streak than 
lesions in animals fed a high cholesterol diet (> 0.5% by weight), and the advanced 
lesions consists primarily of smooth muscle cells, lipid-laden foam cells, and a 
fibromascular cap covering a core composed of extracellular lipid and necrotic 
debris (Daley et al, 1994a; Daley et al, 1994b; Tsukada et al, 1986), which is a 
hallmark of advanced atherosclerosis in humans. There have been a number of 
attempts to define the relationship between atherosclerotic lesion formation and 
diet-induced hypercholesterolemia (Daley et al, 1994a, Bocan et al, 1993; Daley 
et al, 1994b, Kolodgie et al, 1996) in low cholesterol fed rabbits. Consistent with 
these findings, our results showed that feeding a low cholesterol containing diet 
(0.33% by weight) to rabbits for 22.4 weeks was more than sufficient to produce a 
significant number of early sudanophilic lesions. The fatty streak lesion areas in 
aortas of these hypercholetcrolemic rabbits (HLP-C) was 21.5%. Feeding of 
dietary TRF (16.2 mg%) or Tocomin (6.97 mg%) mixed with 0.33% cholesterol 
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rich diet lo HLP-T| and HLP-17 rabbits was associated with a significant reduction 
in the formation of fatty streak lesions in the aortas, with average areas of 10.3% 
and 13.3%, respectively. This represents a reduction of 2.1- and 1.6-fold, 
respectively, when compared to HLP-C control values. These results demonstrate 
that dietaiy tocotrienols mediated a significant protection against fatty streak lesion 
formation in the aortas of rabbits in both the treated groups. 
Our results demonstrate that 14.3% aortic area of rabbits fed a nonoxidized 
cholesterol rich diet was covered by fatty streak lesions. Feeding the above 
cholesterol rich diet containing 5% oxidized cholesterol to HLP2-C rabbits 
revealed an average fatty streak lesion area of 27.7%o. Thus, veiy small quantities 
of oxidized cholesterol in the rabbit diet (16.4 mg/day) increased fatty streak 
lesions in the aortas by approximately 100%. This demonstrates that cholesterol in 
the diet is considerably more atherogenic when present in the oxidized form. 
Tocotrienols (TRF), being a potent hypolipidemic and antioxidant agents, when 
supplemented together with nonoxidized cholesterol rich diet (HLP|-T) blocked 
the formation of fatty streak lesions to 6.0%), which represents a decline of 2.4-
fold. In oxidized cholesterol rich diet containing TRF fed rabbits (HLP2-T) the 
area of fatty streak lesions in aortas was substantially reduced to 6.1%, which is 
4.1-fold lower than the conesponding hyperlipidemic control (HLP2-C) values. 
These results show that efficacy of dietaiy tocotrienols in terms of inhibiting the 
vascular lesions formation in rabbits fed together with oxidized cholesterol was 
significantly higher than nonoxidized cholesterol plus TRF fed rabbits. 
Since it has been established by other investigators (Staprans et al., 1996b, 
Kolodgie et a/., 1996; Collens. 1957) that a wide biological variability occurs 
among rabbits with respect to individual responsiveness to dietary cholesterol and 
that the severity of arterial lesions correlates with the serum cholesterol 
concentration, the data was also calculated as a function of plasma cholesterol 
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exposure (expressed as mmol choleslerol.L"'. day). When lesions in rabbit aortas 
are expressed as ratios of arotic lesion divided by the cholesterol exposure for each 
rabbit, our data also show a -100% increase in aortic lesions in the oxidized 
cholesterol diet group (HLP2-C). Similarly, the reduction in the formation of fatty 
streak lesions in die aortas of HLPi-T and HLP2-T labbits was 1.9- and 3.2- fold, 
respectively, when compared to respective hyperlipidemic controls. Thus, our 
results, even when adjusted for plasma cholesterol levels, demonstrate that the 
atherogenecity of dietary cholesterol is significantly increased by oxidation. In 
addition. TRF-mediated inhibition of fatty steak lesions formation was more 
significant in HLP2-T rabbits. 
Several previous studies have examined the atherogenesis mediated by 
oxidized dietary cholesterol in animal models. Cook and MacDougali (1968) fed 
male rabbits cholestane triol at 0.1% diet weight and observed sudanophilic lesions 
in the aorta after only 27 days. Matthias et al. (1987) failed to reproduce Cook"s 
findings in rats but reported angiotoxicity resulting from cholestane triol ingestion. 
Jacobson et al. (1985) observed a five-fold increase in coronaiy atherosclerosis in 
White Carneau pigeons after feeding oxidized cholesterol in amounts that are 
comparable to the average US dietary intake, in comparison to pure cholesterol fed 
controls. However, no difference in aortic lipids was found. Imai et al. (1980) 
reported grossly visible thickening in the major branches of rabbit pulmonaiy 
arteries after 3 consecutive intra\'enous injections of cholestane triol or 25-
hydroxycholesterol. On the other hand. Higley et al. (1986) reported that oxidized 
cholesterol has a protective effect on cholesterol-induced atherosclerosis in rabbits. 
However, in this study, oxidized cholesterol concentrations in the diet were high 
(120 to 240 mg/day), and observations of Osada et al. (1994) indicate that such 
high concentrations of oxidized cholesterol impair the absorption of cholesterol 
from the diet. Thus, it is likely in the experiments of Higley et al. (1986) that high 
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quantities of oxidized cholesterol in the diet reduced the absorption of TC, which 
resulted in decreased serum cholesterol levels and consequently decreased fatty 
streak lesions in the aorta. By increasing plasma cholesterol levels to > 1100 mg/dl 
during a 12-week period, Staprans et al. (1998) found that dietaiy oxidized 
cholesterol (5%) accelerated the development of aortic atherosclerosis in 
cholesterol fed rabbits. This study represents the initial demonstration in mammals 
that oxidized cholesterol in the diet accelerates atherosclerosis (Staprans ef al., 
1998). Similarly, Mahfouz et al. (1997) reported that dietary cholesterol oxidation 
products caused more severe atherosclerotic lesions than did pure cholesterol at 
plasma cholesterol levels >1400 mg/dl over 11 weeks. Based on these findings. 
Rong et al. (1999). used a cholesterol oxidation products mixture resembling that 
found in plasma, atherosclerotic lesions, and in vivo circulating oxidized LDL of 
hypercholesterolemic rabbits (Hodis et al., 1991: Hulten et al., 1996; Hodis et al.. 
1994). In this study injections of cholesterol oxidation products mixture led to 
significantly greater foam cell formation in these moderately hypercholesterolemic 
rabbits. The positive and strong correlation between the sudanophilic lesion area 
and total plasma cholesterol oxidation products exposure verifies that when plasma 
cholesterol concentrations approximate the threshold levels required for fatty 
streak fonnation, cholesterol oxidation products are better determinants for the 
progression of lesion formation (Rong et al., 1999). In the present investigation, 
the oxidized cholesterol (5%) containing cholesterol rich diet (0.33%) fed to 
HLP2-C rabbits for 10 weeks, contained 42% 7-ketocholesterol, 20% 7 \S-
hydroxycholesterol, 16% p-epoxycholesterol. 12% a-epoxycholesterol, 7% 7 a-
hydroxycholesterol and 3% 25 p-h}droxycholesterol. as cholesterol oxidation 
products. This resulted in -100% increase in fatty streak lesions in the aorta in 
comparison to nonoxidized choleslerol fed rabbits (HLP|-C). These results are 
completely consistent with the findings of Staprans et al. (1998), Mahfouz el al. 
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(1997) and Rong et al. (1999). However, in these studies therapeutic interventions 
in the prevention and treatment of atherosclerosis was not investigated. 
Atherosclerosis is a complex process that is still not completely understood. 
The mechanisms by which oxidized cholesterol facilitate vascular cholesterol 
accumulation remain to be elucidated. However, there are several potential 
mechanisms by which oxidized cholesterol in circulating lipoproteins could 
accelerate atherosclerosis (Smith and Johnson, 1989; Guardioia et al., 1996). 
Oxidized cholesterol is cytotoxic to many cells, including endothelial cells, and 
numerous studies have shown that 7 a-hydroxycholesterol, 7 (3-hydroxycholesterol 
and 7-ketocholesterol are all ver}' cytotoxic to arterial wall cells in vitro (Hughes et 
al, 1994; Sevanian et al. 1995: Chiisolm et a!., 1994; Peng et ai, 1992; Peng et 
al., 1979; Coffey et al.. 1995). Staprans et al. (1998) have demonstrated that 
rabbits ingesting a diet containing oxidized cholesterol have elevated 7 a-
hydroxycholesterol. 7 p-hydroxycholesterol and 7-ketocholesterol in their serum p-
VLDL fraction. Endothelial injury has been proposed to be a major factor in 
initiating the atherogenic process that leads to fatty streak formation (Ross, 1986). 
Other investigators have reported that oxidized cholesterol induces endothelial cell 
injury in rabbits and rats in vivo (Imai et al., 1980; Taylor et al., 1979, Matthias et 
al., 1987; Peng et al.. 1985; Colles et al., 1996). Thus, oxidized cholesterol 
mediating endothelial injury is one potential mechanism by which oxidized 
cholesterol in the diet could accelerate fatt}' streak formation. A second potential 
mechanism by which oxidized cholesterol in lipoproteins could accelerate 
atherosclerosis is by inducing foam cell formation. Oxidized p-VLDL has been 
shown to degrade by macrophages at an accelerated rate compared with native P-
VLDL (Parlhasaralhy et al.. 1989; Haratz et al., 1988). In addition, oxidized p-
VLDL leads to increased lipid accumulation in smooth muscle cells (Davis and 
Bowyer, 1989; Horrigan et al 1991). Another possible mechanism could involve 
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increased uptake (Sevanian et al.. 1995) or retention (Kilsdonk et al., 1995; Cao ef 
ai, 1995) of cholesterol by vascular cells associated with activation of ACAT 
(Cheng et al, 1995; Brown et ai, 1975), analogous to ACAT activation by 
hypercholesterolemia (Bocan et al. 1991; Kolodgie et al, 1996; St Clair, 1976). 
Some reports have shown that cholesterol oxidation products inhibit cholesterol 
efflux, either by disrupting intracellular cholesterol trafficking or by inhibiting 
cholesterol transfer to HDL (Kilsdonk et al, 1995; Fielding et al, 1997; Gelissen 
et al., 1996). In addition, cholesterol oxidation products have been shown to 
damage lysosomes, similar to the effects of oxidized LDL and core aldehydes 
(Hoppe. 1997). which could inhibit CE hydrolases and other lysosomal enzymes 
and facilitate CE accumulation (Hoff and Hoppe, 1995). In conclusion, after 
consuming a meal containing oxidized cholesterol, the vascular tissues are exposed 
to lipoproteins containing oxidized cholesterol, which by a variety of mechanisms 
could initiate or accelerate aortic fatty streak formation and atherosclerosis. 
Our combined results demonstrate a strong hypolipidemic, antioxidant and 
antiatherosclerotic impacts of tocotrienols (TRF or Tocomin), when fed to rabbits 
together with a cholesterol or oxidized cholesterol rich diet. The LDL-specific and 
tissue-specific possible mechanisms of antioxidant effects of tocotrienols may be 
similar to events depicted in Figure 1.7. The incoiporation of antioxidants into 
LDL protects LDL against oxidation and leads to the reduced formation of 
oxidized LDL. In addition, incorporation of antioxidants into vascular cells may 
reduce the clinical expression of vascular disease by reducing vascular cell 
oxidation of LDL and the cellular responses to oxidized LDL, resulting in less 
monocyte adhesion, less foam cell formation, less cytotoxicity to vascular cells, 
and improved vascular function. Furthermore, cellular antioxidants protect against 
the endothelial dysfunction associated with atherosclerosis by preserving 
endothelium-derived nitric oxide activity. 
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It is well known that the typical diet in India as well as in Western countries 
contains high concentrations of cholesterol oxidation products. Food processing, 
heat treatment and diying, fiying, deep-frying, cooking at high temperature and 
prolonged storage, particularly at room temperature, induces cholesterol oxidation. 
Oxidized cholesterol products are present in various food products, including dairy 
products, eggs, meat, fish and deep fried nuts. Many bakeiy products due to the 
presence of butter and eggs also contain oxidized cholesterol products. Oxidized 
cholesterol found in these food sources clearly provides a good exogenous source 
of cholesterol oxidation products, and our results suggest that these foods may be a 
risk factor for atherosclerosis. The results indicate that for moderate experimental 
hypercholesterolemia, a situation more relevant to physiological 
hypercholesterolemia in humans, circulating cholesterol oxidation products may 
play an important role in inducing formation of early atherosclerotic lesions. As 
indicated above, good quantity of cholesterol oxidation products are present in 
cholesterol containing diets, foam cell lesion formation induced by cholesterol 
oxidation products rather than cholesterol cannot be overlooked. In conclusion, our 
results demonstrate that dietary tocolrienols (Till" or Tocomin), being a potent 
anticholesterol, antioxidant and antiatherosclerotic agents, have a therapeutic role 
in the prevention and treatment of atherosclerosis. 
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Feeding of 0.33% cholesterol rich diet to rabbits for 22.4 weeks was 
associated with a substantial hyperlipidemia. The efficacy of TRF or Tocomin in 
the prevention of experimental hyperlipidemia in rabbits has been shown by 
feeding of 16.2 mg% TRF or 6.97 mg% Tocomin together with a cholesterol rich 
diet for 22.4 weeks. TRF and Tocomin significantly prevented the increase in 
plasma TG, TC, VLDL-C, and LDL-C levels in comparison to rabbits fed 
cholesterol rich diet alone. However, elevated plasma HDL-C, HDL3-C and HDL2-
C levels were not reduced significantly in TRF and Tocomin treated rabbits. Both 
Tocomin and TRF caused a substantial improvement in the ratios of HDL-C/ TC. 
HDL-C/ LDL-C, TC/ HDL-C and LDL-C/ HDL-C, in comparison to ratio values 
of hyperlipidemic control indicating the initiation of normalization process of lipid 
parameters. 
In response to oxidative stress, evoked in experimental hyperlipidemia in 
rabbits, as reflected by increased formation of plasma lipid peroxides, higher base 
line levels of diene conjugation (BDC) of LDL. as modified in vivo, increased 
rates of conjugated diene formation in LDL and decrease in lag phase time of LDL 
oxidation in vitro, was substantial}}' blocked by TRF or Tocomin when fed 
together with cholesterol rich diet. Similarly, TRI^  and Tocomin significantly 
blocked the LDL oxidation and restored the lag phase time close to normal value. 
The combined results demonstrate that strong hypolipidemic impacts of TRF or 
Tocomin in conjunction with it"s potent antioxidant property can provide an 
additional therapeutic benefit in the prevention and treatment of hyperlipidemia 
and atherosclerosis. Consistent with above results, feeding of the cholesterol rich 
diet to rabbits for 22.4 weeks was also associated with the formation of fatty streak 
lesions in the aortas of hyperlipidemic rabbits. The average areas in aortas of these 
rabbits covered by fatty streak lesions was 21.5%, whereas TRF or Tocomin 
supplemented groups revealed an a\erage lesion areas of 10.3%) and 13.3%, 
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respectively. Therefore, feeding of dietary TRF or Tocomin together with 
cholesterol rich diet caused a signillcant reduction in the formation of aortic fatty 
streak lesions by 2.1- and 1.6-fold, respectively. These results demonstrate that 
tocotrienois (TRF or Tocomin) being a potent anticholesterol and antioxidant 
agents mediated a significant protection against the form a^tion of early 
atherosclerotic lesions in the aortas induced by cholesterol feeding to rabbits. 
Based on strong hypolipidemic, antioxidant and antiatherosclerotic 
properties of tocotrienois (TRF or Tocomin) fed together with a cholesterol rich 
diet to rabbits for 22.4 weeks: we have investigated the role of dietary oxidized 
cholesterol in experimental hyperlipidemia, oxidative modification of LDL and in 
the acceleration of fatty streak lesions in the aorta of rabbits. In addition, 
therapeutic role of TRF in the prevention and treatment of experimental 
hyperlipidemia and atherosclerosis induced by cholesterol oxidation products was 
investigated. After 10 weeks of feeding to rabbits either a 0.33% cholesterol rich 
diet or the same diet containing 0.33% cholesterol of which 5% was oxidized, 
plasma TO, TC including FC and EC, VLDL-C, LDL-C, HDL-C and it's 
subfractions, HDL3-C and HDLi-C were substantially increased but to a similar 
extent. Supplementation of 50 mg% of TRF to these diets significantly blocked the 
increase in the above lipid parameters, except HDL-C, HDL3-C and HDL2-C 
levels were not reduced significantly. Similarly, HDL-C/ TC and HDL-C/ LDL-C 
ratios were increased, whereas TC/ HDL-C and LDL-C/HDL-C ratios were 
reduced in TRF-treated rabbits, when compared to ratios obtained from respective 
hyperlipidemic controls, indicating a strong antiatherogenic propert}' of 
tocotrienois. hi contrast to plasma TC, feeding of cholesterol rich diet containing 
5% oxidized cholesterol was associated with a significantly higher increase in 
hepatic TC level than nonoxidized cholesterol fed rabbits, hi addition, the decrease 
in liver TC mediated bv TRF in oxidized cholesterol fed rabbits was two-fold 
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greater than TRF plus nonoxidized cholesterol fed animals. The combined results 
demonstrate a strong cholesterol lowering property of tocotrienols (TRF), which 
were significantly more effective in the livers of oxidized cholesterol fed rabbits. 
The oxidative stress. e\oked in oxidized cholesterol fed rabbits was 
significantly higher than nonoxidized cholesterol fed rabbits. This differential 
effect was reflected in several indices of oxidative stress, such as plasma and liver 
lipid peroxidases, baseline le\els of ex vivo diene conjugation of LDL, rates of 
conjugated diene formation and TBARS contents of LDL. and lag phase time of/>? 
vitro LDL oxidation. These oxidative parameters were substantially more 
pronounced in rabbits fed oxidized cholesterol, apparently due to the presence of 
cholesterol oxidation products. Tocotrienols being very potent antioxidants, 
significantly blocked the above mentioned oxidative parameters in both groups. 
However, tocotrienols were significanth' more potent in blocking the increasing 
plasma and liver lipid peroxidases as well as ex vivo and in vitro LDL oxidation, 
when supplemented with a diet enriched in oxidized cholesterol. Feeding of 0.33% 
cholesterol rich diet containing 5% oxidized cholesterol, which is rich in 
cholesterol oxidation products, caused a further increase in oxidative stress, which 
in turn decreased the lag time from a control value of 75 to 15 min, in comparison 
to a decline of 30 min in nonoxidized cholesterol fed rabbits. Similarly, feeding of 
TRF together with oxidized cholesterol rich diet significantly increased the 
resistance of LDL to oxidative modification, as shown by an increase in lag time 
from 15 to 70 min, which is ver\ close to normal value of 75 min. However, in 
nonoxidized cholesterol plus TRF fed rabbits the restoration of lag time was only 
from 30 to 60 min. 
Consistent with the above results, feeding of nonoxidized cholesterol rich 
diet resulted in the formation of fall)' streak lesions in the aorta of rabbits, which 
covered an area of 14.3%. An a\'erage fatty streak lesion area of 27.7% was found 
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in the aortas of rabbits fed a cholesterol rich diet containing 5% oxidized 
cholesterol. Thus, intake of a very small quantity, that is. 16.4 mg/ day of dietary 
oxidized cholesterol increased the falty streak lesions by -100%. These results 
demonstrate that cholesterol in the diet is considerably more atherogenic when part 
of it is in the oxidized form. Consistent with a strong hypolipidemic and 
antioxidant action of tocotrienols, supplementalion of TRF with oxidized 
cholesterol blocked the formation of fatty streak lesions by 4.1-fold, whereas TRF 
feeding together with nonoxidized cholesterol caused a reduction of 2.4-fold. 
These results show that the efficacy of dietary tocotrienols in terms of inhibiting 
the formation of vascular lesions in oxidized cholesterol fed rabbits was 
significantly higher than non-oxidized cholesterol plus TRF fed animals. These 
results indicate that for moderate experimental hypercholesterolemia, a situation 
more relevant to physiological hypercholesterolemia in humans, circulating 
cholesterol oxidation products may play an important role in inducing formation of 
early atherosclerotic lesions. Because cholesterol oxidation products are often 
present in cholesterol containing diets, foam cell lesion formation induced by 
oxidized cholesterol rather than cholesterol needs to be further investigated. In 
addition, the mechanism of action of tocotrienols in the inhibition of accelerated 
aortic atherosclerosis in rabbits fed a cholesterol rich diet containing 5% oxidized 
cholesterol also needs further investigation. 
It is well established that Western as \\ell as Asian, including Indian diets, contain 
high concentrations of oxidized cholesterol products, and our results suggest that 
these foods may be a risk factor for atherosclerosis. Based on our combined results 
of long-term (22.4 weeks) cholesterol feeding experiment and a 10-week 
cholesterol feeding experiment containing 5% oxidized cholesterol, it can be 
concluded that dietary tocotrienols (TRF or Tocomin) are potent hypolipidemic, 
antioxidant and antiatherosclerotic agents. Therefore, daily intake of dietary TRF 
131 
or Tocomin will be useful in the prevention and treatment of atherosclerosis. 
Furthermore, tocotrienols (TRF or Tocomin) will be an excellent source of vitamin 
E with substantial and potent antioxidant activity. 
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